|
11th International AIDS ConferenceVancouver, British Columbia — July 7-12, 1996 |
Table of Contents - MondayMo = Monday, Tu = Tuesday, We = Wednesday, Th = Thursday, Lb = Late-Breaker Cite as: Int Conf AIDS. 1996 Jul 7-12;11:Abstract No. xx |
| PLENARY Abstracts - Monday, July 8 Mo.01 thru Mo.05 |
|
| Mo.01* | Advances in Antiretroviral Therapy and Viral Load Monitoring Int Conf AIDS 1996 Jul 7-12; 11:2 (abstract no. Mo.01) Hammer, Scott; Division of Infectious Diseases, Deaconess Hospital and Harvard Medical School, Boston, MA USA Recent developments in the field of antiretroviral therapy have led to substantial advances in the approach to management of HIV infected persons. |
| Mo.02 | HIV genetic diversity. Int Conf AIDS 1996 Jul 7-12; 11:2 (abstract no. Mo.02) McCutchan FE, Salminen MO, Carr JK, Burke DS; Henry M. Jackson Foundation, Rockville, MD, USA. Fax: 301-762-7460. E-mail: fmccutchan@hiv.hjf.org. Introduction: HIV-1 evolves by the rapid accumulation of mutations and by recombination; both processes are actively contributing to its genetic diversity. Many new full-length sequences of HIV-1 isolates have been obtained, permitting, for the first time, a complete evaluation both of the genetic relationships among s |
| Mo.03 | The epidemic of HIV among young gay men. Int Conf AIDS 1996 Jul 7-12; 11:2 (abstract no. Mo.03) de Wit J; Dept. of Social and Organizational Psychology, University of Utrecht, Utrecht, The Netherlands. Fax: 31-30-253-7584. E-mail: wit@fsw.ruu.nl. Summary: The AIDS crisis is not over was the title of a manifestation in the Museum of Modern Art in Amsterdam in the early 1990s. Given that this outcry is still valid to date, it is also the leading thought of this presentation on the HIV epidemic among young gay men. It will be argued that in industrialised nations, |
| Mo.04 | Narcotic drug abuse, the Swedish experience. Int Conf AIDS 1996 Jul 7-12; 11:2 (abstract no. Mo.04) Grunewald A; Akersberga, Sweden. Fax: 46-8540-60669. The restrictive Swedish drug policy is considered to be successful in keeping narcotic drug abuse on a relatively low level and has therefore attracted international attention. The Swedish laws are well adjusted to the three UN Conventions on Narcotic Drugs (1961, 1971, 1988). The combination of resources for preventiv |
| Mo.05 | The failure of prohibition as a drug control strategy: the case of AIDS. Int Conf AIDS 1996 Jul 7-12; 11:2 (abstract no. Mo.05) Drucker E; Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA. Fax: 718-798-6378. E-mail: drucker@aecom.yu.edu. Illicit drug use and addiction are now the single most dynamic feature of the global AIDS epidemic, capable of igniting explosive regional spread of HIV infection: In southeast Asia, over 1 million new HIV infections have occurred in the past decade. The failure to effectively regulate addictive drugs through prohibiti |
| ORAL Abstracts - Monday, July 8 Mo.A.100 thru Mo.D.603 |
|
| Mo.A.100 | Chemically inactivated whole HIV vaccine induces cellular responses in mice. Int Conf AIDS 1996 Jul 7-12; 11:4 (abstract no. Mo.A.100) Addawe MD, Fabrizzi F, Dourmashkin R, Wilson S, Oxford JS; Department of Academic Virology and Retroscreen Ltd., London Hospital Medical College, London, UK. Objectives: To investigate the immune response in mice to an experimental whole virus chemically inactivated HIV-1 vaccine. Methods and Results: Groups of female mice (Balb/c) were immunised with two doses (10 micrograms and 1 microgram) of a whole HIV MN virus grown in C8166 cells. The vaccine production procedure inv |
| Mo.A.101 | Efficacy evaluation of conventional dual-subtype HIV vaccine. Int Conf AIDS 1996 Jul 7-12; 11:4 (abstract no. Mo.A.101) Yamamoto JK, Mison M, Elyar J, Tellier MC, Pu R; Univ. of Florida, Dept. of Pathobiology, College of Vet. Med., Gainesville, FL. Fax: 904-392-7128. Objective: To evaluate the immunogenicity and prophylactic efficacy of dual-subtype infected cell vaccine against homologous and heterologous FIV subtype challenges in domestic cats. Methods: Dual-subtype FIV vaccine was developed from two singly-infected (subtype A or D) cell lines that were inactivated and mixed with |
| Mo.A.102 | Adenovirus host range mutant-SIV recombinant vaccine trial in rhesus macaques. Int Conf AIDS 1996 Jul 7-12; 11:4 (abstract no. Mo.A.102) Buge SL, Lubeck M, Kalyan N, Cheng S, Richardson E, Markham P, Miller C, Udem S, Robert-Guroff M; NIH, Bethesda, MD. Fax: 301-496-8394. Objective: To evaluate a prime-boost vaccine regimen using an adenovirus host range mutant (Ad5hr)-SIVsm envelope recombinant and native SIV251 gp120 for protective efficacy against vaginal transmission of SIV. Methods: Six adult female macaques were immunized orally and intranasally at 0 weeks and intratracheally at 1 |
| Mo.A.103 | Immunization with SIVmne envelope (gp160) vaccines protected macaques against intrarectal challenge by uncloned virus. Int Conf AIDS 1996 Jul 7-12; 11:4 (abstract no. Mo.A.103) Polacino P, Stallard V, Klaniecki J, Brown C, Watanabe R, Morton WR, Benveniste RE, Hu SL; University of Washington, Seattle, WA, USA. Objective: Envelope (gp160)-based vaccines, when used in a live virus priming and subunit protein boosting regimen, protected macaques from intravenous and intrarectal challenge by a cloned homologous virus SIVmne E11S. In the present study, we investigated the breadth of the protective immunity elicited by the envelop |
| Mo.A.104 | Immune responses in cynomolgus macaques infected with pathogenic or attenuated SIV. Int Conf AIDS 1996 Jul 7-12; 11:4 (abstract no. Mo.A.104) Rud EW, Sheering A, Bogdanovic D, Ko D, Vogel T, Cook N, Hall G, Cranage MP, Parenteau M, Beausoleil N, Fournier J; Health Canada, LCDC, National Laboratory for HIV Pathogenesis, Ottawa, Ontario, Canada. Fax: 613-957-7238. E-mail: erud@hpb.hwc.ca. Objective: To determine the immune responses induced by infection of macaques with either an attenuated or pathogenic variant of SIVmac32H and ultimately to correlate these to the protection induced against subsequent heterologous challenge with virus derived from SIVsmm. Methods: Three groups of 8 cynomolgus macaques |
| Mo.A.103 | Immunization with SIVmne envelope (gp160) vaccines protected macaques against intrarectal challenge by uncloned virus. Int Conf AIDS 1996 Jul 7-12; 11:4 (abstract no. Mo.A.103) Polacino P, Stallard V, Klaniecki J, Brown C, Watanabe R, Morton WR, Benveniste RE, Hu SL; University of Washington, Seattle, WA, USA. Objective: Envelope (gp160)-based vaccines, when used in a live virus priming and subunit protein boosting regimen, protected macaques from intravenous and intrarectal challenge by a cloned homologous virus SIVmne E11S. In the present study, we investigated the breadth of the protective immunity elicited by the envelop |
| Mo.A.140 | The peripheral deletion of Vgamma9/Vdelta2 in HIV-infected donors is associated with a proliferative anergy to non-peptidic ligand TUBAg and a defect in cytokine secretion. Int Conf AIDS 1996 Jul 7-12; 11:5 (abstract no. Mo.A.140) Boullier S, Poccia F, Lecoeur H, Fournieo JJ, Gougeon ML; Unite D'oncologie Virale, Institut Pasteur, Paris, France. Objectives: Since we have previously reported a strong peripheral decrease of peripheral Vdelta2 gammaT lymphocytes in asymptomatic HIV-infected donors, the objective of this study was to characterize whether this decrease was associated with an alteration of the repertoire and the functions of these gamma cells. |
| Mo.A.141 | IL-15 supports anti-HIV-1 cytotoxic T cell and NK activity with less induction of HIV-1 replication than IL-2. Int Conf AIDS 1996 Jul 7-12; 11:5 (abstract no. Mo.A.141) Skolnik PR, Wang A, Fabry J, Lieberman J; New England Medical Center, Boston, MA. Fax: 617-636-3216. E-mail: paul.skolnik@es.nemc.org. Objective: To determine the effects of interleukin-15 (IL-15) on HIV-1 replication and specific anti-HIV cytotoxic T cell (CTL) activity in comparison with IL-2 , which shares beta and gamma receptor chains with IL-15. Methods: IL-15- or IL-2-prestimulated PBMC from HIV-seronegative donors (N=6) were infected with HIV- |
| Mo.A.142 | Characterization of antibody, cytokine and complement levels in cervicovaginal (CVL) fluid in HIV-infected and uninfected women. Int Conf AIDS 1996 Jul 7-12; 11:5 (abstract no. Mo.A.142) D'Amico RD, Sha BE, Landay AL, Spear GT, Massad LS, Padnick J, Payne G, Charles LA, Benson CA; Section of Infectious Disease, Rush Medical College, Chicago IL. Objective: To characterize antibody, cytokine, and complement levels in CVL fluid and to determine associations with HIV status, concurrent genital infection, and/or cervical dysplasia or HPV . Methods: Twenty-one women participating in the Women s Interagency HIV Study underwent CVL collection using 10 cc of sterile N |
| Mo.A.143 | Mechanisms of down-modulation and release of TNF receptor induced by HIV-1 on cultured human monocytes. Int Conf AIDS 1996 Jul 7-12; 11:5 (abstract no. Mo.A.143) Rimaniol AC, Boussin FD, Dormont D, Bach JF, Zavala F; Hopital Necker, Paris, France. Fax: 33-1-43-06-23-88. Objective: To investigate the cellular mechanisms involved in the profound remodeling of the TNF receptor expression induced by HIV-1 LAI infection of human blood monocytes. Methods: Adherent monocytes isolated from blood of HIV-1 seronegative donors were cultured for various periods in RPMI 1640 medium supplemented wi |
| Mo.A.144 | 2-5A synthetase: activation by HIV-1 TAR RNA and RRE RNA and modulation by propentofylline in HIV-1 infected CEM cells. Int Conf AIDS 1996 Jul 7-12; 11:6 (abstract no. Mo.A.144) Leuck J, Scheffer U, Muller WE, Schroder HC; Inst. of Physiological Chemistry, University, Mainz, Germany. Fax: 49-6131-395243. E-mail: leuck@mzdmza.zdv.uni-mainz.de. Objective: To determine the structural elements of HIV-1 RNAs (TAR RNA and RRE RNA) that are able to activate the antiviral 2 ,5 -oligoadenylate (2-5A) system and to search for compounds that prevent the decrease in interferon (IFN)-inducible 2-5A synthetase activity during later stages of infection. Methods: Human T l |
| Mo.A.145 | Secretion of multiple chemokines in U1 cells: auto-crine upregulation of viral expression by MCP-1. Int Conf AIDS 1996 Jul 7-12; 11:6 (abstract no. Mo.A.145) Biswas P, Delfanti F, Vicenzi E, Sozzani S, Moro M, Mantovani A, Poli G; San Raffaele Scienific Institute, Milan, Italy. Fax: 39-2-2643-7989. Objective: To investigate the role of chemokines on HIV expression in the latently infected promonocytic UI cell line that is characterized by virus inducibility by several cytokines. Methods: HIV expression was measured in culture supernatants by the reverse transcriptase (RT) activity assay. Chemokine secretion: RANT |
| Mo.A.150 | Efficacy of a DNA vaccination to induce neutralizing antibody and cytotoxic cells against HIV-1. Int Conf AIDS 1996 Jul 7-12; 11:6 (abstract no. Mo.A.150) Fukushima J, Hamajima K, Asakura Y, Bukawa H, Tsuji T, Xin KQ, Nishioka K, Cullen BR, Okuda K; Yokohama City University School of Medicine, Yokohama, Japan. Fax: 81-45-787-2509. E-mail: jfukusim@med.yokohama-cu.ac.jp. Objective: The efficacy of DNA vaccines for protecting HIV-1 infection was studied by using expression plasmids for Gag, Env, and Rev proteins. Methods: We constructed expression vectors for HIV-1 genes driving cytomegalovirus promoter. These expression plasmids were injected with cationic liposomes into mice, rabbits, |
| Mo.A.151 | The combination of DNA and peptide vaccines induces strong immunities against HIV-1 in both humoral and CMI. Int Conf AIDS 1996 Jul 7-12; 11:6 (abstract no. Mo.A.151) Hamajima K, Fukushima J, Kaneko T, Bukawa H, Tsuji T, Xin KQ, Asakura Y, Okuda K, Nishioka K, Okuda K; Yokohama City University, Yokohama, Japan. Fax: 81-45-787-2509. Objective: We have reported that the synthetic peptide vaccine (VC1) against HIV induced a high level of neutralizing antibodies for various HIV isolates, and the DNA vaccine against HIV induced prolonged high CTI level. In the present study, we examined whether the combination of DNA vaccine and the peptide vaccine co |
| Mo.A.152 | A macromolecular multicomponent peptide vaccine candidate induces mucosal immunity against HIV-1. Int Conf AIDS 1996 Jul 7-12; 11:6 (abstract no. Mo.A.152) Hiroki B, Asakura Y, Tsuji T, Xin KQ, Sasaki S, Hamajima K, Fukushima J, Kawamoto S, Fujita K, Okuda K; Yokohama City University School of Medicine, Yokohama, Japan. Fax: 81-45-785-8438. Objective: To induce HIV-1-specific mucosal IgA antibody with neutralizing activity is of importance for development of HIV vaccine. Induction of secretory IgA antibody against HIV-1 was studied by oral, rectal and vaginal immunization with a new synthetic peptide vaccine candidate (VC1). Method: VC1 was composed of pe |
| Mo.A.153 | High dose HIV-1 MN recombinant gp160 (rgp160) vaccine induces anti-v3 MN, and IgG1-4 and IgA anti-rgp160 antibodies. Int Conf AIDS 1996 Jul 7-12; 11:7 (abstract no. Mo.A.153) Gorse GJ, McElrath MJ, Belshe RB, Corey L, Matthews T, Eibl M, Kennedy D, Frey S, Hsieh R, Walker MC; Division of Infectious Diseases, Saint Louis Univ. Health Sciences Center, St. Louis, MO. Fax: 314-771-3816. E-mail: gorsemd@sluvca.slu.edu. Objective: To evaluate the safety and immunogenicity of a mammalian cell-produced HIV-1 MN rgp160 vaccine (IMMUNO-AG) at a high dose in low-risk, HIV-1 uninfected volunteers. Methods: In an ongoing, double-blind, randomized study, subjects received 800 micrograms MN rgp160 at 0,1, and 6 months (N=8) or at 0,2, and 8 mo |
| Mo.A.154 | Chimeric human immunodeficiency virus gag particles as an antigen presenting vehicle. Int Conf AIDS 1996 Jul 7-12; 11:7 (abstract no. Mo.A.154) Nariyoshi H, Yasuda A, Kurata T, Kojima A; Dept. of Pathology, NIH, Tokyo, Japan. Fax: 3-5285-1189. E-mail: nhoshika@nih.go.jp. Objective: Viral antigens usually show the highest immunogenicity when they form virus-like particle structures. In this study, we examined whether human immunodeficiency virus (HIV) Gag particles work as immunogenic carriers for a hepatitis C virus (HCV) core epitope. Methods: The HIV-1 gag gene (BH10) was deleted of |
| Mo.A.155 | Immunogenicity of a live recombinant canarypox virus expressing gp120tm-MN/gag/protease-LAI (vCP205) boosted with a p24e/v3-MN peptide (CLTB-36) in HIV-negative volunteers (anrs vac 03). Int Conf AIDS 1996 Jul 7-12; 11:7 (abstract no. Mo.A.155) Salmon D, Excler JL, Finkielsztejn L, Chapuis L, Heshmati F, Gluckman JC, Autran B, Meignier B, Klein M, Sicard D; Hopital Cochin, Medecine Interne, Paris, France. Fax: 33-1-43 26 88 92. E-mail: Laufink@pratique.fr. 30 healthy volunteers at low risk for HIV infection were immunized with vCP205 at 105.8 TCID50 and or CLTB-36 240 micrograms, and randomly assigned. Results: At month 7 of lymphoproliferative response (LPR) and cytotoxic T lymphocyte activity (CTL) were as follows: (table: see text) Neutralizing antibodies to HIV-1 MN |
| Mo.A.156 | HIV-1 Pr55gag virus-like particles allow the access of polyproteins and defined epitopes to the MHC-I presentation-pathway. Int Conf AIDS 1996 Jul 7-12; 11:7 (abstract no. Mo.A.156) Ludwig D, Schirmbeck R, Reimann J, Wolf H, Wagner R; Institut fur Medizinische Microbiologie und Hygiene, Universitat Regensburg, Regensburg, Germany. Fax: +49 941 944 6402. Objective: In many viral infections, cell mediated immunity, in particular the cytotoxic T-cell response, plays a key role in the control of a viral infection. There is striking evidence to suggest that this may be also in the case of an HIV infection. Therefore we tested the capacity of different types of chimeric Pr5 |
| Mo.A.160 | Limited detection of HIV-1 subtypes by the Roche Amplicor Diagnostic polymerase chain reaction assay. Int Conf AIDS 1996 Jul 7-12; 11:7 (abstract no. Mo.A.160) Gleeson T, Montpetit M; HIV Genetics, Ottawa, Ontario, Canada. Fax: 613-957-7258. E-mail: mmontpetit@hpb.hwc.ca. Objective: To determine the effects of primer-template mismatches on Roche Amplicor Diagnostic polymerase chain reaction (PCR) results for HIV-1 strains not belonging to genetic subtype B. Methods: Computer analysis (OLIGSAN program) of homology between the Roche Amplicor PCR primer pair SK431/SK462 and 100 HIV-1 strai |
| Mo.A.161 | The effects of mutations on HIV-1 quantitation by RT/PCR. Int Conf AIDS 1996 Jul 7-12; 11:7 (abstract no. Mo.A.161) Christopherson CD, Kwok S; Roche Molecular Systems, Alameda, CA, USA. Fax: (510)814-2810. Primer design and amplification conditions were previously shown to effect 3 terminal mismatch tolerance (Kellog et. al., NAR 1990). In this study, we investigated the effect of internal primer-template mismatches on reverse transcription (RT)-PCR and of probe-template mismatches on probe capture efficiency. Templates |
| Mo.A.162 | Sensitive HIV antigen assay detecting HIV-1 group M, HIV-1 group O and HIV-2 core proteins. Int Conf AIDS 1996 Jul 7-12; 11:8 (abstract no. Mo.A.162) Louwagie J, Garrett PE, Mertens G, Van Geel A, Pollet D, van den Abeele A, Saman E; Innogenetics, Zwijdrecht, Belgium. Fax: 32 3 252 37 98. Objectives: To study the sensitivity and specificity of a newly developed antigen assay for the broad spectrum detection of HIV capsid antigens in human serum and to validate the confirmatory and immune complex dissociation reagents. Methods: The INNOTEST HIV Antigen mAb is a sandwich ELISA, based on a human immunoglob |
| Mo.A.163 | Use of synthetic peptides for differentiation between HIV 1 group M and group O, and for classification of group M (A - E) and group O strains into subtypes. Int Conf AIDS 1996 Jul 7-12; 11:8 (abstract no. Mo.A.163) Brust S, Knapp S, Gurtler LG; Behringwerke AG, Marburg, Germany. Fax: 49-6421-39-4680. E-mail: brust1@msmbwma.marburg.hoechst-ag.dbp.de. Objective: To develop synthetic peptide based immuno assays to differentiate between HIV 1 group M and group O infections. Furthermore to establish synthetic peptide based immuno assays suitable to classify Anti-HIV 1 positive sera into subtype A - E of group M and into different subtypes of group O. Methods: Relevant |
| Mo.A.164 | Sequencing HIV isolates using the GeneChip HIV PRT assay. Int Conf AIDS 1996 Jul 7-12; 11:8 (abstract no. Mo.A.164) Miyada CG, Liang V, Tran HM, Mittman M, Morris M, Kaplan P; Affymetrix, Inc., Santa Clara, CA, USA. Fax: 408-481-0422. E-mail: garry_miyada@affymetrix.com. Objective: To develop a fast method to accurately sequence HIV isolates using a novel method of hybridization to high-density arrays of oligonucleotide probes. Methods: The GeneChip HIV PRT Assay includes a high-density oligonucleotide array with probes complementary to the protease gene and 242 amino terminal residues |
| Mo.A.260 | Novel biological means of control of HIV and AIDS. Int Conf AIDS 1996 Jul 7-12; 11:8 (abstract no. Mo.A.260) Gallo RC; Institute of Human Virology, Medical Biotechnology Center, University of Maryland at Baltimore, Baltimore, MD, USA. Fax: 410-706-1952. E-mail: gallo@umbi.umdl.edu. 1) The C-C Cytokines (Rantes, MIP-1alpha, and MIP-1 ): These are a subset of chemokines which in turn are a subset of cytokines. Their known role was in inflammation. Last year we reported the discovery (Science, 270: 1560, 1995) that these molecules were potent inhibitors of HIV-1 and HIV-2 infection. We noted that th |
| Mo.A.270 | Plasma factors in human blood alter the entry and neutralization properties of HIV-1: implications for gp120-based vaccine approaches. Int Conf AIDS 1996 Jul 7-12; 11:8 (abstract no. Mo.A.270) Nara PL, Merges M, Wu SC, Spouge J; Virus Biology Section, LTCB, DBS, NCI-FCRDC, Frederick, MD. Fax: 301-846-6194. Conventional virology suggests one important aspect of viral tropism/pathogenicity is mediated by specific virus ligands interacting with specific cellular receptors. Factors, however, which govern and/or influence the specificity of these interactions within the host may involve colloidal or soluble molecules capable |
| Mo.A.271 | Removal of V3-specific antibodies from the serum of infected patients has minimal effect on neutralization of primary isolates of clade E HIV-1. Int Conf AIDS 1996 Jul 7-12; 11:9 (abstract no. Mo.A.271) Stamatos NM, VanCott TC, Mascola J, Loomis LD, Louder M, Birx DL; Walter Reed Army Institute of Research, Rockville, MD. Fax: 301-762-4177. E-mail: nstamatos@HIV.hjf.org. Objective: To determine the role of V3-specific antibodies in mediating neutralization of primary clade E viral isolates. To compare these results with previous reports demonstrating a minimal role for V3-specific antibodies in neutralizing primary clade B viruses. Methods: Sera from 3 HIV-infected patients from |
| Mo.A.272 | Role of factor H in resistance of HIV against complement-mediated destruction. Int Conf AIDS 1996 Jul 7-12; 11:9 (abstract no. Mo.A.272) Stoiber H, Pinter C, Spruth M, Mullauer B, Clivio A, Manfred P; Dierich Institut fur Hygiene, Universitat Innsbruck, Insbruck, Austria. Objective: In the study, presented here, the binding site of complement factor H (CFH) to the HIV envelope was mapped and a new functional CFH polymorphism was analyzed Methods: The binding of CFH-derived peptides, covering the whole short consensus repeat (SCR) 13, to gp120 and gp41 was determined by ELISA and inhibit |
| Mo.A.273 | Cross-clade neutralization of HIV-1 by homologous and heterologous sera and identification of three isolates that predicts the neutralizing capacity of sera across HIV-1 clades. Int Conf AIDS 1996 Jul 7-12; 11:9 (abstract no. Mo.A.273) Nyambi PN, Lewi P, Nkengasong J, Janssens W, Fransen K, Peeters M, Willems B, Heyndrickx L, Andries K, Ndumbe P, van der Groen G; Institute of Tropical Medicine, Antwerpen, Belgium. Fax: 32 3 247 63 33. Objectives: To study the neutralization spectra of 14 sera and of 16 primary isolates of individuals infected with HIV-1 group M (subtype A-H) and group O. To identify a limited number of primary HIV-1 key isolates which allow to predict the neutralization spectrum of a serum. Methods: Serum (SNS) and isolate neutraliz |
| Mo.A.274 | Inactivation of HIV-1 by recombinant antibodies. Int Conf AIDS 1996 Jul 7-12; 11:9 (abstract no. Mo.A.274) Parren PW, Fisicaro P, Barbas CF 3d, Burton DR; The Scripps Research Institute, Dept of Immunology and Molecular Biology, La Jolla, CA, USA. Fax: (619) 554-6360. E-mail: parren@scripps.edu. Objective: To isolate broadly neutralizing recombinant antibodies to HIV-1 and characterize neutralization in vitro and in vivo. Methods: Antibody phage display libraries were prepared from long-term HIV-1 seropositve donors. In initial experiments, monomeric HIV-1 envelope subunits were used for enrichment and screeni |
| Mo.A.275 | Beta-chemokines inhibit HIV-1 entry into CD4+ cells via the C-C CKR-5 co-receptor. Int Conf AIDS 1996 Jul 7-12; 11:37 (abstract no. Mo.A.275) Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayana C, Maddon PJ, Koup RA, Moore JP, Paxton WA; The Aaron Diamond AIDS Research Center, New York, NY. Fax: (212) 725-1126. The beta-chemokines MIP-1alpha, MIP-1beta and rantes inhibit infection of CD4+ T-cells by primary, NSI HIV-1 strains at the virus entry stage, and also block env-mediated cell-cell membrane fusion. CD4+ T-cells from some HIV-1 exposed-uninfected individuals cannot fuse with NSI HIV-1 strains and secrete high levels of |
| Mo.A.280 | Phase I/II evaluation of candidate AIDS vaccines. Int Conf AIDS 1996 Jul 7-12; 11:9 (abstract no. Mo.A.280) Graham BS; Vanderbilt University School of Medicine, Nashville, TN, USA. Development of a preventive vaccine for AIDS. Project: The AIDS Vaccine Evaluation Group (AVEG) sponsored by NIAID consists of 6 University-based clinical testing sites, 2 central laboratories, a central data processing and analysis unit, and administrative support to select vaccine candidates, evaluate safety, |
| Mo.A.281 | HIV immunity induced by canarypox (ALVAC)-MN gp160,-SF2 rgp120 or both. Int Conf AIDS 1996 Jul 7-12; 11:10 (abstract no. Mo.A.281) Clements ML, Weinhold K, Siliciano R, Schwartz D, Matthews T, Graham B, Keefer M, McElrath J, Gorse G, Hsieh R, Duliege A, Excler J, Meigner B, Tartaglia J, Paoletti E; Center for Immunization Research, Baltimore, MD, USA. Fax: 410-550-6898. Objective: To evaluate the priming and boosting effect of two recombinant HIV vaccines. Methods: 106 and 107 TCID50 of recombinant canarypox (ALVAC)-HIVMN gp160 and 50 micrograms HIV-1SF2 rgp120 in MF59, were given i.m. to uninfected, vaccinia-naive and vaccinia-immune adults at 0, 1 or 2, 6 or 9, and 12 months. ALVAC- |
| Mo.A.282 | AVEU 022: safety and immunogenicity of live recombinant canarypox vector containing the envelope, gag and protease genes of HIV-1 in seronegative adult volunteers. Int Conf AIDS 1996 Jul 7-12; 11:10 (abstract no. Mo.A.282) Corey L, Weinhold K, McElrath J, Excler JL, Duliege AM, Clements ML, Belche R, Dolin R, Graham B; NIAID AVEU, Univ. of Washington, Pasteur Merieux Corp. and The Biocine Corp., Seattle, WA. Fax: 1-206-621-4178. E-mail: lcorey@u.washington.edu. Objective: To define the immunogenicity and safety of vCP205, a recombinant canarypox vaccine that expresses the P55 gag gene (LAI strain), P15 protease (LAI strain), gp120 (MN strain), and transmembrane region of gp41 (TM) (LAI strain). Methods: Seventy six seronegative (SN) volunteers at low risk of HIV infection, re |
| Mo.A.283 | Induction of potentially protective immunity in humans with a recombinant subunit HIV-1 vaccine. Int Conf AIDS 1996 Jul 7-12; 11:10 (abstract no. Mo.A.283) Francis DP, McElrath MJ, Berman PW, Belshe RB, Fast P; Genenvax, South San Francisco, CA, USA. Fax: 415-225-3957. E-mail: francis.don@gene.com. Objective: To induce protective immunity against HIV-1 using a safe vaccine. Methods: Two candidate vaccines, one from strain LAI and one from strain MN, consisting of envelope glycoprotein (gp 120) were produced in CHO cells using recombinant DNA technology. Chimpanzees vaccinated with these vaccines were intravenousl |
| Mo.A.284 | Safety, immunity, and risk behavior in HIV-1-uninfected volunteers representing diverse risk populations following recombinant envelope vaccinations: a three-year followup. Int Conf AIDS 1996 Jul 7-12; 11:10 (abstract no. Mo.A.284) McElrath MJ, Montefiori D, Wolff M, Clements M, Gorse G, Keefer M, Graham B, Duliege AM, Francis D, Matthews T, Fast P, Corey L; Univ of Washington, Seattle WA, USA. Fax: 1-206-621-4178. E-mail: kd@u.washington.edu. Objectives: Through the conduct of a phase II multicenter placebo-controlled double-blind vaccine trial in HIV(-) volunteers with either high or low HIV-1 risk behavior, to compare the clinical and immune responses, to determine the kinetics of HIV-1 neutralizing Ab responses after 4 immunizations, and to evaluate risk |
| Mo.A.285 | Genetic and immunologic characterization of viruses infecting MN-rgp120 vaccinated volunteers. Int Conf AIDS 1996 Jul 7-12; 11:10 (abstract no. Mo.A.285) Berman PW, Gray A, Ashby M, Eastman D, Wrin T, Vennari JA, Francis D, Gregory T, Fast P, Schwartz D, Gorse G, McElrath MJ; Genetech, Inc., South San Francisco, CA. Fax: (415) 225-2006. Objective: To determine whether individuals who acquired HIV-1 infections, through high risk behavior, during vaccine safety and immunogenicity studies, were infected by viruses with envelope glycoproteins that resembled the vaccine immunogen, MN-rgp 120. Methods: 10 of 507 adults participating in Phase I and II vaccin |
| Mo.A.380 | Enhanced fidelity of 3TC-selected M184V HIV reverse transcriptase. Int Conf AIDS 1996 Jul 7-12; 11:11 (abstract no. Mo.A.380) Wainberg MA, Hsu M, Gu Z, Inouye P, Quan Y; McGill University AIDS Centre-Jewish General Hospital, Montreal, Quebec, Canada. Fax: 514-340-7537. E-mail: mdwa@musica.mcgill.ca. Objective: To determine the basis of success of 3TC in recent clinical trials that have reported increased CD4 counts and diminished viral burden. Specifically, we asked whether these findings might be attributable to an increase in fidelity of HIV reverse transcriptase conferred by the M184V substitution responsible f |
| Mo.A.381 | Mutations associated with 3TC-resistance enhance the polymerase fidelity of HIV-1 RT. Int Conf AIDS 1996 Jul 7-12; 11:11 (abstract no. Mo.A.381) Prasad VR, Drosopoulos W; Dept. of Microbiology & Immunology, Albert Einstein College of Medicine, Bronx, NY, USA. Fax: 718-430-8711. E-mail: Prasad@aecom.yu.edu Vinayaka. Objective: To determine whether mutations associated with 3TC-resistance confer an increased polymerase fidelity to HIV-1 reverse transcriptase. Methods: Recombinant wild type, Met184Val, Glu89Gly and Met184Val/Glu89Gly HIV-1 RT heterodimers were purified. These RTs were assayed in vitro, with model template-primers, f |
| Mo.A.382 | In vivo evidence for modulation of HIV-1 dynamics by target cell availability and cellular immunity. Int Conf AIDS 1996 Jul 7-12; 11:11 (abstract no. Mo.A.382) Goudsmit J, De Wolf F, Lukashov VV, Van Oers RH, Bakker M, Boucher CA, Danner SA; Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. Fax: 31-20-6916531. Objective: To assess the role of availability of HIV-1 susceptible cells and T cell immunity in the maintenance of HIV-1 steady-state levels during infection. Materials and Methods: Two late stage HIV-1 infected male homosexuals received two syngeneic bone marrow transplants (BMT) each, one with and one without prior h |
| Mo.A.383 | Retroviral fitness and drug selection pressure. Int Conf AIDS 1996 Jul 7-12; 11:11 (abstract no. Mo.A.383) Harrigan PR, Bloor S, Nowak M, Larder BA; Clinical Virology, Beckenham Kent, UK. Objective: To quantitate the effects of mutations conferring resistance to antiretrovirals such as zidovudine ( AZT ) on viral fitness and drug selection pressure. To allow estimation of steady state levels of given viral variants and patterns of development of drug resistance. Methods: Cultures of defined mixtures of |
| Mo.A.390 | Determinants of long-term non-progression: the relative contribution of viral burden and strain variation. Int Conf AIDS 1996 Jul 7-12; 11:11 (abstract no. Mo.A.390) Sheppard HW, Krowka J, Ascher M, Cuevas B, Dondero D, Lu E; Viral and Rickettsial Disease Laboratory, Calif. Dept. Health Services, Berkeley, CA, USA. Fax: (510)540-2127. E-mail: hsheppar@HIVnet.fhcrc.org. Objective: To determine the relative contribution of virus burden and virus strain variation to differences in the rate of progression from HIV-1 infection to AIDS. Do long-term non-progressors harbor attenuated strains of HIV-1? Methods: Longitudinal studies of virus burden (measured as cellular provirus or plasma RNA |
| Mo.A.391 | HIV-1-specific cytotoxic T lymphocyte and proliferative responses in peripheral blood mononuclear cells (PBMC) of subjects with stable non-progressing HIV-1 infection. Int Conf AIDS 1996 Jul 7-12; 11:11 (abstract no. Mo.A.391) Kalams SA, Harrer T, Harrer E, Billingsly M, Trocha AK, Shea A, Jones N, Hartman KE, He S, Johnson RP, Buchbinder SP, Walker BD; MGH-East, Charlestown, MA, USA. Fax: (617) 726-5411. Objective: To determine the immune correlates of long-term non-progression in HIV-1 infected subjects Methods: Long term non-progressors were asymptomatic gay men with CD4 counts greater than 500 cells/mm3, and a duration of infection of longer than 10 years. Control subjects were infected less than 7 years and had CD4 |
| Mo.A.392 | Characterization of a polyclonal cytolytic T lymphocyte response to human immunodeficiency virus in individuals without clinical progression. Int Conf AIDS 1996 Jul 7-12; 11:12 (abstract no. Mo.A.392) Lubaki MN, Dhruva B, Quinn TC, Siliciano RF, Bollinger RC; Johns Hopkins University, Ross Research Building, Baltimore, MD. Fax: 410-955-7889. E-mail: NLUBAKI@WELCHLINK.WELCH.JHU.EDU. Objective: To characterize a detailed clonal analysis of the cytolytic T lymphocyte (CTL) response to HIV-1 in two individuals who have been infected with HIV-1 for greater than 10 years and have maintained an absolute CD4 counts of greater than 800 cells/mm3. Methods: HIV-1-specific CTL activity was measured in fresh |
| Mo.A.393 | Immunological studies on the french cohort of 70 HIV-1-infected long-term non progressors (LTNP). Int Conf AIDS 1996 Jul 7-12; 11:12 (abstract no. Mo.A.393) Hadida F, Bonduelle O, Candotti D, Bouley JM, Costagliola D, Agut H, Rouzioux C, Goubar A, Clauvel JP, Sicard D, Autran B; Laboratoire D'Immunologie Cellulaire, Paris, France. Fax: (33 1) 42 17 74 90. Objective: To study the immunological parameters associated to the LTNP status with special regards for the CD4+ T helper cell reactivity to HIV. Methods: A cohort of 70 LTNP was recruited in 1994 on the following criteria: infection for at 8 years, positive or null CD4 T cell slope for the last 5 years above 600/mm3, |
| Mo.A.394 | HIV phenotype and interleukin-2/interleukin-10 ratio are associated markers of protection and progression in HIV infection. Int Conf AIDS 1996 Jul 7-12; 11:12 (abstract no. Mo.A.394) Clerici M, Balotta C, Salvaggio A, Riva C, Trabattoni D, Papagno L, Berlusconi A, Rusconi S, Villa ML, Moroni M, Galli M; Cattedra di Immunologia, Universita degli Studi di Milano, Milano, ITALY. Fax: 39-2-3821-0350. E-mail: mago@imiucca.csi.unimi.it. Objective: To establish possible correlations between virologic and immunologic markers of protection and progression in HIV-infected individuals. Methods: We cross-sectionally analysed the rate and extent of HIV replication; HIV phenotype; in vitro-stimulated cytokine production [interferon gamma and interleukin-2 (ty |
| Mo.A.395 | Microsatellite polymorphisms of the human TNF locus are associated with the rate of HIV disease progression. Int Conf AIDS 1996 Jul 7-12; 11:12 (abstract no. Mo.A.395) Khoo SH, Pepper L, Snowdon N, Wilkins EG, Valleley P, Ollier W; Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, UK. Background: The rate of immunological deterioration and progression to AIDS differs markedly between HIV-positive individuals, and may be influenced by cofactors, HIV phenotype and the host T-cell response. Production of TNFalpha stimulates viral replication and may accelerate progression and CD4 depletion. MHC polymor |
| Mo.A.400 | SIV-superinfection immunity in macaques is influenced by the dose of attenuated virus. Int Conf AIDS 1996 Jul 7-12; 11:12 (abstract no. Mo.A.400) Sharpe SA, Whatmore AM, Cook N, Polyanskaya N, Hall G, Rud E, Stott EJ, Cranage MP; CAMR, Porton Down, Salisbury, Wilts, United Kingdom. Fax: 44 1980 611310. Objective: To determine if the dose of live attenuated SIVmac used to immunise macaques influences the outcome of subsequent challenge with virulent, non-clonal virus. Methods: Ten rhesus macaques were inoculated with the SIVmac molecular clone C8, which has an attenuated phenotype in vivo due to a 12bp in-frame deleti |
| Mo.A.401 | Immune parameters among highly exposed, persistently seronegative (HEPS) Thai women. Int Conf AIDS 1996 Jul 7-12; 11:13 (abstract no. Mo.A.401) Rungruengthanakit K, Duerr A, Suriyanon V, Flowers L, Nagachinta T, Tansuhaj A, Kunangern D, de Boer M, Nelson KE; Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand. Fax: 66 53 221849. Objective: To investigate immunologic parameters associated with lack of sexual transmission of HIV to women despite repeated exposure to a single HIV-infected (HIV+) partner. Methods: Highly exposed persistently seronegative (HEPS) women were selected from an ongoing study of HIV transmission from HIV-infected (HIV+) |
| Mo.A.402 | Are high-risk HIV-seronegative Zambian women resistant or just lucky? Int Conf AIDS 1996 Jul 7-12; 11:13 (abstract no. Mo.A.402) Krowka JF, Allen S, Weinstein S, Santamaria C, Cuevas B, Gestner M, Sheppard H; California Dept. of Health Services, Berkeley, CA, and UCSF, San Francisco, CA. Fax: 510-540-2579. E-mail: SFJOHNK1@AOL. COM. Objective: To determine if T cell responses play a role in preventing infection of high-risk HIV-seronegative (HIV-) Zambian women. Methods: Blood from matched high-risk (married to HIV+ men) and low-risk HIV- Zambian women were analyzed to compare peripheral blood lymphocyte (PBL) proliferative responses to Candida, a |
| Mo.A.403 | Superinfection of HIV-2-infected pigtail macaques using two distinct isolates: identification of a window period for susceptibility. Int Conf AIDS 1996 Jul 7-12; 11:13 (abstract no. Mo.A.403) Otten RA, Ellenberger DL, Adams DR, Fridlund CA, Jackson E, Schochetman G, Rayfield MA; HIV Laboratory Investigations Branch, DASTLR, NCID, CDC, Atlanta, GA, USA. Fax: (404)639-1010. E-mail: rxol @ciddas1.em.cdc.gov. Objective: To establish and study homotypic mixed infections with two phenotypically and genotypically distinct primary isolates of HIV-2 using an established animal modeling system for human retroviral infection. Methods: Challenge stocks (102 macaque infectious doses) for a high syncytia-forming isolate from |
| Mo.A.404 | Immune correlates of protection in HIV vaccine efficacy trials in nonhuman primates. Int Conf AIDS 1996 Jul 7-12; 11:13 (abstract no. Mo.A.404) Heeney JL, Bogers WM, Mooij P, Teeuwsen V; Biomedical Primate Research Centre, Rijswijk, The Netherlands. Fax: +31-15-2843986. E-mail: heeney@bprc.nl. Objectives: To determine the nature of HIV-1 vaccine induced immune responses which correlate with protection from homologous as well as heterologous challenge with different isolates of HIV-1 in chimpanzees and SHIV in rhesus monkeys respectively. Methods: Within the ECCF programme a comparison of immune responses was |
| Mo.A.405 | Antagonism of vaccine-induced HIV-specific CD4+ T cells by primary HIV infection. Int Conf AIDS 1996 Jul 7-12; 11:13 (abstract no. Mo.A.405) Kent SJ, Greenberg P, Hoffman M, Corey L, McElrath MJ; Macfarlane Burnet Centre for Medical Research, Fairfield, Australia. Fax: + 61 3 9482 6152. E-mail: kent@burnet.mbcmr.unimelb.edu.au. Objective: Defining immune responses to HIV-1 vaccines which lead to favorable or unfavorable outcomes upon HIV-1 exposure will ultimately improve HIV vaccine design. Methods: T helper (Th) cell responses to HIV-1 were cloned and analyzed in a recipient of a candidate HIV-1 vaccine who subsequently became infected with |
| Mo.A.406 | Induction of primary isolate-neutralizing antibodies by candidate HIV-1 vaccines. Int Conf AIDS 1996 Jul 7-12; 11:14 (abstract no. Mo.A.406) Zolla-Pazner S, Berman P, Gregory T, Robert-Guroff M, Natuk R, Sinangil F, Steimer K; V.A. Hospital, New York, NY, USA. Fax: 212-951-6321. E-mail: ZOLLASo1@MCRCR6.MED.NYU.EDU. Objective: To determine if antibodies (Abs) that neutralize HIV-1 primary isolates are induced in chimpanzees and humans immunized with various candidate HIV-1 vaccines. Methods: Coded panels of sera from HIV-infected humans and from uninfected humans and chimpanzees immunized with various HIV-1 vaccines were tested fo |
| Mo.A.500 | Stimulation of HIV-1 LTR-directed transcription by the ras pathway requires the novel transcription factors RBF-1 and RBF-2. Int Conf AIDS 1996 Jul 7-12; 11:14 (abstract no. Mo.A.500) Bell B, Sadowski I; Department of Biochemistry and Molecular Biology, UBC, Vancouver, B.C., Canada. Fax: (604) 822-5227. E-mail: brbell@unixg.ubc.ca. Objective: We sought to determine the cis-acting DNA sequences necessary for the stimulation of HIV-1 transcription in response to the Ras signal transduction pathway in Jurkat T cells. Methods: We used cotransfection of activated Ras alleles with HIV-LTR-CAT reporter contructs to map the cis-acting DNA sequences essen |
| Mo.A.501 | Regulation of HIV transcription in T cells and macrophages: critical role of NF-kB activation, and its control by nuclear IkBalpha. Int Conf AIDS 1996 Jul 7-12; 11:14 (abstract no. Mo.A.501) Virelizien JL, Alcami J, Arenzana-Seis dedos F, Italy RT; Concerted Action ("R'ocio" project) of Eu Biomed programme, and Unite d'Immunologie Virale, Institut Pasteur, Paris, France. Objective: How HIV uses the environment of T cells and macrophages to benefit its own latency and replication needs to be understood to better adapt future antiviral interventions to the original strategy of this human lentivirus. Project: A network of European laboratories (project ROCIO, Concerted Action of the BIOME |
| Mo.A.502 | Cloning of a novel human protein that regulates NF-kB activity and delineation of phosphorylation events on Sp1: implications for HIV-1. Int Conf AIDS 1996 Jul 7-12; 11:14 (abstract no. Mo.A.502) Jin DY, Chun RF, Jeang KT; Molecular Virology Section, LMM, NIAID, NIH, Bethesda, MD, USA. Fax: (301) 402-0226. E-mail: kj7e@nih.gov. Objective: To characterize the direct effector mechanisms that activate HIV-1 LTR transcription factors Sp1 and NF-kB by identifying novel regulatory second messengers and phosphorylation events. Methods: cDNA libraries were screened to identify a novel human antioxidant (AOE372). Full-length sequence of this cDNA was |
| Mo.A.503 | Transdominant mutants of IkBalpha interfere with HIV-1 gene expression and replication. Int Conf AIDS 1996 Jul 7-12; 11:14 (abstract no. Mo.A.503) Hiscott J, Lin R, Beauparlant P, Kwon H, Clarke M, Gessani S, Belardelli F, Wainberg M; Lady Davis Institute, Montreal, Quebec, Canada. Fax: 514-340-7576. E-mail: MIJH@MUSICA.McGILL.CA. Objectives: NF-kB/Rel transcription factors participate in the coordinate activation of HIV-1 and cytokine gene expression. In the present study, transdominant negative mutants of IkBalpha were examined for their ability to interfere with Tat-TNF activation of the HIV-1 LTR and HIV-1 replication. Methods: Point mutatio |
| Mo.A.510 | Survey on HIV-1 group O infection in 12 different African countries. Int Conf AIDS 1996 Jul 7-12; 11:14 (abstract no. Mo.A.510) Peeters M, Mboup S, Gueye A, Liegeois F, Patrel D, Vanden Haesevelde M, Delaporte E; Service de Bacterio - virologie Hopital de Dantec B.P., Dakar, Senegal. Fax: 22121 64 42. Objective: To determine to what extend HIV-1 group O strains are present in different African countries Materials and Methods: 11985 sera from 12 different African countries were tested ( Senegal , Mali , Togo , Burkina Faso , Niger , |
| Mo.A.511 | HIV-1M diversity analysed by serological subtyping: what assay, what antigens, significance? Int Conf AIDS 1996 Jul 7-12; 11:15 (abstract no. Mo.A.511) Barin F, Plantier JC, Buzelay L, Poisson F, Simon F, Peeters M; laboratoire de Virologie, CHU Bretonneau, France. Fax: (33) 47473610. Objective: To develop performing assays for serological subtyping of HIV-1M infection and determine their value for epidemiological studies of HIV-1M diversity. Methods: We synthesized 30 aa long peptides representing the consensus sequences of the V3 regions from I) 8 subtypes defined by genetic analysis (Myers et al, |
| Mo.A.512 | Detection of incident HIV infection using a reflex algorithm of laboratory testing methods. Int Conf AIDS 1996 Jul 7-12; 11:15 (abstract no. Mo.A.512) Galli RA, Major C, Fearon M, Swantee C, Francis A, Gregory B; HIV Laboratory, Ontario Ministry of Health, Etobicoke, Ontario, Canada. Fax: (416) 235-6194. Objective: To examine the efficacy of a laboratory testing algorithm for detection of incident cases of HIV in a population with varying exposure categories, with particular focus on the window period of infection. Methods: A retrospective analysis of the results of 256,265 specimens that were applied to a laboratory a |
| Mo.A.513 | Multicentre evaluation of alternative methods for CD4 lymphocyte determination. Int Conf AIDS 1996 Jul 7-12; 11:15 (abstract no. Mo.A.513) Lyamya EF, Schechter M, Echeverria de Perez G, Vercauteren G; Department of Microbiology/Immunology, Muhimbili Medical Centre, Dar es Salaam, Tanzania. Fax: +255 51 44 544. Objective: To evaluate the performances of four simpler and cheaper alternative methods for CD4 lymphocyte determination as compared to the reference method, (flow cytometry) in less-industrialized countries ( Brazil , Tanzania , Venezuela ). Methods: The performance of the FACScount (Becton Dicki |
| Mo.A.520 | HIV-1 secreted viral antigens(SVA), polyphosphazene adjuvant, and SHIV challenge model. Int Conf AIDS 1996 Jul 7-12; 11:15 (abstract no. Mo.A.520) Lu Y, Touzjian N, Kushner N, Chutkowski C, Qian H, Jenkins S, Payne L, Roberts B; Virus Research Institute, Cambridge, MA, USA. Fax: 617-864-6334. E-mail: 72054.701@compuserv.com. Objective: To evaluate the efficacy of novel HIV-1 vaccine formulations composed of secreted viral antigens plus a unique adjuvant in rhesus monkeys. Methods: 1) HIV-1 SVA are prepared from a fibroblast cell line that is transformed with a genetically engineered HIV-1 provirus that is able to express all major viral pr |
| Mo.A.521 | Immunogenicity of modified, recombinant HIV-1 virus-like particles in rhesus monkeys. Int Conf AIDS 1996 Jul 7-12; 11:15 (abstract no. Mo.A.521) Wagner R, Teeuwsen V, Deml L, Heeney J, Wolf H; Inst. of Medical Microbiology, University of Regensburg, Germany. Fax:.49 941 944 6402. E-mail: Ralf. Wagner@klinik.uni.rejensburg.de. Objective: To develop a safe antigen delivery systems, which contributes towards defining the role of different arms of the immune system, that confer protection Methods: When expressed in insect cells, the HIV group specific antigen (gag) self assembles to highly immunogenic virus-like particles (VLP). The immunogenic |
| Mo.A.522 | Induction of HIV-1 nef specific CTLs by nef expressing DNA vaccine. Int Conf AIDS 1996 Jul 7-12; 11:16 (abstract no. Mo.A.522) Asakura Y, Hamajima K, Fukushima J, Kaneko T, Tsuji T, Sasaki S, Bukawa H, Mohri H, Ohkubo T, Okuda K; Yokohama City University, Yokohama, Japan. Fax: 81-45-787-2509. Objective: Recent studies have revealed the importance of HIV-1 specific CTLs for preventing the establishment of infection and prolongation of entire clinical course in the infected individuals. Among many epitopes of HIV-1 CTL determinants, Nef is thought to be one of the essentials in preventing the establishment of |
| Mo.A.523 | Induction of immune responses by DNA of HIV-1 regulatory and structural genes. Int Conf AIDS 1996 Jul 7-12; 11:16 (abstract no. Mo.A.523) Wahren B, Hinkula J, Benthin R, Lundholm P, Svanholm C, Okuda K, Schwartz S; MTC, Karolinska Institute, Swedish Institute for Infectious Disease Control, Stockholm, Sweden. Fax: +46-8-272231. Objectives: We aim to induce immunity to HIV by vaccination with regulatory and structural genes. Methods: The selected genes of HIV-1 tat, nef, rev, envelope gp160 and nucleoprotein were transactivated by the human cytomegalovirus promoter IE and named pHCMVsrev, pHSCVtat, pHCMVnef, pCMVgp160 and pCMVp37gag. Intramusc |
| Mo.B.110 | Persistent oral ulcers in HIV infection: clinicopathologic correlation with salivary human herpes viruses. Int Conf AIDS 1996 Jul 7-12; 11:16 (abstract no. Mo.B.110) Flaitz CM, Boldogh I, Nichols CM, Albrecht T; Department of Stomatology, Dental Branch, University of Texas-Houston Hlth Sci Ctr, Houston, TX. Fax: 713-792-2383. Objective: The purpose of this prospective study was to characterize the clinical and histopathologic features of persistent oral ulcers (POUs) in HIV infection and correlate these findings with various human herpes viruses (HHVs) in saliva. Methods: Sixty-two consecutive HIV-positive patients with POUs (duration great |
| Mo.B.111 | A long-term randomized controlled clinical trial comparing fluconazole and itraconazole in the treatment of AIDS patients with candida esophagitis. Int Conf AIDS 1996 Jul 7-12; 11:16 (abstract no. Mo.B.111) Barbaro G, Grisorio B, Calderon W, Di Lorenzo G, Barbarini G; Clinic of Infectious and Tropical Diseases IRCCS, S. Matteo University of Pavia, Pavia, Italy. Fax: 39-382-423320. Introduction: Contrasting opinions exist about the pharmacological treatment of esophageal candidiasis in HIV-positive patients and little information is actually available regarding the response of Candida esophagitis to antifungal therapy. Aim of the study has been to assess the long-term therapeutic efficacy of fluc |
| Mo.B.112 | Fluconazole resistant mucosal candidiasis in advanced HIV infection. Int Conf AIDS 1996 Jul 7-12; 11:16 (abstract no. Mo.B.112) Fichtenbaum CJ, Koletar S, Yiannoutsos C, Chen D, Cohn S, Pottage J, Powderly W; Fax: 314-361-5231. E-mail: fichtenbaum@visar.wustl.edu. Objective: To define the epidemiology of fluconazole resistant candidiasis in advanced HIV infection. Methods: ACTG 816 is a prospective, multicenter observational study of the incidence, risk factors and outcome of resistant mucosal candidiasis in HIV-infected persons with CD4+ lymphocyte counts less than 100 cells/mm |
| Mo.B.113 | Complications in gastrointestinal CMV disease-prevalence, characteristics and clinical outcome. Int Conf AIDS 1996 Jul 7-12; 11:17 (abstract no. Mo.B.113) Heise W, Arasteh K, Mostertz P, Schmidt W, Biniek B, Grosse G, L'age M; Auguste-Viktoria-Hospital, Berlin, Germany. Fax: 0049-30-7903 2005. Objective: To determine the prevalence of life-threatening complications such as bleeding, perforation or obstruction in Cytomegalovirus ( CMV ) gastrointestinal(GI) disease in AIDS. Methods: CMV disease in the GI tract was diagnosed in 257 symptomatic patients with AIDS. Life-threatening complications were defined as |
| Mo.B.114 | Clinical manifestations, extraintestinal complications and long-term course of intestinal Enterocytozoon bieneusi microsporidiosis. Int Conf AIDS 1996 Jul 7-12; 11:17 (abstract no. Mo.B.114) Briner D, Meister TH, Luthy R, Weber R; Division of Infectious Diseases, University Hospital of Zurich, Zurich, Switzerland. Fax: 41-1-255 32 91. Objective: To determine the clinical manifestations, complications, and the long-term course of E. bieneusi-infection. Methods: 55 HIV+ patients (5 women, 50 men) with E. bieneusi-infection were studied. Patients were prospectively followed in the ongoing Swiss HIV cohort study (SHCS) which included the evaluation of p |
| Mo.B.115 | Prospective evaluation of the clinical significance of intestinal microsporidiosis in 2 cohorts of HIV-infected patients. Int Conf AIDS 1996 Jul 7-12; 11:17 (abstract no. Mo.B.115) Albrecht H, Sobottka I, Ziellmann M, Meyer S, Jackle S, Stellbrink HJ, Greten H; University Clinic Eppendorf, Hamburg, Germany. Fax: xx49-40-47175187. E-mail: albrecht@uke.uni-hamburg.de. Objective: To determine the clinical significance of intestinal microsporidiosis in two different cohorts of HIV-infected patients and to compare the sensitivity and specificity of different diagnostic methods. Methods: Two prospective studies were performed: a) Between November 1993 and September 1994 stool samples of |
| Mo.B.116 | Itraconazole oral solution (IS) compared with fluconazole (F) for treatment of esophageal candidiasis (EC). Int Conf AIDS 1996 Jul 7-12; 11:17 (abstract no. Mo.B.116) Moskovitz BL, Wilcox CM, Darouiche R, Wu J, Mallegol I; Janssen Research Foundation, Titusville, NJ. Fax: 609-730-3044. Objective: To demonstrate comparable safety and equivalent efficacy of IS, a cyclodextrin formulation with greater bioavailability than itraconazole capsules, to F for treatment of EC in immunocompromised patients. Methods: This was a double-blind, double-dummy study. Patients were randomized equally to IS or F, 100-20 |
| Mo.B.117 | Itraconazole oral solution (IS) for the treatment of oropharyngeal candidiasis (OC): results of two randomized, blinded studies. Int Conf AIDS 1996 Jul 7-12; 11:17 (abstract no. Mo.B.117) Darouiche RO, Graybill JR, Vazquez J, Murray P, Wu J, Moskovitz BL; VA Medical Center, Houston, TX, USA. Fax: 713-794-7045. Objective: To compare the safety and efficacy of IS (cyclodextrin formulation) with clotrimazole and fluconazole (F) in HIV+ patients (pts) with OC. Patients: Study 1 (IS vs C) = 162 total pts enrolled, 134 HIV+ enrolled, 123 HIV+ evaluated; Study 2 (IS vs F) = 190 HIV+ pts enrolled, 179 evaluated; all pts evaluated ha |
| Mo.B.118 | Gastric hypochlorhydria is associated with mycobacterium avium complex (MAC) infection in patients with HIV/AIDS. Int Conf AIDS 1996 Jul 7-12; 11:18 (abstract no. Mo.B.118) Koch J, Scott MK, Morgan D, Steuerwald M, Lor E, Cello JP; Div. of GI, San Francisco General Hospital, San Francisco, CA. Fax: 415-641-0745. E-mail: hannes@itsa.ucsf.edu. Purpose: To determine the association between gastric hypochlorhydria and MAC infection in patients with HIV/AIDS. Methods: Evaluation of gastric fluid aspirate in patients with HIV/AIDS (study group) and patients not HIV-infected (control group) undergoing elective endoscopy (off all proton pump inhibitors and histami |
| Maintenance of long-term virus suppression in patients treated with the HIV-1 protease inhibitor Crixivan (indinavir). Int Conf AIDS 1996 Jul 7-12; 11:18 (abstract no. Mo.B.170) Emini EA, Condra JH, Schleif WA, Massari FE, Leavitt RY, Deutsch PJ, Chodakewitz JA; Merck Research Laboratories, West Point, PA, USA. Fax: 215-652-0994. E-mail: emilio_emini@merck.com. Objective: Loss of Indinavir-mediated virus suppression seen in some patients during treatment with the inhibitor has been shown to be associated with the selection of viral variants expressing reduced Indinavir susceptibility. However, the apparent probability and timing of resistant virus selection varies widely amon |
|
| Concurrent ritonavir and rifabutin increases risk of rifabutin-associated adverse events. Int Conf AIDS 1996 Jul 7-12; 11:18 (abstract no. Mo.B.171) Sun E, Heath-Chiozzi M, Cameron DW, Hsu A, Granneman RG, Maurath CJ, Leonard JM; Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL, USA. Fax: 847-938-3711. E-mail: sune@randb.abbott.com. Rifabutin is used for the prophylaxis and treatment of MAC infection in AIDS patients. Dose-related side effects include uveitis, skin discoloration, and arthralgia/arthritis.1 Ritonavir (ABT-538) is a potent inhibitor of the HIV protease, and has demonstrated clinical and virologic efficacy in a placeb |
|
| Efficacy and safety of triple combination therapy with Invirase (saquinavir/SQV/HIV protease inhibitor), Epivir (3TC/lamivudine) and Retrovir (ZDV/zidovudine) in HIV-infected patients. Int Conf AIDS 1996 Jul 7-12; 11:18 (abstract no. Mo.B.172) Baruch A, Mastrodonato-Delora P, Schnipper E, Salgo M; Hoffmann-La Roche, Nutley, New Jersey. Fax: (201) 812-3629. Objective: To provide activity and safety data for SQV in combination with ZDV and 3TC Methods: A total of 33 HIV+ patients, naive to antiretroviral therapy and with CD4 counts 150-500 cells/mm3 were enrolled in an exploratory, single arm open-label study of combination treatment with SQV 600 mg tid, 3TC 150 mg bid and |
|
| Extended follow-up of safety and activity of agouron's HIV proteinase inhibitor ag1343 (Viracept) in virological responders from the UK phase I/II dose finding study. Int Conf AIDS 1996 Jul 7-12; 11:18 (abstract no. Mo.B.173) Moyle GJ, Youle M, Higgs C, Monaghan J, Peterkin J, Chapman S, Nelson M; Kobter Centre, Chelsea And Westminister Hospital, London, UK. Fax: UK 171 938 3460. Introduction: In the first 28 day open-label phase I/II dose escalation trial with AG1343, HIV-positive therapy naive persons, with baseline CD4 200-500 cells/mm3 and viral loads greater than or equal to 20000 copies/ml (by bDNA) were treated with doses of 771 (N=10) and 1026 mg (base equivalent)/day (N=10) of AG1343 [ |
|
| Indinavir (MK 639) drug interaction studies. Int Conf AIDS 1996 Jul 7-12; 11:18 (abstract no. Mo.B.174) McCrea JB; Clinical Pharmacology, Merck Research Laboratories, West Point, PA, USA. Fax: 610-834-0213. Objective: To evaluate potential pharmacokinetic interactions between indinavir (MK 639; IDV) with drugs that are P-450 3A substrates and/or with drugs that are frequently prescribed to HIV-infected patients. Methods: Seven studies used a 3-period crossover design: IDV given alone, in combination with the other drug of |
|
| A triple combination of Ritonavir+AZT+ddC as a first line treatment of patients with AIDS: update. Int Conf AIDS 1996 Jul 7-12; 11:19 (abstract no. Mo.B.175) Mathez D, Bagnarelli P, De Truchis P, Gorin I, Katlama C, Pialoux G, Ruggeri C, Saimot AG, Tubiana R, Chauvin JP, Clementl J, Leibowitch J; Hopital Raymond Poincare, Garches, France. Objective: To combine one potent HIV-1 protease inhibitor with 2 synergistic nucleoside analogues in treatment-nave patients with advanced HIV infections. Patients and methods: 29 virus-culture positive HIV-1 infected adults with less than 250 CD4/microgram 1 were offered an ethical review board-approved open label com |
|
| Evaluation of the safety and efficacy of SPV-30 (boxwood extract) in patients with HIV disease. Int Conf AIDS 1996 Jul 7-12; 11:19 (abstract no. Mo.B.180) Pharo A, Salvato P, Thompson C, Stokes D, Mastman B, Keister R; Twelve Oaks Hospital, Houston, TX. Fax: (713) 960-7910. Objective: To determine if SPV-30, an all natural boxwood evergreen extract, manufactured by Arkopharma in France is safe and efficacious in HIV disease. Methods: HIV-1 viral load measured by RNA PCR and dDNA, CD4 counts and CD8, counts were evaluated in 173 HIV patients. Baseline viral load ranged from virtually no HI |
|
| Nationwide longitudinal outcomes study of HIV/AIDS alternative therapies. Int Conf AIDS 1996 Jul 7-12; 11:19 (abstract no. Mo.B.181) Standish LJ, Calabrese C, Reeves C; Bastyr University AIDS Research Center, Seattle, WA, USA. Fax: 206-517-3599. E-mail: ljs@bastyr.edu. Objective: The Bastyr University AIDS Research Center was established in October 1994 by the NIH s Office of Alternative Medicine. The mission of the Center is 1) to describe forms and patterns of use of alternative medical (AM) therapies for the treatment of HIV+ patients, either prescribed by practitioners or self-ad |
|
| Mo.B.182 | A standardized clinical assessment tool on the use of alternative therapies by HIV-positive individuals. Int Conf AIDS 1996 Jul 7-12; 11:19 (abstract no. Mo.B.182) Sabo CE, Paterson MA, Carwein VL; University of Nevada, Las Vegas, College of Health Sciences Las Vegas, NV. Fax: 702-895-1356. E-mail: csabo@ccmail.nevada.edu. There is currently no standardized clinical tool to assess the use of alternative therapies in HIV-positive individuals. Project: A tool which can be used to assess the use of alternative therapies in HIV-positive individuals is developed based on a survey of 127 HIV-positive individuals who used alternative the |
| Mo.B.183 | Use of alternative treatments for HIV: patterns and correlates. Int Conf AIDS 1996 Jul 7-12; 11:19 (abstract no. Mo.B.183) Collins RL, Kanouse DE, Senterfitt JW, McCutchan AJ, Wenger NS, Fleishman JA, Marshall GN, Kelly MD, Grant I, Bozzette SA; RAND, Santa Monica, CA, USA. Fax: (310) 451-6917. E-mail: RebeccaCollins@rand.org. Objective: To determine the extent to which those who use alternative treatments fail to disclose this to medical providers or substitute these treatments for more conventional therapies, and to identify correlates of these behaviors. Methods: One hundred forty HIV+ persons being followed at the UCSD Neurobehavioral Re |
| Mo.B.184 | Evolving strategic planning in complementary therapies: a national care, treatment & support approach. Int Conf AIDS 1996 Jul 7-12; 11:20 (abstract no. Mo.B.184) Bhatia R, McDonald J; Health Canada, HPSB, AIDS Care, Treatment Division, Ottawa, Ontario, Canada. Fax: 613-941-3526. In North America, upwards of 70% of HIV-positive persons make use of complementary therapies. In Canada , few resources have been committed and little done to take a national approach to the use and place of complementary therapies in HIV/AIDS treatment. Project: In November of 1995 the AIDS Care, Treatment and |
| Mo.B.190 | A training program to enhance nurses' clinical assessment of HIV patients via standardized procedures. Int Conf AIDS 1996 Jul 7-12; 11:20 (abstract no. Mo.B.190) Katsufrakis PJ, Hummel D, Saunders JM, Nyquist JG; Pacific AIDS Education and Training Center, University of Southern California, Los Angeles, CA. Fax: (213)342-2663. Nurses approach to health promotion, symptom management and integrated care is needed by patients with HIV. This program increases nursing participation in primary care of HIV/AIDS patients, necessary in the face of increasing numbers of patients, inadequate access to care, and burnout of existing providers. Pro |
| Mo.B.191 | Who is serving whom: the challenge of continuity and customer service. Int Conf AIDS 1996 Jul 7-12; 11:20 (abstract no. Mo.B.191) Veldhorst G, Grondin M, Harrison H; The Wellesley Hospital, Toronto, Ontario, Canada. Fax: 416-926-7924. People living with HIV receiving care at a medium sized teaching hospital were concerned that the traditional models in which nursing care was delivered was not satisfactorily meeting their needs. Frequent interactions with the health care system and the complex physical manifestations affecting the body, mind a |
| Mo.B.193 | Knowledge and attitudes regarding HIV infection among auxiliary nurses working at IMIP's hospital. Int Conf AIDS 1996 Jul 7-12; 11:20 (abstract no. Mo.B.193) Araujo WS, Souza E, Santos R, Mendonca K, Cantarutti L; Instituto Materno Infantil de Pernambuco (IMIP), Recife, Pernambuco, Brazil. Fax: 55-81-2226591. Objective: To determine the current knowledge and attitudes of auxiliary nurses (AN) working at Instituto Materno Infantil de Pernambuco s (IMIP) Hospital, reference center for mother and child health and HIV infection in children, in a cross-sectional study. Methods: On July 1995, 100 out of 400 AN working at IMIP wer |
| Mo.B.194 | Continuity of nursing care in an HIV outpatient clinic. Int Conf AIDS 1996 Jul 7-12; 11:20 (abstract no. Mo.B.194) Wilkinson M, Pullen S, Phillips M; Grahame Hayton Unit, Ambrose King Centre, Royal London Hospital, England, UK. Project: To implement a system providing continuous care by the same nurse throughout a patient s stay in the clinic. The nursing staff comprised of three registered general nurses, all with post-registration HIV training and varying levels of both general and HIV nursing and research experience. A total of 344 patient |
| Mo.B.195 | Health care personnel education on AIDS. Int Conf AIDS 1996 Jul 7-12; 11:20 (abstract no. Mo.B.195) Simpson C, Augustine J; C.M.C. Hospital, Vellore, India. Issues: Nursing personnel have irrational fear towards AIDS Care. Projects: Education plays a major role in prevention of HIV infection and enhancement of compassionate care to AIDS patients. Hence, inservice education was arranged in all the clinical departments, by the supervisor. Protocols on AIDS care was prepared |
| Mo.B.196 | Outcomes of an undergraduate HIV/AIDS nursing elective: insightful learning to promote quality care. Int Conf AIDS 1996 Jul 7-12; 11:21 (abstract no. Mo.B.196) Wyness MA, Goldstone I, Trussler T; University of British Columbia, Vancouver, BC, Canada. Fax: (604) 822-7466. E-mail: wyness@nursing.ubc.ca. Research has shown that nursing students knowledge about HIV/AIDS is frequently inadequate and that fostering the values, attitudes, skills and professional confidence required to provide quality nursing care is the major challenge for educators. Project: An undergraduate HIV/AIDS elective was developed in colla |
| Mo.B.290 | Effect of nucleoside analogue RT inhibitors on plasma HIV RNA and CD4 count as an indicator of clinical effect. Int Conf AIDS 1996 Jul 7-12; 11:21 (abstract no. Mo.B.290) Phillips AN, Eron J, Bartlett J, Hill AM; HIV Research Unit, Dept. Primary Care and Population Sciences, Royal Free Hospital School of Medicine, London, UK. Fax: UK 171-794-1224. E-mail: andrew@rfhsm.ac.uk. Objective: To assess the extent to which the effect of combination therapy with zidovudine + lamivudine ( 3TC ) on plasma HIV RNA and the CD4 count is translated into a clinical effect. Methods: For 620 patients randomised in the North American NUCA3001 (n=366; zdv/3TC vs zdv vs 3TC in zdv nai |
| Mo.B.291 | A randomized, comparative trial of ZDV versus ZDV plus ddI versus ZDV plus ddC in persons with CD4 cell counts of less than 200/mm3. Int Conf AIDS 1996 Jul 7-12; 11:21 (abstract no. Mo.B.291) Saravolatz LD, Collins G, Hodges D, Winslow D, Pettinelli C; Infectious Diseases Division, Henry Ford Hospital, Detroit, MI. Fax: (313) 876-2993. Terry Beirn Community Programs for Clinical Research on AIDS 007 Protocol Team, NIAID, Bethesda, Maryland, USA Objective: To compare the efficacy of zidovudine (ZDV) alone, ZDV given with didanosine (ZDV + ddI ), and ZDV given with |
| Mo.B.292 | HIV viral load changes in delta patients. Int Conf AIDS 1996 Jul 7-12; 11:21 (abstract no. Mo.B.292) Brun-Vezinet F; Laboratoire de Virologie, Hopital Bichat, Paris, France. Fax: 33 1 46 27 02 08. Objective: To study correlation between viral load changes, immunological evolution and clinical outcome in a subset of Delta 1 AZT-naive patients. Methods: A total of 230 patients were recruited in 22 selected centers in France , UK and Netherlands for virological studies including viral load quantitation. |
| Mo.B.293 | Suppression of plasma HIV RNA by reverse transcriptase inhibitors prevents AIDS and death in ACTG 175; combination and monotherapy with ZDV, ddI and ddC. Int Conf AIDS 1996 Jul 7-12; 11:21 (abstract no. Mo.B.293) Katzenstein DA, Hammer S, Hughes M, Gundacker H, Jackson B, Fiscus S, Lathey J, Rasheed S, Reichman R, Elbeik T, Japour A, D'Aquila R, Scott W, Griffiths B, Winters M, Merigan T, Hirsch M; Stanford University Medical Center, Stanford, CA. Fax: 415-725-2395. E-mail: ml.dak@forsythe.stanford.edu. Objective: To Determine the importance of CD4 cells, quantitative HIV plasma viremia and syncytia inducing (SI) virus on 50% CD4 cell decline, AIDS, and death in a study of reverse transcriptase inhibitor (RTI) Therapy; specifically ZDV, ZDV/ ddI , ZDV/ ddC , |
| Mo.B.294 | A randomized, double-blinded comparative trial of the effects of zidovudine, didanosine and nevirapine combinations in antiviral naive, AIDS-free, HIV-infected patients with CD4 counts 200-600/mm3. Int Conf AIDS 1996 Jul 7-12; 11:22 (abstract no. Mo.B.294) Myers MW, Julios GM; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA. Fax: (203) 798-5433. Objective: To compare the safety, tolerability, immunological and virological activity of 2 and 3 drug combination therapy regimens including zidovudine (ZDV), didanosine ( ddI ) and |
| Mo.B.295 | Delavirdine (DLV) combined with zidovudine (ZDV) or didanosine (ddI) produces sustained reduction in viral burden and increases in CD4 count in early and advanced HIV-1 infection. Int Conf AIDS 1996 Jul 7-12; 11:22 (abstract no. Mo.B.295) Freimuth WW, Chuang-Stein CJ, Greenwald CA, Wathen LK, Edge-Padbury BA, Cox SR, Daenzer CL, Wang Y, Carberry PA; Pharmacia & Upjohn, Inc., Kalamazoo, MI. Objective: Delavirdine a potent non-nucleoside reverse transcriptase inhibitor, effectively inhibits both RNA- and DNA-directed polymerase functions of HIV-1 reverse transcriptase and has been shown to be synergistic with ZDV (in ZDV sensitive and resistant strains) and ddI |
| Mo.B.300 | Traditional medicine is a valid local alternative for the treatment of chronic diarrhea and Herpes zoster in AIDS patients in Kampala, Uganda. Int Conf AIDS 1996 Jul 7-12; 11:22 (abstract no. Mo.B.300) Homsy J, Kabatesi D, Kwamya L, Tusaba C, Kasolo S, Okello M, Ssentamu L, Mwebe D, Nshakira N, Mubiru F, King R, Katabira E; TASO THETA Project, Kampala, Uganda. Fax: 256-41-530'619 or 267'113 or 268'498. E-mail: msftheta@imul.com. Objective: To evaluate the effectiveness of traditional herbal medicine for the treatment of chronic diarrhea (CD) and Herpes Zoster (HZ) in HIV-infected patients in Kampala, Uganda . Methods: Trials were conducted in 2 phases. In phase I, test patients were selected, enrolled and followed-up at 3 healers clinics by t |
| Mo.B.301 | Alternative therapy use in HIV-positive women. Int Conf AIDS 1996 Jul 7-12; 11:22 (abstract no. Mo.B.301) Meneilly GP, Carr R, Brown L; Oak Tree Clinic, Vancouver, BC, Canada. Fax: 604-875-3063. E-mail:gmeneilly@unixg.ubc.ca. Objective: To characterize the use of alternative therapies in a group of HIV-positive women. Methods: Forty-two percent (26/62) of female patients attending an ambulatory HIV clinic were identified as using alternative therapies. Using a structured telephone interview, the use of alternative therapies in this populati |
| Mo.B.302 | A model of collaborative naturopathic and allopathic medicine in primary HIV health care. Int Conf AIDS 1996 Jul 7-12; 11:22 (abstract no. Mo.B.302) Luby KP, Rubin G; Rubin G The delivery of health care to patients with HIV is continually evolving, driven predominantly by our own patients as they pursue alternatives to allopathic medicine. This has necessitated openmindedness on the part of physicians and commitment to cooperation on the part of complementary therapists to ensure com |
| Mo.B.303 | Meta-survey of plant and herb material as a treatment for HIV. Int Conf AIDS 1996 Jul 7-12; 11:22 (abstract no. Mo.B.303) Chang RY, Kong XB; Cornell Medical College, New York, NY, USA. Fax: 212-717-3367. E-mail: changr@mskcc.org. Objective: To identify the current scope and nature of plant and herbal compounds and extracts potentially useful in anti-HIV treatment, and their state of research and development. Methods: A comprehensive search of the published literature since 1982 on all plant and herbal compounds or extracts screened for anti-HIV |
| Mo.B.304 | Effects of aerobic and resistive exercise on symptoms, immune status, and viral load in HIV+ men and women. Int Conf AIDS 1996 Jul 7-12; 11:23 (abstract no. Mo.B.304) Smith BA, Neidig J, Nickel J, Frid D, Para M, Fass R; The Ohio State University, Columbus, OH, USA. Fax: 614-292-4948. E-mail: Smith.73@OSU.edu. Objective: The effect of aerobic and resistive exercise on HIV+ adults has not been completely characterized. This experimental study will evaluate a supervised aerobic and resistive exercise protocol in 60 HIV+ adults with CD4 counts of 200-499. Impact on symptoms, immune markers, viral load, mood states, body composi |
| Mo.B.305 | Herbal medicine: an alternative therapy in poor rural areas. Int Conf AIDS 1996 Jul 7-12; 11:23 (abstract no. Mo.B.305) Ssemukasa M, Apio S; Concern Worldwide, Masaka, Uganda. Fax: 256-481-20514. In Rakai District, Uganda , most families with sick people due mainly to HIV/AIDS cannot afford the high cost of Western Medicine and are often reluctant to use the cheaper local herbal medicine due to uncertainty about their effectiveness. Health facilities in health centres are unavailable to the majority of the popu |
| Mo.B.310 | Disease patterns in AIDS-related focal brain lesion (FBL)-causing disorders: a prospective cohort study on neuroradiological and clinical characteristics combined with CSF PCR analysis. Int Conf AIDS 1996 Jul 7-12; 11:23 (abstract no. Mo.B.310) Ammassari A, De Luca A, Cingolani A, Fortini M, Scoppettuolo G, Murri R, Cattani P, Grillo R; Clinic Of Infection Diseases, Catholic University, Gemelli, Rome, Italy. Fax: 00396-3058512. Objective: 1. To identify disease patterns based on the combination of neuroradiological and clinical characteristics as well as PCR tests on cerebrospinal fluid (CSF) for the diagnosis of different focal brain lesion (FBL)-causing disorders in HIV+ patients (pts); 2. To build a decision-making algorithm to be employed |
| Mo.B.311 | Molecular characterization of JCV strains detected in CSF, PBMCs and urine of AIDS patients with and without PML. Int Conf AIDS 1996 Jul 7-12; 11:23 (abstract no. Mo.B.311) Ferrante P, Caldarelli-Stefano R, Omodeo-Zorini E, Losciale L, Mediati M, Vago L, Cagni A, Cereda P, Maserati R; Institute of Medical Microbiology, University of Milan, Milano, Italy. Objective: To establish the frequency and the distribution of JC virus (JCV) among AIDS patients with and without progressive multi-focal leukoencephalopathy (PML) and the relevance of different JCV strains in the pathogenesis of this demyelinating disease. Methods: JCV DNA was searched, using a nested polymerase chain |
| Mo.B.312 | A prospective, randomized trial of trimethoprim-sulphamethoxazole versus pyrimethamine-sulfadiazine in AIDS patients with cerebral toxoplasmosis. A preliminary report. Int Conf AIDS 1996 Jul 7-12; 11:23 (abstract no. Mo.B.312) Torre D, Casari S, Speranza F, Orani A, Angarano G, Chiodo G, Fiori GP, Carosi GP; Department of Infectious Diseases, Varese, Italy. Fax: 0332-265586. Objectives: The efficacy of trimethoprim-sulphamethoxazole (TMP-SMZ) in cerebral toxoplasmosis (CT) of patients with AIDS has not yet been established in randomized trial. Some retrospective studies showed that TMP-SMZ is effective in CT in AIDS patients. To determine the efficacy and tolerance of TMP-SMZ versus standa |
| Mo.B.313 | Cerebral dendritic arborization is associated with degree of cognitive impairment in HIV infection. Int Conf AIDS 1996 Jul 7-12; 11:24 (abstract no. Mo.B.313) Marcotte TD, Masliah E, Heaton RK, Ellis RJ, Wiley C, Mallory M, McCutchan JA, Atkinson JH, Grant I; University of California, San Diego, CA, USA. Fax: 619-543-1235. E-mail: igrant@ucsd.edu. Objective: To determine if cortical dendritic arborization, assessed at autopsy, correlates with cognitive functioning during life in individuals who had HIV infection and varying neurocognitive impairment. Methods: Midfrontal cortical sections from 19 subjects who received a comprehensive neuropsychological (NP) and n |
| Mo.B.314 | Cerebrospinal fluid (CSF) HIV-1 RNA levels correlate with AIDS dementia complex (ADC). Int Conf AIDS 1996 Jul 7-12; 11:24 (abstract no. Mo.B.314) Brew BJ, Pemberton L, Cunningham P, Law M; NCHECR, Sydney, Australia. Fax: 612 332 1837. E-mail: B.Brew@UNSW.edu.au. Objectives: To determine the relationships between levels of CSF HIV-1 RNA and i) the presence and severity of ADC, ii) central nervous system (CNS) infections and iii) CSF 2 microglobulin and neopterin levels. Methods: 26 patients were assessed neurologically, neuropsychologically, by CT brain scan and CSF analysis, w |
| Mo.B.315 | Evidence for biochemical changes in the frontal lobe of HIV-infected individuals without ADC. Int Conf AIDS 1996 Jul 7-12; 11:24 (abstract no. Mo.B.315) Lenkinski RE, Lopez-Villegas D, Frank I; Hospital of the Univ. of Pennsylvania, Philadelphia, PA. Objective: There has been recent interest in employing proton Magnetic Resonance Spectroscopy (MRS) to study the effects of HIV infection in the CNS. Since it has been shown that neuronal damage occurs in the intermediate or late stages of disease our goal was to determine whether MRS could detect metabolic alterations |
| Mo.B.410 | Saquinavir (invirase, SQV) vs. HIVID (zalcitabine, ddC) vs. combination as treatment for advanced HIV infection in patients discontinuing/unable to take retrovir (zidovudine, ZDV). Int Conf AIDS 1996 Jul 7-12; 11:24 (abstract no. Mo.B.410) Salgo MP, Beattie D, Bragman K, Donatacci L, Jones M, Montgomery L; Hoffmann-La Roche, Nutley, NJ. Fax: (201) 812-3629. Objective: The objective of this randomized, double-blind, phase II/III, multicenter study was to compare the safety, tolerability and efficacy of SQV and ddC , alone and in combination, based on clinical endpoints and laboratory markers of immunological and virologic activity. Methods: A total of 978 HIV-infected pati |
| Mo.B.411 | Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir: update. Int Conf AIDS 1996 Jul 7-12; 11:24 (abstract no. Mo.B.411) Cameron DW, Heath-Chiozzi M, Kravcik S, Mills R, Potthoff A, Henry D; Ottawa General Hospital, Ottawa, Ontario, Canada. Fax: 613-737-8682. E-mail: bcameron@aixl.uottawa.ca. Objective: Ritonavir is a potent, orally bioavailable HIV protease inhibitor. We designed and conducted an international multi-centre randomized placebo-controlled clinical trial of ritonavir 600 mg twice daily for outcomes of death and new AIDS-defining illnesses or selected recurrences (pneumocystis pneumonia, esopha |
| Mo.B.412 | Extended follow-up of patients in a study of indinavir at 800 mg q8h (2.4 g/d), 1000 mg q8h (3.0 g/d) and 800 mg q6h (3.2 g/d). Int Conf AIDS 1996 Jul 7-12; 11:25 (abstract no. Mo.B.412) Steigbigel R, Berry P, Teppler H, Mellors J, Drusano G, Leavitt R, Hildebrand C, Jonas L, Nessly M, Deutsch P, Chodakewitz J; State Univ. of New York at Stony Brook, Stony Brook, NY. Fax: 516-444-7518. Objectives: To obtain long-term (48 weeks) information on the antiviral effect of indinavir (IDV) at greater than or equal 2.4 g/d. Methods: IDV studies have demonstrated that initiation of therapy with 2.4 g/d results in greater and more sustained changes in CD4 counts and viral RNA than lower doses over 24 weeks. |
| Mo.B.413 | A randomized phase II study of VIRACEPT, a novel HIV protease inhibitor, used in combination with stavudine (d4T) vs. stavudine (d4T) alone. Int Conf AIDS 1996 Jul 7-12; 11:25 (abstract no. Mo.B.413) Gathe J Jr, Burkhardt B, Hawley P, Conant M, Peterkin J, Chapman S; Houston Clinical Research Network, Houston, TX, USA. Fax: (713) 528-4923. Objective: To evaluate the safety and efficacy of the combination of VIRACEPT and d4T versus d4T alone. Methods: A total of 33 HIV-positive have been enrolled in a ongoing pilot clinical study of the safety and efficacy of the combination of VIRACEPT and d4T versus d4T alone. Patients are d4T-naive with CD4 cell counts |
| Mo.B.414 | Causes of long term efficacy and/or drug failure in protease (PR) inhibitor monotherapy. Int Conf AIDS 1996 Jul 7-12; 11:25 (abstract no. Mo.B.414) Schapiro JM, Winters MA, Vierra M, Vanhove G, Jacobsen H, Gingeras TR, Crawford SD, Mous J, Blaschke TF, Merigan TC; Stanford University School of Medicine, Stanford, CA. Fax: 415-725-2395. E-mail: JMS.Leland.Stanford.edu. We conducted a clinical trial in 40 HIV+ volunteers who received 3600 or 7200 mg/day saquinavir monotherapy for 24-88 weeks depending on virological and immunological response. Although almost all patients showed a significant rise in CD4 counts and drop in viral load, the duration of this response varied widely throug |
| Mo.B.415 | Safety and efficacy of ritonavir administered at two potentially maximum tolerated doses. Int Conf AIDS 1996 Jul 7-12; 11:25 (abstract no. Mo.B.415) Hicks CB, Lehman L, Eron, Horton J, Jemsek J, Kelly N, Leonard J; Duke University Medical Center, Durham, NC, USA. Fax: 919-681-8474. E-mail: cbhicks@acpub.duke.edu. Objective: To evaluate the antiviral activity/safety of ritonavir in an open-label study of potentially maximum tolerated doses in HIV-infected patients with greater than or equal50 CD4 cells/mm3. Methods: Multicenter, open-label study of 30 HIV-infected patients with CD4 cell counts greater than or equal 50 CD4/mm3, v |
| Mo.B.420 | Hormonal and chronobiological impairment of GH-IGFI-IGFBP3 axis in HIV-infected patients (CDC C3) with wasting syndrome. Effects of treatment with recombinant human GH. Int Conf AIDS 1996 Jul 7-12; 11:25 (abstract no. Mo.B.420) Solerte SB, Fioravanti M, Rondanelli M, Vignati G, Scevola D, Locatelli M, Ferrari E, Minoli R; Dept. Internal Medicine, Pavia (Italy). Fax: 0039.382.24270. Objective: It is still unclear the significance of endocrine alterations often described in AIDS patients. The controversy concerns the possible relevance of these changes in the clinical progression of the disease or the evaluation of endocrine dysfunctions as a consequence of HIV infection. On this light we studied t |
| Mo.B.421 | Different body composition changes in men and women with AIDS. Int Conf AIDS 1996 Jul 7-12; 11:26 (abstract no. Mo.B.421) Kotler DP, Engelson ES, Thea DM, Wang J, Pierson RN, Saint-Louis M, Keusch GT; St. Luke's/Roosevelt Hosp. Ctr., New York, NY. Fax: (212) 523-3678. Objective: To compare the effects of gender, race, environment, and disease (AIDS) upon body composition and upon the relative depletion of body cell mass (BCM), fat free mass (FFM) and body fat. Methods: We analyzed the results of body composition studies performed in two cohorts of subjects, totalling 1415 people, in |
| Mo.B.422 | A phase III study of recombinant human growth hormone (mammalian cell-derived) in patients with AIDS wasting. Int Conf AIDS 1996 Jul 7-12; 11:26 (abstract no. Mo.B.422) Berger DS, LaMarca A, Landy H, Kauffman RS, Breitmeyer J; Center for Special Immunology, Chicago, IL, USA. Fax: 312-296-1097. Decreased body cell mass/lean body mass is an independent prognostic factor in AIDS for early mortality and morbidity. A previous Phase III clinical trial of mammalian cell-derived recombinant human growth hormone (r-hGH[m], Serostim , Serono Laboratories, Inc., Norwell MA) resulted in significant weight (wgt) gain, an |
| Mo.B.423 | A prospective study on the safety and effect of nandrolone decanoate in HIV-positive patients. Int Conf AIDS 1996 Jul 7-12; 11:26 (abstract no. Mo.B.423) Bucher G, Berger DS, Fields-Gardner C, Jones R, Reiter WM; Center for Special Immunology, Chicago, IL, USA. Fax: 312-296-1097. Objectives:There have been anecdotal reports of wide anabolic steroid use in HIV-positive patients for hypogonadism, fatigue, depression, and/or wasting. We report the first controlled trial on the safety of nandrolone decanoate (Nd) (Deca-Durabolin, Organon) in HIV-positive individuals. Methods: In a 12-week randomize |
| Mo.B.424 | Fat malabsorption assessed by 14C-triolein breath test in HIV-positive patients in different stages of infection: is it an early event? Int Conf AIDS 1996 Jul 7-12; 11:26 (abstract no. Mo.B.424) Machado FR, Coelho LGV, Chausson Y, Greco DB; Infectious and Parasitic Diseases Service, Belo Horizonte, MG, Brasil. Fax: 55-31-224-8801. Objective: Evaluation of fat absorption in HIV+ patients, in different phases of HIV infection. Methods: Between November 1994 and February 1995, 47 consecutive HIV+ individuals on follow up at the Immunodeficiency Clinic, after informed consent, underwent a 14C-triolein breath test for evaluation of fat absorption. Te |
| Mo.B.425 | Infectious HIV viral load, body mass index and weight change in IDUs and gay men. Int Conf AIDS 1996 Jul 7-12; 11:26 (abstract no. Mo.B.425) Levy DA, Graham N, Munoz A, Saah AJ, Vlahov D, Farzadegam H; Johns Hopkins SHPH, Baltimore, MD, USA. Fax: 410-955-1836. Objective: To examine the relationship between infectious viral load, and body mass index (BMI) and weight change, and to determine if the relationship is modified by other factors known to be associated with weight loss. Methods: Infectious HIV viral load was measured by quantitative microculture on 511 participants i |
| Mo.B.430 | Antiherpes virus treatment and risk of Kaposi's sarcoma in HIV infection. Int Conf AIDS 1996 Jul 7-12; 11:27 (abstract no. Mo.B.430) Mocroft A, Youle M, Gazzard B, Morcinek J, Halai R, Phillips AN; HIV Research Unit, Dept Primary Care and Population Sciences, Royal Free Hospital School of Medicine, London, UK. Fax: 01717941224. Introduction and Objective: With the recent identification of a new herpes virus in patients with Kaposi s sarcoma, there have been several reports on the use of antiherpes therapy (foscarnet, ganciclovir and acyclovir ) and risk of developing Kaposi s sarcoma. We therefore investigated the association between use of a |
| Mo.B.431 | AIDS-associated lymphoma is preceded by the over-expression of molecules associated with B cell activation and immunoglobulin (Ig) isotype switching. Int Conf AIDS 1996 Jul 7-12; 11:27 (abstract no. Mo.B.431) Martinez-Maza O, van der Meijden M, Widney D, Yawetz S; Department of Microbiology & Immunology, UCLA School of Medicine, Los Angeles, CA, USA. Fax: (310) 206-5387. E-mail: omartine@microimmun.medsch.ucla.edu. Objective: To determine if elevated levels of molecules associated with B cell hyperactivation or Ig isotype switching preceded the development of AIDS- lymphoma , we measured serum levels of various immune system factors associated with these processes, including serum sCD23 (a B cell differentiation/activation factor |
| Mo.B.432 | Phase I-II clinical trial supports safety and efficacy of ALRT 1057 topical retinoid gel for Kaposi's sarcoma. Int Conf AIDS 1996 Jul 7-12; 11:27 (abstract no. Mo.B.432) Duvic M, Friedman-Kien AE, Galpin J, Miles SA, Looney DJ, Myskowski PL, Gill G, Truglia J, Yocum R; Department of Dermatology, Houston, TX. Objective: To assess the safety and effectiveness of a new topical retinoid, ALRT 1057 (9-cis-retinoic acid) for the treatment of Kaposi s sarcoma. Methods: Sixty-three patients with biopsy-proven, multiple KS lesions enrolled in a controlled Phase I-II study at 6 centers. Patients applied 0.05% or 0.1% gel to selected |
| Mo.B.433 | Burkitt's lymphoma (BL) in 75 patients (pts), 46 with and 29 without HIV infection: a monoinstitutional study. Int Conf AIDS 1996 Jul 7-12; 11:27 (abstract no. Mo.B.433) Santarossa S, Spina M, Zagonel V, Carbone A, Talamini R, Abbruzzese L, Errante D, Monfardini S, Tirelli U; Division of Medical Oncology and AIDS, Centro di Riferimento Oncologico, Aviano, Italy. Fax: 434/659531. Objective: To compare the clinical features and outcome of pts with BL in HIV setting and in the general population. Methods: We retrospectively analysed 75 pts (46 with and 29 without HIV infection) diagnosed and treated at Aviano Cancer Center, Italy , from May 1987 to June 1995. Results: Pts with BL and HIV infectio |
| Mo.B.434 | Risk factors in mothers of children with Kaposi's sarcoma (KS): a case control study. Int Conf AIDS 1996 Jul 7-12; 11:28 (abstract no. Mo.B.434) Mwidu S, Ziegler JL, Katongole-Mbidde E, Tindyebwa D, Marum L, Newton R, Beral V, Parkin DM, DeCock KM, Jaffe H, Weiss R; The Centre, Harare, Zimbabwe. Fax: 263-4-724384. Objective: To determine the risk factors for childhood KS and to assess whether KSHV (HHV-8), the putative aetiological agent of KS, is transmissible from mother to child. Methods: Since January, 1995, newly diagnosed children with KS (cases) have been registered and their mothers interviewed. For every case 3 children |
| Mo.B.435 | Curative therapy for AIDS cancers. Int Conf AIDS 1996 Jul 7-12; 11:28 (abstract no. Mo.B.435) Miles SA; UCLA Care Center, Los Angeles, CA, USA. Fax: 310-206-3311. Many AIDS clinicians view patients with AIDS-related malignancies as uncurable. Recent laboratory and clinical data suggest that successful treatment may already be here for may of these patients. For example, the recent identification of the Kaposi s sarcoma herpes virus (HHV-8) and partial genomic cloning have provid |
| Mo.B.531 | A rational approach to the use of antiretroviral agents. Int Conf AIDS 1996 Jul 7-12; 11:28 (abstract no. Mo.B.531) Vella S, Floridia M; Laboratory of Virology, Istituto Superiore di Sanita, Rome, Italy. Fax: 39-6-4457-582. E-mail: vella@virus1.iss.infn.it. The number of antiretroviral drugs available for treatment is currently high enough to allow a considerable variety of strategies (e.g. early versus late), of combinations and of sequential regimens, which can also be better tailored to the medical status and preferences of the individual patient. In the design of firs |
| Mo.B.533 | Formulating rational use of anti-retrovirals in Thailand. Int Conf AIDS 1996 Jul 7-12; 11:28 (abstract no. Mo.B.533) Prescott N, Kunanusont C, Phoolcharoen W, Rojanapitayakorn W, Perriens J, Boonyuen D; AIDS Division, Dept of CDC, Ministry of Public Health, Thailand. E-mail:chaiyos@health.moph.go.th. Background: An evaluation of antiretroviral policy options was conducted in 1995- 3 years after initiation of government-subsidised Zidovudine (ZDV) in Thailand . Experts from the World Bank, the World Health Organization , Thai universities, and the Thai Ministry of Public Health formed joint working groups on epidemi |
| Mo.B.540 | Menstrual abnormalities in women with HIV infection. Int Conf AIDS 1996 Jul 7-12; 11:28 (abstract no. Mo.B.540) Cohen MH, Greenblatt R, Minkoff H, Barkan S, Burns D, Denenberg R, Young M, Levine A; Chicago, IL, USA. Fax: (312) 633-4902. E-mail: mcohen@hektoen.org. Objective: To determine the prevalence and etiology of amenorrhea and to describe menstrual abnormalities in women with HIV infection. Methods: The Women s Interagency HIV Study (WIHS) is a multi-site cohort study of HIV-infected women and a comparable at risk uninfected control group. Data for this analysis was availa |
| Mo.B.541 | Reduced fertility among HIV-infected women. Results of cross-sectional and prospective studies in rural Uganda. Int Conf AIDS 1996 Jul 7-12; 11:28 (abstract no. Mo.B.541) Gray RH, Wawer MJ, Wabwire-Mangen F, Sewenkambo N, Serwadda D, Kigonzi G, Paxton L, Li C, Yan Y, McNairn D, Kiwanuka N; Department of Population Dynamics, Johns Hopkins University, School of Hygiene and Public Health, Baltimore, MD, USA. Fax: (410) 955-0792. E-mail: gray@hpcsun01.sph.jhu.edu. Johns Hopkins University, Baltimore, USA, Columbia University, New York, Makerere University, Kampala, Uganda . Objectives: To assess the association between HIV infection, STDs and fertility in two studies from rural Uganda. Methods: Data were derived from two studies in Rakai District, southwestern Uganda. These were |
| Mo.B.542 | Incidence of pregnancy in a European cohort of HIV-infected women. Int Conf AIDS 1996 Jul 7-12; 11:29 (abstract no. Mo.B.542) De Vincenzi I; European Centre for the Epidemiological Monitoring of AIDS, St-Maurice, France. Fax: 33 1 43 96 50 81. E-mail: idvceses@b3e.jussieu.fr. Objective: To analyse the impact of HIV testing on the incidence of pregnancy among HIV-infected women. Methods: The analysis is based on data collected at inclusion in a multicentre European cohort of HIV(+) women with a known date of infection. The incidence of pregnancies conceived in the year preceding the first HI |
| Mo.B.543 | Pregnant HIV-infected women in Europe. Int Conf AIDS 1996 Jul 7-12; 11:29 (abstract no. Mo.B.543) Newell ML; Epidemiology Unit, Institute of Child Health, London, UK. Fax: 0171 813 8233. E-mail: M.Newell@ich.bpmf.ac.uk. Objectives To describe the immunological characteristics and clinical progression of HIV-infected women during and following pregnancy. Methods In the European Collaborative Study, pregnant women and their children are followed-up at regular intervals according to a standard protocol. Clinical and immunological informa |
| Mo.B.550 | Nurses' ethical dilemmas concerning informational privacy of people with HIV/AIDS. Int Conf AIDS 1996 Jul 7-12; 11:29 (abstract no. Mo.B.550) Vrehen HM; Utrecht University Hospital, Utrecht, The Netherlands. Fax: 31-30-2518328. E-mail: h.m.vrehen@digd.azu.nl. The aim of this study was to gain insight into nurses perceptions of ethical dilemmas concerning informational privacy of patients with HIV/AIDS. Ethical dilemmas, described by nurses, their perception of these dilemmas and their dealings with them, were studied. The chosen research method was descriptive, from a quali |
| Mo.B.551 | A profile of health care & informal support services received by persons with HIV & AIDS in Vancouver & British Columbia. Int Conf AIDS 1996 Jul 7-12; 11:29 (abstract no. Mo.B.551) Goldstone I, Schilder A, Hogg RS, Hanvelt R, Craib KJ, Bradford G, Perry T, O'Shaughnessy MV; BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada. Fax: 604-631-5464. E-mail: Kevin@HIVnet.ubc.ca. Objective: To compare activities of daily living(ADL) and self care with services received from the health care system and informal support to persons with HIV(PWH) and AIDS(PWA) in Vancouver with the rest of BC. Methods: The study was conducted jointly by the BCPWA and the BC Centre for Excellence in HIV/AIDS. Eligibl |
| Mo.B.552 | Degree of comfort in providing care to patients with HIV disease: a preliminary study of Vietnamese nurses. Int Conf AIDS 1996 Jul 7-12; 11:29 (abstract no. Mo.B.552) Correll P, Dat N, Kloser P; University of Medicine & Dentistry of New Jersey, Westfield, NJ, USA. Fax: (908) 232-5369. As the number of AIDS patients increases in Vietnam , health care professionals may have fears about providing care to patients with HIV infection. Project: Thirty four nursing students were asked a series of sixteen questions about their comfort level in caring for a patient with AIDS and one question regarding |
| Mo.B.553 | HIV infection in children in school: educating school nurses and public health nurses in the U.S. using a train-the-trainer model. Int Conf AIDS 1996 Jul 7-12; 11:30 (abstract no. Mo.B.553) Gross E, Burr C, Boland M; National Pediatric and Family HIV Resource Center (NPHRC), UMD-New Jersey Medical School, Newark, NJ, USA. Fax: (201) 485-2752. E-mail: gross@daiid.umdnj.edu. HIV-infected children attend day care and school throughout the US. Many of these children have multiple health and educational problems. School is a normal part of childhood providing growth, development, and socialization that the chronically ill HIV-infected child needs. The knowledgeable school nurse can hel |
| Mo.C.120 | Assessment of HIV testing in blood donations: cost analysis of routine screening with HIV-antibody and HIV antigen test in Thailand. Int Conf AIDS 1996 Jul 7-12; 11:30 (abstract no. Mo.C.120) Kongsin S, Rerks-Ngum S; Faculty of Public Health Mahidol University, Bangkok, Thailand. Fax: (662) 644-8833,246-7765. Objectives: 1) To analyze the cost component of routine screening of Thai blood donors by using HIV-Ab (the 2nd and 3rd Generation ELISA) and HIV-Ag. 2) To determine the cost for the detection of the window period. 3) To analyze the effectiveness of donor s self selection methods. Methods: The study design was a cross- |
| Mo.C.121 | Evaluation of HIV testing of the blood supply in Kenya. Int Conf AIDS 1996 Jul 7-12; 11:30 (abstract no. Mo.C.121) Lackritz E, Moore A, Nyamongo J, Herrera G, Granade T, Phillips S, Nahlen B, Janssen R; Centers for Disease Control and Prevention, Atlanta, GA, USA. Fax: 404-639-2029. E-mail: eal3@cidHIV1.em.cdc.gov. Objective: To identify ways to prevent transmission of HIV by blood transfusion in Kenya . Methods: From April through September 1994, we collected demographic and laboratory data on all blood donors in 5 government hospitals in western Kenya and 1 in Nairobi. Donations were tested for HIV-1 antibody by routine hospita |
| Mo.C.122 | Why are AIDS cases in persons with hemophilia and their heterosexual partners in the United States not decreasing? Int Conf AIDS 1996 Jul 7-12; 11:30 (abstract no. Mo.C.122) Sullivan PS, Fleming P, Evatt BL, Ward JW; Centers for Disease Control and Prevention, Atlanta, GA. Objective: Although ten years have passed since the introduction of heat treatment of plasma derivatives and laboratory screening of donated blood, cases of AIDS among persons with hemophilia (PWH) continue to be reported to CDC. This report examines trends in AIDS diagnoses among PWH and their heterosexual partners. M |
| Mo.C.123 | Window period donations in an HIV epidemic area in Thailand. Int Conf AIDS 1996 Jul 7-12; 11:30 (abstract no. Mo.C.123) Sawanpanyalert P, Yanai H, Kitsuwannakul S, Nelson K; Ministry of Public Health, Thailand. Fax: 662-818-4061. E-mail: pathom@health.moph.go.th. Objective: To estimate the risk of donation during the window period of HIV infection in an HIV epidemic area Methods: Six years (1989-1994) of blood donation registry data of a hospital blood bank in the HIV/AIDS epicenter in northern Thailand were doubly-entered in a computer file with names and other identifying inf |
| Mo.C.124 | Residual risk of transfusion-transmitted viral infections (HIV and other viruses) in France. Int Conf AIDS 1996 Jul 7-12; 11:31 (abstract no. Mo.C.124) Pillonel J, Courouce AM; RNSP, Saint-Maurice, France. Fax: 33.1.43.96.65.02. Objective: To estimate the risk of HIV transmission by transfusion of blood given when the donor was within the window period and to compare it with the residual risk of other transfusion-transmitted viral infections (HTLV, HBV, HCV). Methods: A seroconversion incidence model developed by the Retrovirus Epidemiology Do |
| Mo.C.125 | The possible role of commercial plasmapheresis banks on the AIDS epidemic in Mexico. A lesson for developing countries. Int Conf AIDS 1996 Jul 7-12; 11:31 (abstract no. Mo.C.125) Volkow P, Perez-Padilla R, del Rio C, Mohar A; National Institute of Cancer, Mexico. Fax: (525) 655-1437. E-mail: volkow@cenids.ssa.gob.mx. The initial pattern of AIDS epidemic in USA and Mexico was similar until 1987 when a dramatic increase of AIDS cases associated with blood transfusion was observed in Mexico but not in the USA. The highest difference was reached in 1989 when AIDS cases associated with blood transfusion were 1 |
| Mo.C.200 | HIV sentinel surveillance 1992-1995 and development of an estimate of total HIV infections in Myanmar. Int Conf AIDS 1996 Jul 7-12; 11:31 (abstract no. Mo.C.200) Kywe B, Thwe M, Naing H, Ti Ti, Goodwin DJ, Khin OS, Zan E, Zaw M, Lwin T, Kyaw O; AIDS/STD Department of Health, Yangon, Myanmar. Background: HIV surveillance began in Myanmar in 1985; the first HIV infection was indentified in January 1988. Standardized sentinel surveillance administered by the National AIDS Program began in 1992. Tuberculosis patients were added as a sentinel population in 1995. Objective: To measure HIV prevalence among sentin |
| Mo.C.202 | Estimation of underreporting of AIDS cases in France with capture-recapture methods. Int Conf AIDS 1996 Jul 7-12; 11:31 (abstract no. Mo.C.202) Bernillon P, Lievre L, Pillonel J, Laporte A, Costagliola D; Faculte de Medecine Saint-Antoine, Paris, France. Fax: (33-1) 43.07.39.57. E-mail: lievre@b3e.jussieu.fr. Objective: To study concordance between an AIDS surveillance system and a hospital based HIV infection surveillance system in France and to estimate their respective completeness (for AIDS cases) over the 1990-1993 period using a capture-recapture approach. Methods: The first database is a subsample of the AIDS case ma |
| Mo.C.203 | Improving AIDS surveillance data through epidemiology. Int Conf AIDS 1996 Jul 7-12; 11:31 (abstract no. Mo.C.203) Rybicki RJ, Murphy J, Mueller G, Whitman S; Chicago Department of Public Health, Chicago, IL, USA. Fax: (312) 747-9663. Existing AIDS surveillance data can be vastly improved retrospectively, and maintained prospectively, through various initiatives employing epidemiologic techniques. Projects: Reported through December 1995, the AIDS case registry for the city of Chicago contained 11,516 cases. Several initiatives have been cond |
| Mo.C.204 | Effect of the 1993 AIDS case definition change on report delay in Los Angeles county. Int Conf AIDS 1996 Jul 7-12; 11:32 (abstract no. Mo.C.204) Rock Wohl A, Simon P, Bunch G; Department of Health Services, Los Angeles, CA. Fax: (213) 487-4683. Objective: To describe the impact of the 1993 AIDS case definition expansion on the timeliness of AIDS case reporting in Los Angeles County (LAC). Methods: Report delay (RD) was defined as the interval from date of AIDS diagnosis to date of case report. RD was analyzed by year of report, race, sex, mode of HIV exposure |
| Mo.C.205 | AIDS under-reporting may distort the epidemic: the Quebec experience. Int Conf AIDS 1996 Jul 7-12; 11:32 (abstract no. Mo.C.205) Remis RS, Meunier L, Vandal AC, Palmer RWH, Desrochers D; STD/AIDS Prevention and Control Program, Regional Public Health Department, Montreal, PQ, Canada. Fax: (514) 932-1502. E-mail: md22@musica.mcgill.ca. Objectives: To determine the impact of retrospective active case-finding on trends in AIDS incidence in Quebec. Methods: Based on a study of the completeness of AIDS reporting in 1994, we identified acute care hospitals with the largest number of previously unreported AIDS cases. Using predictive ICD-9 codes, we identi |
| Mo.C.206 | Record linkage estimates of reporting completeness for AIDS in Canada indicate increasing rates of incomplete reporting. Int Conf AIDS 1996 Jul 7-12; 11:32 (abstract no. Mo.C.206) Ricketts M, Whitehead J, Lalonde P, Fair M, Woollam P, Nair R, Sutherland D; Laboratory Centre for Disease Control, Ottawa, Ontario, Canada. Fax: 613-952-6668. E-mail: mricketts@hpb.hwc.ca. Objectives: To determine the extent of reporting completeness of AIDS in Canada . Methods: A probabilistic record linkage based on common fields (initials, dates of birth, dates of death, city and province of residence, diagnosis at time of death) was conducted between the National AIDS Case Reporting Surveillance Syst |
| Mo.C.210 | HIV testing behaviour of Canadians. Int Conf AIDS 1996 Jul 7-12; 11:32 (abstract no. Mo.C.210) Sutherland D, Archibald CP, Houston S, Palmer R, Major C, Browne J; Bureau of HIV/AIDS & STD, Health Canada, Ottawa, Canada. Fax: 613-954-5414. E-mail: dsutherl@hpb.hwc.ca. Objective: To examine the HIV testing behaviour of Canadians aged 15 yr and older with respect to the proportion of the population tested, reason for testing, and the demographic and social/behavioural factors associated with testing. Methods: A Canada-wide random-digit-dialling telephone survey of people aged greater |
| Mo.C.211 | Acceptability of antenatal HIV-1 screening. Int Conf AIDS 1996 Jul 7-12; 11:32 (abstract no. Mo.C.211) Kiarie J, Nduati R, John G, Gakuru C, Musia J, Bwayo J, Rogo K, Kamau K, Kreiss J; Department of Pediatrics, University of Nairobi, Nairobi, Kenya. Objectives: To evaluate the acceptability of antenatal HIV-1 screening in Nairobi City Council Clinics and to determine factors associated with failure to return for HIV-1 test results. Methods: Pregnant women presenting to two Nairobi City Council Clinics for routine antenatal screening were offered testing for HIV-1 |
| Mo.C.212 | HIV testing and policy change, an analysis based on statewide HIV testing data, 1994-1995. Int Conf AIDS 1996 Jul 7-12; 11:33 (abstract no. Mo.C.212) Stevenson EM, Thompson SC, Crofts N; Macfarlane Burnet Centre for Medical Research, Victoria, Australia. Fax: +61 3 9482-3123. E-mail: stevenso@burnet.mbcmr.unimelb.edu.au. Objective: In July 1994 Victoria introduced a system of user-pays (U-P) HIV testing which aimed to reduce the amount of unnecessary HIV testing, whilst maintaining access to free testing for those at increased risk. This policy was revised in April 1995 to extend the availability of free testing to all individuals with |
| Mo.C.213 | Local research for local approval - a case study of a rapid HIV serostrip assay for use in developing countries. Int Conf AIDS 1996 Jul 7-12; 11:33 (abstract no. Mo.C.213) Frerichs RR, Zaw M, Lwin S, Oo KY, Eskes N; SDS, Inc., Vancouver, WA , USA. Fax: 1-360-254-7942. E-mail: Salival@aol.com. HIV can be avoided if HIV antibody testing finds blood to be contaminated, current or future sexual partners to be infected, or pregnant women to be carriers. Yet in developing countries widespread testing will not occur unless donor nations or agencies greatly increase the supply of tests, or more realistically |
| Mo.C.214 | Predictors of HIV testing history among men attending an STD clinic in Hollywood, California. Int Conf AIDS 1996 Jul 7-12; 11:33 (abstract no. Mo.C.214) Pearce CL, Katsufrakis PJ, Dyer IE, Richwald GA, Borenstein LA, Courtney JG; LA Gay and Lesbian Community Services Center, Los Angeles, CA, USA. Fax: 213-993-7599. E-mail: pear0087@wonder.em.cdc.gov. Objective: To determine the predictors of HIV testing history among men attending the Los Angeles Gay and Lesbian Community Services Center Sexually Transmitted Disease (STD) Clinic in Hollywood, California. Methods: A total of 438 men who presented for care at the clinic enrolled in the study from Aug. 7 to Oct. 27, 1 |
| Mo.C.215 | HIV testing behavior and beliefs of physicians treating HIV+ injected drug users (IDUs) in southern France. Int Conf AIDS 1996 Jul 7-12; 11:33 (abstract no. Mo.C.215) Cavailler P, Cassuto, Lepeu, Gamby T, Moatti JP, Mayne T, Rotily M; Service Dermatologie, Hopital Saint Joseph, Marseille, France. Fax: 91 77 09 55. Objective: To examine HIV testing behavior and the beliefs of physicians treating IDUs with HIV infection in Southern France . Methods: This was a consecutive convenience sample of the first 100 HIV+ patients with IDU as origin of infection seeking services at outpatient clinics in specific hospitals in Marseille, Nice |
| Mo.C.220 | A profile of female injecting drug users in Zurich based on a meta-analysis of variously recruited drug-user samples. Int Conf AIDS 1996 Jul 7-12; 11:33 (abstract no. Mo.C.220) Wang J, Lanz A, Seidenberg A, Zellweger U, Somaini B; Institut fur Sozial- und Praventivmedizin, Zurich, Switzerland. Fax: (41-1) 257 69 62. E-mail: jwang@ifspm.unizh.ch. Objective: To establish a profile of the female injecting drug user (IDU) population in the city of Zurich, Switzerland . Methods: Taking data from drug user studies carried out during 1989-92, we performed a meta-analysis of 13 datasets collected at Needle Park (arguably one the most diverse samples ever collected any |
| Mo.C.221 | Predictors of HIV infection among women drug users in low and high seroprevalence cities. Int Conf AIDS 1996 Jul 7-12; 11:34 (abstract no. Mo.C.221) Tortu S, Beardsley M, Deren S, Williams M, Stark M, Needle R, Estrada A, Goldstein M, McCoy HV; National Development & Research Institutes, Inc., New York, NY. Introduction: HIV infection in US women continues to increase, especially among ethnic minorities. This study describes and compares sociodemographic variables, behavioral risk factors, and health status variables associated with HIV infection in a multi-site sample of women injection drug users (IDUs) and crack smoker |
| Mo.C.222 | Risk factors for HIV seroconversion among young women in a rural community in the Southeastern United States. Int Conf AIDS 1996 Jul 7-12; 11:34 (abstract no. Mo.C.222) Dominguez K, Ellerbrock TV, Harrington PE, Bush T, Malecki J, Simonds RJ; DHAP, NCHSTP, Centers for Disease Control and Prevention, Atlanta, GA, USA. Fax: 404-639-6118. E-mail: kld0@cidHIVl.em.cdc.gov. Objective: To identify behavioural and sociodemographic risk factors for incident HIV infections among women in a rural community with high HIV seroprevalence. Methods: During 1989-91, 52 (5.1%) of 1011 consecutive pregnant women who registered for prenatal care at a public health clinic in Florida tested HIV-positive |
| Mo.C.223 | Use of intravaginal preparations, presence of lactobacillus in the vagina, and risk for HIV in Zimbabwean women. Int Conf AIDS 1996 Jul 7-12; 11:34 (abstract no. Mo.C.223) van de Wijgert J, Mason PR, Ray CS, Gwanzura L, Maposhere C, Katzenstein D, Padian NS; Zimbabwe AIDS Prevention Project-University of Zimbabwe (ZAPP), Harare, Zimbabwe. Fax: 263-4-739406. E-mail: zapp@healthnet.zw. Objectives: To study use of intravaginal preparations, and its association with gynecological problems, presence of lactobacillus in the vaginal flora, and risk for HIV in commercial sex workers (CSWs) in Harare, Zimbabwe . Methods: 149 CSWs were enrolled and followed up biweekly for 12 weeks. The following procedures |
| Mo.C.224 | Prevalence of domestic violence and childhood abuse among women with HIV and high risk uninfected women. Int Conf AIDS 1996 Jul 7-12; 11:34 (abstract no. Mo.C.224) Deamant C, Cohen M, Barkan S, Richardson J, FitzGerald G, Young M, Holman S, Anastos K, Cohen J, Melnick S; Chicago, IL, USA. Fax: (312) 633-8333. Objective: To determine the prevalence of domestic violence and childhood abuse reported by women with HIV and women at risk for HIV. Methods: The Women s Interagency HIV Study (WIHS) is a multi-site cohort study of and a comparable at risk uninfected control group. This abstract reflects the initial analysis of availa |
| Mo.C.225 | HIV risk behaviors and HIV-related morbidity in a cohort of incarcerated women in Massachusetts. Int Conf AIDS 1996 Jul 7-12; 11:34 (abstract no. Mo.C.225) De Groot AS, Zierler S, Stevens J, Dean D, Ferdinand MM, Jesdale BM, George JA, Scheib RG; TB/HIV Research Laboratory, International Health Institute, Brown University School of Medicine, Providence, RI. Fax: 863-1243. E-mail: Anne_DeGroot @ postoffice.brown.edu. Objective: Due to the nature of the crimes for which women are incarcerated, the seroprevalence of HIV is alarmingly high in women s prisons. We assessed HIV risk behaviors and HIV-related morbidity in a cohort of 291 HIV seropositive (HIV+) women inmates (WI) followed over 3.5 years at the HIV clinic of a large state |
| Mo.C.226 | STD and HIV infection among female non-commercial sex workers (non-CSWs) attending STD clinics in Pune, India. Int Conf AIDS 1996 Jul 7-12; 11:38 (abstract no. Mo.C.226) Gangakhedkar RR, Bentley M, Rompalo AM, Shepherd ME, Mehendale SM, Thilakavathi SM, Amin A, Gadkari DA, Bollinger RC, Quinn TC; Division of Infections Diseases, Johns Hopkins University, Baltimore, MD. Fax: (410) 955-7889. E-mail: rrg@welchlink.welch.jhu.edu. Objective: High HIV incidence has been previously reported among female commercial sex workers (CSWs) and male STD patients in Pune. Since an increasing HIV prevalence has also been reported in low-risk populations, we compared the prevalence of and risk factors for HIV and STDs in women who identified themselves as CS |
| Mo.C.320 | The role of serum micronutrient levels in HIV-1 disease progression. Int Conf AIDS 1996 Jul 7-12; 11:35 (abstract no. Mo.C.320) Tang AM, Graham N, Semba RD, Chandra RK, Saah AJ; Johns Hopkins University, Baltimore, MD, USA. Fax: 410-955-3778. E-mail: tang@share.sph.jhu.edu. Objective: To examine the associations between serum levels of vitamins A, B6, B12, E, and folate with risk of progression to two key outcomes in the natural history of HIV-1 infection - first AIDS diagnosis and mortality. Methods: The study population was drawn from a well-established cohort of gay/bisexual men in the |
| Mo.C.321 | Fraction of patients free of clinical AIDS after CD4 cell count dropping less than 200x106/l in Japanese hemophiliacs infected with HIV-1. Int Conf AIDS 1996 Jul 7-12; 11:35 (abstract no. Mo.C.321) Tatsunami S, Mimaya J, Meguro T, Nakamura S, Kuwabara R, Yago N, Yamada K; Radioisotope Res. Inst., St. Marianna Univ. School of Med. Kawasaki, Japan. Fax: +81 44-975-1846. Objective: To evaluate the distribution of time from the first date of the CD4 cell count dropping less than 200X106/l to the onset of clinical AIDS by 1987 Centers for Disease Control and Prevention case definition in Japanese hemophilia patients infected with HIV-1. Methods: We extracted the variables from the data b |
| Mo.C.322 | Progression of HIV infection and stability of immunologic markers prior to and around seroconversion. Int Conf AIDS 1996 Jul 7-12; 11:35 (abstract no. Mo.C.322) Munoz A, Margolick JB, Chu C, Donnenberg AD, Giorgi JV, Phair JP; Johns Hopkins School of Public Health, Baltimore, MD, USA. Fax: (410) 955-3834. E-mail: munoz@statepi.sph.jhu.edu. Objectives: To determine the prognostic information for HIV disease progression of high within-individual variances of immunologic markers prior to HIV-1 seroconversion (SC) and changes of markers around seroconversion. Methods: The study population was 370 participants of the Multicenter AIDS Cohort Study with known ( |
| Mo.C.323 | HIV-1 RNA levels in early chronic infection: association with AIDS and long term non-progression. Int Conf AIDS 1996 Jul 7-12; 11:35 (abstract no. Mo.C.323) O'Brien TR, Blattner WA, Kroner BL, Goedert JJ; National Cancer Institute, Rockville, MD. Fax: (301) 402-0817. E-mail: OBRIENT@EPNDCE.NCI.NIM.GOV. Objective: To determine the risk of AIDS and proportion of subjects who were long-term non-progressors (LTNP), by HIV-1 RNA levels measured in early chronic infection. Methods: We measured HIV-1 RNA by PCR (Roche Monitor assay) in arcHIVed serum specimens collected from 188 persons enrolled in a long-term study of hemo |
| Mo.C.324 | Incidence and prognostic significance of symptomatic primary HIV-1 infection in homosexual men. Int Conf AIDS 1996 Jul 7-12; 11:35 (abstract no. Mo.C.324) Veugelers PJ, Strathdee SA, Kaldor JM, Page-Shafer KA, Schechter MT, Coutinho RA, Keet I, van Griensven G; Municipal Health Service, Amsterdam, Netherlands. Fax: +31-20-5555 533. E-mail: paulus@sara.nl. Objective: To investigate incidence and prognostic significance of symptomatic primary HIV-1 infection in homosexual men from prospective cohort studies in Vancouver, Sydney, Amsterdam and San Francisco. Methods: We compared incidence rates of self-reported diarrhoea, fever, night sweats, cough and fatigue during the i |
| Mo.C.325 | Predictors of disease progression and survival among AZT-treated individuals followed after HIV seroconversion. Int Conf AIDS 1996 Jul 7-12; 11:36 (abstract no. Mo.C.325) Rezza G, Galai N, Pezzotti P, Vlahov D, Graham NM; Istituto Superiore di Sanita, Roma, Italy. Fax: (39)(6) 445 6741. E-mail: PATRIZIO@ISS.IT. Objective: The aim of the study was to evaluate indicators of response to antiretroviral treatment with zidovudine ( AZT ) in terms of progression to AIDS and death in a cohort of HIV-seroconverters. Methods: We selected a treated cohort of individuals from a large group of 1024 seroconverters belonging to three differ |
| Mo.C.330 | A birth cohort analysis of 75,097 European AIDS cases. Int Conf AIDS 1996 Jul 7-12; 11:36 (abstract no. Mo.C.330) Houweling H, Heisterkamp SH, Jager JC, Coutinho RA; Dept Infect Dis Epidemiol, Natl Inst Public Hlth (RIVM), the Netherlands. Fax: +31 30 2744409. E-mail: ciehh@rivm.nl. Objectives: To study AIDS incidence in the European project on Multinational AIDS scenarios (contract BMH1-CT-941723) with particular reference to the youngest groups at risk through sexual and needle-sharing risk behaviours. Methods: AIDS incidence data (European AIDS Centre, Paris) for Aus, Bel, Ger, Gre, Ita, Ire, N |
| Mo.C.331 | HIV prevalence among U.S. childbearing women, 1989-1994. Int Conf AIDS 1996 Jul 7-12; 11:36 (abstract no. Mo.C.331) Davis SF, Steinberg S, Jean-Simon M, Rosen D, Gwinn M; CDC, DHA, Atlanta, GA, USA. Fax: (404)639-2029. E-mail: sxd1@cdcHIV1.em.cdc.gov. Objective:To describe trends in HIV prevalence among childbearing women in the United States . Methods: In an anonymous, population-based national serosurvey, greater than or equal to 2 million newborn specimens were tested annually for maternal antibody to HIV. Based on data from 35 states conducting the survey contin |
| Mo.C.332 | Trends in AIDS incidence in the United States, 1990-1994. Int Conf AIDS 1996 Jul 7-12; 11:36 (abstract no. Mo.C.332) Ward JW, Karon J, Fleming P, Gayle H; Centers for Disease Control and Prevention, Atlanta, GA, USA. Fax: (404) 639-2029. E-mail: jww4@cidHIV1.em.cdc.gov. Objective: To describe national trends in estimated AIDS incidence rates (A-I) from 1990 through 1994. Methods: We examined cases of persons greater than or equal 13 years with AIDS-opportunistic illnesses (Ol) diagnosed (dx) in 1990-1994 and reported through September 1995. Data were adjusted for reporting delays, unr |
| Mo.C.333 | Enhanced surveillance for HIV infection in British Columbia, Canada. Int Conf AIDS 1996 Jul 7-12; 11:36 (abstract no. Mo.C.333) Cook DA, Patrick DM, Rekart ML, Middleton PJ, Strathdee SA, Spencer D, Rees T, MacDougall R, Marcin K; Centre for Disease Control, Vancouver, BC, Canada. Fax: 604-660-6073. E-mail: dacook@bcsc02.gov.bc.ca. Objective: To make better use of data from diagnostic HIV testing by eliminating duplicate tests and collecting complete risk and ethnic information while protecting the confidentiality of HIV seropositive patients. Methods: From January 1 to September 30, 1995 868 HIV-positive specimens were identified. Physicians wer |
| Mo.C.334 | Overview of the HIV epidemic among injecting drug users in England and Wales. Int Conf AIDS 1996 Jul 7-12; 11:37 (abstract no. Mo.C.334) Madden PB, Bennett D, Lamagni T, Brady T, Hughes G, Mortimer J, Kaye P; Public Health Laboratory Service, Communicable Disease Surveillance Centre (PHLS, CDSC), London, UK. Fax: 44 181 200 7868. Objective: To assess the state of the HIV epidemic in Injecting Drug Users (IDUs) in England and Wales. Methods: Data were obtained from: routine reporting of AIDS cases and HIV infections; the voluntary unlinked anonymous HIV and hepatitis B core antibody prevalence monitoring programme (Saliva survey); the PHLS Colla |
| Mo.C.335 | Case-control study of HIV seroconversion in health care workers after percutaneous exposure to HIV-infected blood; implications for postexposure management. Int Conf AIDS 1996 Jul 7-12; 11:37 (abstract no. Mo.C.335) Cardo D, Srivastava P, Ciesielski C, Culver D, Marcus R, McKibben P, Abiteboul D, Lot F, Heptonstall J, Bell D; Centers for Disease Control (CDC), Atlanta, GA. Fax: 404-639-6459. E-mail: DMBl@CIDHIPl.EM.CDC. GOV. Objective: To assess risk factors for HIV seroconversion in health care workers (HCWs) after percutaneous exposure (PE) to HIV-infected blood. Methods: Cases were HCWs who seroconverted to HIV after a PE to HIV-infected blood, reported from national surveillance in the U.S., France , and Un |
| Mo.C.340 | Asymptomatic genital tract infections in a rural district of Uganda. Int Conf AIDS 1996 Jul 7-12; 11:37 (abstract no. Mo.C.340) Paxton LA, Sewankambo N, Wawer MJ, Gray R, Wabwire-Mangen F, Serwadda D, McNairn D, Konde-Lule J, Li C, Kiwanuka N; Entebbe, Uganda. Fax: 256-42-20049. E-mail: lpaxton@mukla.gn.apc.org. Introduction: Previous research suggests that genital tract infections (GTIs) may be important in the transmission of HIV. As part of a study to determine if mass treatment of GTIs Will reduce HIV transmission, we documented the prevalence of asymptomatic infections in a representative sample of the rural population of |
| Mo.C.341 | Is asymptomatic urethritis in men an obstacle to effective STD control? A community study in Mwanza, Tanzania. Int Conf AIDS 1996 Jul 7-12; 11:37 (abstract no. Mo.C.341) Buve A, Mosha F, Watson-Jones D, Mugeye K, West B, Gabone R, Gavyole A, Todd J, Hayes R, Grosskurth H, Mabey D, Laga M, Mayaud PH; Institute of Tropical Medicine, Antwerp, Belgium. Fax: 32-3-2476532. E-mail: ABUVE@MICROBIOL.ITG.BE. Objectives: A community based study carried out in Mwanza Region in 1991-1992 found that at least 6.6% of men in the general population were infected with N gonorrhoea and/or C trachomatis and that about 90% of these men were asymptomatic. The objectives of the present study were to confirm the above findings and (1) t |
| Mo.C.342 | Cost-effectiveness of management strategies of acute urethritis. Int Conf AIDS 1996 Jul 7-12; 11:37 (abstract no. Mo.C.342) de Clerck M, Crabbe F, Vuylsteke B, Laga M; Institute of Tropical Medicine, Antwerpen, Belgium. Fax: 32-3-247 63 32. Objective: The most effective antibiotics (3rd generation cephalosporines) for the treatment of gonorrhoea are in most developing countries unaffordable. The objective of this study was to evaluate alternative treatment strategies (using a cheaper, less effective antibiotic first, or using Gram stain to confirm the pre |
| Mo.C.343 | STD/HIV/AIDS: chemists and the community. Int Conf AIDS 1996 Jul 7-12; 11:38 (abstract no. Mo.C.343) Pradhan MP, Srestha O, Basnyat A, Murgrditchian D; AIDSCAP, Arlington, VA, USA. Fax: (703) 516-9781. Up to 90% of Nepal s population does not have access to comprehensive health care services. Local chemists (pharmacists) are often the first point of encounter for men and women seeking treatment for sexually transmitted diseases (STDs). Project: To reach chemists serving large numbers of men and women who are a |
| Mo.C.344 | Survey of STDs seen among private physicians in Jamaica. Int Conf AIDS 1996 Jul 7-12; 11:38 (abstract no. Mo.C.344) Brathwaite AR, Figueroa JP; AIDSCAP, Arlington, VA, USA. Fax: (703) 516-9781. Objective: A survey of physicians in private practice in Jamaica was conducted between March and September of 1993. It attempted to provide a descriptive analysis of the occurrence of conventional STDs seen in their practices. Methods: Questionnaires were delivered by field officers to a convenient sample of 371 privat |
| Mo.C.345 | Validation of the WHO diagnostic algorithm and development of an alternative scoring system for the management of vaginal discharge in Malawi. Int Conf AIDS 1996 Jul 7-12; 11:38 (abstract no. Mo.C.345) Dallabetta G, Daly C, Wangel AM, Hoffman I, Canner J, Lule G, Lema V, Liomba N; AIDSCAP, Arlington, VA, USA. Fax: (703) 516-9781. Objective: To evaluate the performance of the World Health Organization (WHO) algorithm for the detection of cervical infection in women presenting with vaginal discharge and modify the risk assessment score for optimum effectiveness in Malawi . Methods: 550 women presenting with nonulcerative genitourinary complaints |
| Mo.C.440 | Declining prevalence of gonorrhoea (GC) and chlamydia (CT) in female sex workers (FSW), Chiang Rai, Thailand, 1991-94. Int Conf AIDS 1996 Jul 7-12; 11:38 (abstract no. Mo.C.440) Kilmarx PH, Limpakarnjanarat K, Uthaivoravit W, St Louis ME, Young N, Korattana S, Kaewkungwal J, Mastro TD; CDC, Atlanta, GA, USA. Fax: (404)639-8610. E-mail: pbk4@cpsstd1.em.cdc.gov. Objective: To assess the Thai government condom-promotion HIV-prevention campaign, we investigated risk factors for and temporal trends in prevalent GC and CT in a defined cohort of FSW in Thailand using accurate laboratory methods. Methods: From 1991 to 1994, FSW were enrolled and evaluated with interview, physical ex |
| Mo.C.441 | Rapid decline in sexually transmitted disease prevalence among brothel-based sex workers in La Paz, Bolivia: the experience of Proyecto Contra SIDA, 1992-1995. Int Conf AIDS 1996 Jul 7-12; 11:38 (abstract no. Mo.C.441) Levine WC, Higueras G, Revollo R, Vega J, Aliaga A, Tinajeros F, Garnica M, Lewis J, Ugarteche J, Kaune V, Estenssoro M, Wright-Deaguero L, Pareja R, Negron E, Posner J, Ransom R, Melgar M, Kuritsky J; Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA. Fax: 404-639-8610. E-mail: WCL2@cpsstdl.em.cdc.gov. Objective: Efforts to decrease sexually transmitted diseases (STDs) among female sex workers (FSWs) have been most successful in countries responding to massive HIV epidemics (e.g., Thailand ), and in intensive research settings (Projet SIDA, Zaire ). Proyecto Contra SIDA/ Bolivia |
| Mo.C.442 | HIV seroincidence and STD prevalence during an intervention study among female sex workers in Abidjan, Cote D'Ivoire: preliminary findings. Int Conf AIDS 1996 Jul 7-12; 11:39 (abstract no. Mo.C.442) Ettiegne-Traore V, Ghys PD, Diallo MO, Yeboue KM, N'Gbichi JM, Soroh D, Kadio JC, Coulibaly IM, Greenberg AE, Laga M; Projet RETRO-CI, Abidjan, Cote d'Ivoire. Fax: (225) 24-29-69. Objectives: To compare the HIV seroincidence rate in female sex workers (FSW) before and during an intervention study, and to study the effect of two different STD diagnosis and treatment strategies on STD prevalence during this study. Methods: A cross-sectional study (CS) of STD and HIV infection in FSW has been condu |
| Mo.C.443 | Community-based trial of mass STD treatment for HIV control, Rakai, Uganda: preliminary data on STD declines. Int Conf AIDS 1996 Jul 7-12; 11:39 (abstract no. Mo.C.443) Wawer MJ, Sewankambo NK, Gray RH, Serwadda D, Paxton L, Quinn TC, Wabwire-Mangen F; Center for Population and Family Health, Columbia Univ., New York, NY. Fax: 212-304-5272. Objectives: To implement a randomized trial of intensive STD control via mass treatment; to determine the effect of STD control on the incidence/prevalence of STDs and on HIV incidence. Design: In this community-based, single blinded, controlled trial, 58 villages in Rakai District were grouped into 10 clusters encompa |
| Mo.C.444 | Cost-effectiveness of improved STD treatment services as a preventive intervention against HIV in Mwanza region, Tanzania. Int Conf AIDS 1996 Jul 7-12; 11:39 (abstract no. Mo.C.444) Gilson L, Mkanje R, Grosskurth H, Picard J, Mayaud P, Todd J, Mabey D, Hayes R; Johns Hopkins School of Public Health, Baltimore, MD, USA. Fax: +1-410-614-1419. E-mail:rhayes@phnet.sph.jhu.edu. Objective: To measure the impact of improved STD management, using the syndromic approach at the primary health care level, on HIV incidence in rural Tanzania , and to estimate the cost-effectiveness of the intervention. Methods: Community-randomized trial in which HIV incidence was compared in six communities with imp |
| Mo.C.450 | Fifteen years of AIDS in Brazil: epidemiological features and trends of adult female AIDS cases. Int Conf AIDS 1996 Jul 7-12; 11:39 (abstract no. Mo.C.450) Castilho EA, Gomes MRO, Chequer P, Rodrigues LG; Programa Nacional de DST/AIDS, Ministerio da Saude, Brasilia, Brazil. Fax: 55-61-3152519. E-mail: rebeca@gaia.fns.ms.gov.br. Objective: To outline the epidemiological features and trends of adult female AIDS cases in Brazil . Methods: Descriptive statistics of the 76,396 cases of AIDS reported to the National AIDS Program by December 1995, comparing the first five year period (FP) to the last five year period (LP). Results: AIDS cases among |
| Mo.C.451 | The demographic impact of HIV mortality on population structure: empirical evidence from the 1991 Ugandan census. Int Conf AIDS 1996 Jul 7-12; 11:39 (abstract no. Mo.C.451) Low-Beer D, Stoneburner R, Mukulu A; St John's College, Cambridge, UK. Fax: 44-1223-3333392. Objective: To describe the impact and geographic extent of HIV mortality on population structure in Uganda . Methods: The 1991 Uganda Census was analyzed at the parish, sub-district and district levels to identify possible impacts of HIV. Criteria to identify impacts were developed from scenarios of age specific mortal |
| Mo.C.452 | Migration, ethnicity and gender: HIV risk factors for women on the sugar cane plantations (bateyes) of the Dominican Republic (DR). Int Conf AIDS 1996 Jul 7-12; 11:40 (abstract no. Mo.C.452) Brewer T, Hasbun J, Ryan C, Sanchez J, Butler de Lister M, Hawes S, Constanzo J, Lopez J, Holmes K; CFAR, Seattle, WA. Fax: (206)-720-4209. E-mail: toye@u. washington.edu. Objective: To determine risk factors for HIV infection among women living on the bateyes of large private sugar cane company in the DR (estimated off season adult population 18,500, 1.4 males:1 female). Methods: 23 of the 98 bateyes were randomly selected and visited by a mobile medical unit. Volunteers were interviewe |
| Mo.C.453 | Risk factors for HIV infection in Mexico City. Int Conf AIDS 1996 Jul 7-12; 11:40 (abstract no. Mo.C.453) Teran-Toledo X, Hernandez TG, del Rio C, Uribe ZP; CONASIDA (National AIDS Council), Mexico City, Mexico. Fax: (525) 528-4220. Objectives: To determine the prevalence of HIV infection and analyze risk factors for infection among persons who were seen at AIDS Testing Centers in Mexico City between Jan 93 and Dec 95. Methods: We studied sociodemographic characteristics and risk behavior among 10,749 men and 2,757 women who were tested for HIV in |
| Mo.C.454 | Human immunodeficiency virus reaches small villages in rural India. Int Conf AIDS 1996 Jul 7-12; 11:40 (abstract no. Mo.C.454) Singh S, Singh N; Department of Laboratory Medicine, All India Institute of Medical Sciences, New Delhi, India. Fax: 91-11-686-2663/686-8516. E-mail: ssingh@medinst.ernet.in. Objectives: On routine HIV screening of hospitalized patients, a female patient who was admitted at AIIMS for fever, hepatosplenomegaly and megaloblastic anaemia, was found to be positive for HIV antibodies. Following this, a study was planned to determine the seroprevalence of HIV infection in her native village. The |
| Mo.C.455 | Rising HIV infection rates and STD prevalence herald AIDS epidemic in Vietnam. Int Conf AIDS 1996 Jul 7-12; 11:40 (abstract no. Mo.C.455) Lieu TT, Giang LT, Lap VD, Thuc NC, Thinh T, Mandel J, Lindan C; Ho Chi Minh City AIDS Committee, Ho Chi Minh City, Vietnam. Fax: 011-848-299-810. Objective: To describe the epidemiology of HIV and STD s in Vietnam s largest city and current HIV epicenter, Ho Chi Minh City (HCMC), using current surveillance data. Methods: Surveillance data in HCMC has been collected since the mid-1980 s from multiple sources including D.V. Hospital (HCMC s main STD hospital) and |
| Mo.C.460 | Decreasing annual incidence of HIV among IDUs in Stockholm in spite of continued HIV risk behaviour. Int Conf AIDS 1996 Jul 7-12; 11:40 (abstract no. Mo.C.460) Kall K, Julander I, Krook A, Olin R, Stendahl P; Dept. of Social Medicine, Karolinska Institute, Stockholm, Sweden. Fax: +46-8-401 84 99. Objective: To follow the annual HIV incidence among injecting drug users (IDUs) in Stockholm. Methods: Since 1987 all identified IDUs at the Remand Prison in Stockholm were invited to participate in a study consisting of a structured interview and an HIV antibody test. During 1994 test for Hepatitis B and C (HBV and HC |
| Mo.C.461 | Understanding the dynamics of HIV infection among injecting drug users in Rome in the 1990s: the combined use of crosssectional, longitudinal and behavioral data. Int Conf AIDS 1996 Jul 7-12; 11:40 (abstract no. Mo.C.461) Zaccarelli M, Gattari P, Spizzichino L, Portaleone A, Venezia S, Rezza G; Drug Dependency Unit RM/E, Santo Spirito Hospital, Rome, Italy. Fax: 39-6-5592581. E-mail: spallanz@flashnet.it. Objective: To monitor the trend of HIV infection among injecting drug users (IDUs), attending a large drug unit in Rome, between 1990 and 1995, using three different combined approaches. Methods: A routine program, including HIV test and a brief standard interview, was offered every 3-6 months to all IDUs undergoing dr |
| Mo.C.462 | Drug injectors' social networks can be risk factors for syringe sharing. Int Conf AIDS 1996 Jul 7-12; 11:41 (abstract no. Mo.C.462) Neaigus A, Friedman SR, Jose B, Curtis R, Goldstein M, Ildefonso G, Des Jarlais DC; National Development and Research Institutes, Inc., New York, NY, USA. Fax: 212 334 8417. E-mail: alnea@ix.netcom.com. Objective: To determine whether injecting drug users (IDUs) social networks help explain why some IDUs engage in receptive syringe sharing (injecting with a syringe after another injector used it first). Methods: Face-to-face structured interviews and HIV antibody testing were conducted with 767 street-recruited IDUs i |
| Mo.C.463 | Explaining an outbreak: determinants of HIV seroconversion among injection drug users in Vancouver. Int Conf AIDS 1996 Jul 7-12; 11:41 (abstract no. Mo.C.463) Patrick DM, Strathdee SA, Ofner M, Archibald CP, Craib KJP, Cornelisse PG, Schechter MT, Eades G, O'Shaughnessy MV, Rekart ML; BC Centre for Disease Control, Vancouver, British Columbia, Canada. Fax: 604-775-0808. E-mail: dmpatric@bcsc02.gov.bc.ca. Objective: A major increase in new positive HIV tests among injection drug users (IDUs) prompted a case-control investigation to establish factors associated with seroconversion. Methods: Cases were IDUs with a new positive HIV test documented after January 1, 1994, who had a documented negative test within the prior 1 |
| Mo.C.464 | Younger age of initiating injecting drug use is associated with risky behaviors and HIV infection in short-term injectors. Int Conf AIDS 1996 Jul 7-12; 11:41 (abstract no. Mo.C.464) Doherty MC, Garfein RS, Monterroso E, Brown D, Huang H, Park M, Vlahov D; Johns Hopkins SHPH, Baltimore, MD. Fax: 410-550-5385. E-mail: mdoherty@phnet.sph.jhu.edu. Objective: To describe the events surrounding initiation of injecting drug use (IDU) and other risks of HIV infection, by age of initiation, in a cohort of short-term injectors. Methods: In Baltimore, 18-25 year old IDUs (N=218) recruited via street outreach, were interviewed regarding the circumstances of initiating I |
| Mo.C.465 | The relative importance of young and recent-onset injection drug users in the Amsterdam HIV epidemic, 1986-1995. Int Conf AIDS 1996 Jul 7-12; 11:41 (abstract no. Mo.C.465) Fennema JS, van Ameijden EJ, van den Hoek JA, Coutinho RA; Municipal Health Service, Amsterdam, the Netherlands. Fax: +31-20-5555 533. E-mail: fennema@sara.nl. Objective: To study whether young and/or recent-onset injecting drug users (IDU) are at increased risk for HIV infection, and to assess trends from 1986 through 1995 in risk behaviors and HIV incidence among subgroups of IDU. Methods: Associations of age (less than 26, 26-30, greater than 30 year) and time since onset |
| Mo.C.570 | Core groups cause primary infection to dominate HIV transmission even when more than 90% of virus is excreted during later stages of infection. Int Conf AIDS 1996 Jul 7-12; 11:42 (abstract no. Mo.C.570) Koopman JS, Welch G, Jacquez JA, Simon CP, Lange K, Pollock S, Foxman B; Dept. of Epidemiology SPH-1, Ann Arbor, MI. E-mail: jkoopman@sph.umich.edu. Objective: To evaluate how core group structure affects the proportion of viral excretion during primary infection which causes primary infection to dominate HIV transmission dynamics. Methods: The role of primary and late stages of HIV infection on transmission dynamics is a function of both: 1) how much virus is made |
| Mo.C.571 | Risk of HIV transmission during the seroconversion versus the post-seroconversion period. Int Conf AIDS 1996 Jul 7-12; 11:42 (abstract no. Mo.C.571) Duerr A, Mundee Y, Flowers L, Xia J, Kamtorn N, Prasertwitayakij W, Nantachit N, Vannareumol P, Jeeyapant S, Nelson KE; Centers for Disease Control and Prevention, Atlanta, GA, USA. Fax:(770) 488-5965. E-mail: axd9@ccddrh 1.em.cdc.gov. Objective: Plasma viremia is very high shortly after infection with HIV. Whether this represents a time of high risk of sexual transmission was investigated in a study of HIV-infected Thai blood donors and their wives. Methods: Couples were selected from an ongoing study of HIV transmission from HIV-infected (HIV+) mal |
| Mo.C.572 | HIV infectivity by contraceptive method from a partner study in northern Thailand. Int Conf AIDS 1996 Jul 7-12; 11:42 (abstract no. Mo.C.572) Nagachinta T, Duerr A, Gargiullo PM, Yutabutra Y, Wannarat A, Tovanabutra S, Sennan S, Suriyanon V, de Boer M, Celentano DD, Nelson KE; CONRAD, Atlanta, GA, USA. Fax:(770) 488-5965. E-mail: txn3@ccddrh1.em.cdc.gov. Objective: To measure HIV male to female infectivity (probability of transmission per intercourse) associated with use of different contraceptive methods or pregnancy in an ongoing partner study in Chiang Mai, Thailand . Methods: The study population includes HIV-positive blood donors and their regular female sexual pa |
| Mo.C.573 | HIV infectivity: information from epidemiological studies of heterosexual transmission. Int Conf AIDS 1996 Jul 7-12; 11:42 (abstract no. Mo.C.573) Shiboski S, Padian N; Department of Epidemiology & Biostatistics, University of California San Francisco (UCSF), San Francisco, CA. Fax: (415) 476-6014. E-mail: steve@biostat.ucsf.edu. Objective: To investigate the utility of epidemiological studies of heterosexual HIV transmission in providing quantitative information about properties of the infectivity, or per contact infection risk. Also, to present methods for analysis of data from studies of HIV transmission which make appropriate use of exposur |
| Mo.C.900 | Sexual abuse is an independent predictor of sexual risk-taking among young HIV-negative gay men: results from a prospective study at baseline. Int Conf AIDS 1996 Jul 7-12; 11:15 (abstract no. Mo.C.900) Strathdee SA, Hogg RS, Martindale SL, Cornelisse PG, Craib KJ, Schilder A, Montaner JS, O'Shaughnessy MV, Schechter MT; B.C. Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC. Fax: (604) 631-5464. E-mail: steff@hivnet.ubc.ca. Objective: To identify predictors of sexual risk-taking among young HIV-negative men having sex with men (MSM) enrolled in a prospective study of HIV-1 incidence and associated risk factors in Vancouver, Canada . Methods: MSM aged 18-30 who had not previously tested HIV+ were recruited through physicians, clinics and o |
| Mo.C.901 | Increased HIV-1 seroprevalence among female factory workers using injectable hormones in Addis Ababa, Ethiopia. Int Conf AIDS 1996 Jul 7-12; 11:15 (abstract no. Mo.C.901) Fontanet A, Ayalew T, Sahlu T, Messele T, Bindels PJ, Rinke de Wit TF, Yeneneh H, Coutinho RA; Ethiopian-Netherlands AIDS Research Project (ENARP), Addis Ababa. Fax: 251-1-752533 Objective: To determine risk factors associated with HIV-1 infection among female factory workers in Addis Ababa, Ethiopia . Methods: Two-hundred and forty-five female factory workers were interviewed on socio-demographic characteristics, health practices and sexual behaviors before being tested for HIV-1 antibodies fr |
| Mo.C.902 | Post-seroconversion HIV-1 viral load predicts progression to AIDS and death among seroconverters in a prospective study of homosexual men. Int Conf AIDS 1996 Jul 7-12; 11:15 (abstract no. Mo.C.902) Craib KJ, Strathdee SA, Hogg RS, Leung B, Montaner JS, Cassol S, Schechter MT, O'Shaughnessy MV; BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada. Fax: (604) 631-5464. E-mail: kevin@hivnet.ubc.ca. Objective: To compare the predictive potential of baseline HIV-1 serum RNA with baseline and serial CD4 measurements in terms of progression to AIDS and survival in the Vancouver Lymphadenopathy AIDS Study (VLAS) cohort of gay men. Methods: We identified a total of 92 participants who seroconverted during the period 19 |
| Mo.C.903 | Effects of urethritis therapy on the concentration of HIV-1 in seminal plasma. Int Conf AIDS 1996 Jul 7-12; 11:15 (abstract no. Mo.C.903) Hoffman I, Maida M, Royce R, Costello DC, Kazembe P, Vernazza P, Dyer J, Zimba D, Nkata E, Kachenje E, Banda T, Mughogho G, Koller C, Schock J, Gilliam B, Fiscus S, Dallabetta G, Eron J, Cohen M; Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC. Fax: (919) 966-5775. E-mail: hoffman@med.unc.edu. Objectives: To determine 1) if men with urethritis excrete a higher concentration of HIV in their semen than men without urethritis, and 2) if therapy for urethritis decreases the concentration of HIV in the semen. Methods: Malawian men with urethral discharge were evaluated with a gram stain, cultures for N.gonorrhea |
| Mo.C.904 | Two million HIV infections prevented in Thailand: estimate of the impact of increased condom use. Int Conf AIDS 1996 Jul 7-12; 11:16 (abstract no. Mo.C.904) Robinson NJ, Silarug N, Surasiengsunk S, Auvert B, Hanenberg R; INSERM, Saint-Maurice, France. Fax: 331-45183889. E-mail: robinson@citi2.fr. Objectives: To evaluate the impact on the spread of HIV infection of increased condom use between female commercial sex workers (CSWs) and their clients in Thailand since 1989, and to assess the future course of spread of HIV infection assuming condom use is maintained at current levels. Methods: The objective was addr |
| Mo.C.905 | Declines in HIV prevalence in Ugandan pregnant women and its relationship to HIV incidence and risk reduction. Int Conf AIDS 1996 Jul 7-12; 11:16 (abstract no. Mo.C.905) Stoneburner RL, Asiimwe-Okiror G, Musinguzi J, Opio A, Biryahwaho B, Byabamazima C, Turyaguma P; Office of AIDS and STD, WHO, Geneva, Switzerland. Fax: 41-22-791-4834. E-mail: stoneburnerr@who.ch. Objectives: To related changes in HIV prevalence in pregnant women attending antenatal clinic (ANC) sentinel surveillance sites to HIV incidence declines and behavior change. Methods: HIV prevalence was analyzed in pregnant women at 6 ANC sentinel surveillance sites from 1990-95 by age. An age structured HIV epidemiolo |
| Mo.D.130 | Attitudes and training of health care workers on AIDS in Hong Kong. Int Conf AIDS 1996 Jul 7-12; 11:42 (abstract no. Mo.D.130) Lau JTF, Lee SS; Centre for Clinical Trials and Epidemiological Research, Prince of Wales Hospital, Shatin, Hong Kong. Fax: 852-2645-3098. E-mail: JLAU@CUHK.HK. Objectives: To understand AIDS-related knowledge/attitudes among health care workers (HCW) in Hong Kong ; to study factors affecting avoidance of treating AIDS patients. Methods: The sampling frame consisted of the membership lists of the relevant professional bodies. Self-administered questionnaires were sent to 20,80 |
| Mo.D.131 | The experience of creating a working cooperative society formed by people living with HIV. Int Conf AIDS 1996 Jul 7-12; 11:42 (abstract no. Mo.D.131) Anania S; PROMUSIDA (Municipal AIDS Program), Rosario, Argentina. The Carpe Diem Cooperative Society is an alternative way of facing limitations and labor discrimination suffered by people living with HIV Project: Two years ago we were hired by the PROMUSIDA (Municipal Program against AIDS), because of our condition of people living with HIV, to take part in prevention work wi |
| Mo.D.132 | Impact of HIV/AIDS on older people (study conducted in San Pa Thong district of Thailand-1995). Int Conf AIDS 1996 Jul 7-12; 11:43 (abstract no. Mo.D.132) Godfrey P; Asia Training Centre On Aging, Faculty of Nursing, Chiang Mai University, Chiang Mai, Thailand. Fax: (66 53) 221294. A powerful misconception in society is that older people are no longer sexually active therefore not at any risk of contracting HIV/AIDS. People no matter what their age, have sexual feelings and desires and many older people are sexually active, especially those who have lost their spouse/partner, the only sexual outl |
| Mo.D.133 | HIV+ women do have rights. Int Conf AIDS 1996 Jul 7-12; 11:43 (abstract no. Mo.D.133) Williamson K, Dolph-Leonard A; Dolph-Leonard A HIV-infected women are discriminated against when pursuing traditional roles placed on women. Project: Two HIV-infected women created and conducted a survey at the University of Houston, Houston, Texas. A pre-assessment was given prior to their presentation and a post-assessment followed. Their presentations con |
| Mo.D.134 | Achieving a climate of social support and non-stigmatisation of people with HIV and AIDS in Germany. Int Conf AIDS 1996 Jul 7-12; 11:43 (abstract no. Mo.D.134) Muller W, Christiansen G, Toppich J; Federal Centre for Health Education (FCHE), Cologne, Germany. Fax: ++49/221/8992-300. Possibilities for using campaigns as a means of influencing the attitudes prevailing in the population towards persons with HIV and AIDS. Project: The AIDS prevention campaign, which is now in its 10th year, is accompanied by evaluation studies which examine the changes in knowledge, attitudes and behaviour by w |
| Mo.D.135 | On being HIV+ and homosexual workshop. Int Conf AIDS 1996 Jul 7-12; 11:43 (abstract no. Mo.D.135) Parsons MR; Parsons MR PHA = Person living with HIV/AIDS A true understanding of what we face as PHA s and homosexuals. For employees of ASO s to be able to empathise accurately with us. Project: A workshop that helps HIV- people working with HIV+ people better understand our issues. The workshop is built around two main exercises 1. |
| Mo.D.136 | Attitudes of medical practitioners towards HIV infection and AIDS patients. Int Conf AIDS 1996 Jul 7-12; 11:43 (abstract no. Mo.D.136) Thyagarajan R, Shobana S, Joseph RA, Venkatesh T, Ravinathan R, Vimala RR; Kilpauk Medical College, Madras, India. Objective: Are medical personnel ready to treat their clients if the HIV status is known to be positive? Methods: General practitioners & specialists among the medical profession practicing in both urban and rural areas were circulated with a questionnaire and later interviewed personally; assuring them that the in |
| Mo.D.137 | Rehabilitation of people with HIV/AIDS (case studies and experiences from community health development centre-CHDC-Lalitpur, Nepal. Int Conf AIDS 1996 Jul 7-12; 11:38 (abstract no. Mo.D.137) Gurung P, Gurung SM; U.M. Community Health Development Center, Kathmandu, Nepal. Fax: 977-1521831. HIV positive women, in particular, are unfortunate victims of cruel stigmatization. So Community Health Development Center (CHDC) has taken the lead in the rehabilitation of such women in Nepal . In course of medical treatment as well as psychological counseling of such persons, a good deal of information regarding the |
| Mo.D.230 | Care of chronically ill/HIV disease at home: adequacy, coping capacities and support needs in selected Zambian communities. Int Conf AIDS 1996 Jul 7-12; 11:44 (abstract no. Mo.D.230) Sichone M, Mulenga D, Msiska R, Fylkesnes K; National AIDS/STD/TB & Leprosy Programme, Lusaka, Zambia. Objective: To determine factors influencing the adequacy of care of chronically ill/HIV disease at household level. Methods: Chronically ill patients (CIP, sick 30 + days) were identified by interviewing head of households. Households were sampled by 1) arbitrary selection of communities 2) systematic sampling of house |
| Mo.D.231 | Standardized training for lay care-givers: the metropolitan Toronto experience. Int Conf AIDS 1996 Jul 7-12; 11:44 (abstract no. Mo.D.231) Miller JL, Murrant GM; Trinity Home Hospice, Toronto, Ont. Fax: 416-364-2231. E-mail: trinity.home.hospice@beachnet.org. There are transferrable training skills which can enable family and community care-givers to competently provide a safe and comfortable environment in which their loved ones can die of AIDS-related illnesses at home. Effective transfer of these skills can assist in overcoming the challenges of limited material |
| Mo.D.232 | Where to now for home care? A southern Africa perspective. Int Conf AIDS 1996 Jul 7-12; 11:44 (abstract no. Mo.D.232) Jackson H, Kerkhoven RG, Woelk G; Southern Africa AIDS Information Dissemination Service (SAfAIDS), Avondale, Harare, Zimbabwe. Fax: 263 4 336195. E-mail: safaids@healthnet.zw. In subSaharan Africa home care (HC) support services are the predominant organisational response to AIDS care but serious problems arise over 1) quality 2) coverage and 3) cost and sustainability of HC programmes. Project/Research: Problems in providing adequate, sustainable HC services must be seriously address |
| Mo.D.233 | Care counselling model provides support in resource poor families. Int Conf AIDS 1996 Jul 7-12; 11:44 (abstract no. Mo.D.233) Kolondo D; Napham, Lilongwe 3, Malawi. Objective: The objectives of this plenary presentation are to examine the long term needs of people living with HIV/AIDS and their families for counselling and suggesting ways of involving other families or community to support services for the resource poor patients or families. Method: The presentation is based on th |
| Mo.D.234 | The health promotion center: a home based care model for supporting people living with HIV/AIDS in Thailand. Int Conf AIDS 1996 Jul 7-12; 11:44 (abstract no. Mo.D.234) Guyer J, Wooti S; Church of Christ in Thailand AIDS Ministry, Bangkok, Thailand. Fax: 66-2-236-7000. For people living with HIV/AIDS to have a quality life, support must be given in the home for both the individual and their community. Project: The Health Promotion Center (HPC), the home-based care section of the CCT AIDS Ministry, was begun in 1992 to support people living with HIV/AIDS (PLWHA) in living at ho |
| Mo.D.235 | The HIV/AIDS treatment information network: a community-based model for PHAs and their caregivers. Int Conf AIDS 1996 Jul 7-12; 11:44 (abstract no. Mo.D.235) Brown GW; Community AIDS Treatment Information Exchange (CATIE) Toronto, Ontario, Canada. A fundamental goal of AIDS activists and service providers has been for PHAs to be able to manage their own health care. A crucial precondition of such empowerment is access to reliable information on all forms of HIV treatment. Project: The Community AIDS Treatment Information Exchange provides a range of servi |
| Mo.D.236 | The family of persons living with AIDS as home care givers: the role of women. Int Conf AIDS 1996 Jul 7-12; 11:44 (abstract no. Mo.D.236) Solis AA, Arteaga R, Castaneda O, Osorio M, Perez R, Reyes C, Texcucano V; Accion Humana por la Comunidad AC, Mexico DF, Mexico. Fax: 52(5)772 07 78. E-mail: amac@ laneta.apc.org. The family is the foremost possibility of support for persons living with AIDS (PWA). Despite this however, the commitment of caring lies basically on the women of the family. Project: On the basis of proposal of primary health care, the methodology of popular education has been used to develop an orientation pr |
| Mo.D.240 | Outreach program towards deaf people targetting prevention of AIDS. Int Conf AIDS 1996 Jul 7-12; 11:45 (abstract no. Mo.D.240) Grivois L, Houette A; AIDS program Advisor for the City of Paris, Paris, France. Fax: 011 33 1 43 47 70 04. Deaf people do not have access to traditional prevention program; living in a closed community, the risk for contamination is higher when a member of that community brings in the virus. Project: The City of Paris, through her Mobile Unit for Prevention of AIDS (EMIPS, in French) has initiated a complete approach |
| Mo.D.241 | Cost effective AIDS awareness programme on commercial farms in Zimbabwe. Int Conf AIDS 1996 Jul 7-12; 11:45 (abstract no. Mo.D.241) Kerry K, Margie C; Commercial Farmers' Union, Harare, Zimbabwe. Fax: 263-14-750754. Main Objective: To implement a cost effective HIV peer education project among commercial farmers and employees in Zimbabwe . Introduction: Approx. 17% of the population live on commercial farms in Zimbabwe. This sector is the second largest employer after the government. To maintain a viable agricultural economy and r |
| Mo.D.242 | Drug intervention/awareness among IDUs in the slums. Int Conf AIDS 1996 Jul 7-12; 11:45 (abstract no. Mo.D.242) Kanga K; Sharan, New Delhi, India. Fax: 91-11-6858501. Population vulnerable to HIV/AIDS through IDU usage in the slums require innovative and appropriate intervention and awareness. Project: Given the rapid increase in the number of IDUs in Delhi slums, an intervention using client perceptions through planning stages was developed. To this effect, a Harm Reduction |
| Mo.D.243 | Street based AIDS outreach program for injecting drug users (IDUs). Int Conf AIDS 1996 Jul 7-12; 11:45 (abstract no. Mo.D.243) Maharjan SH, Singh M; Lifesaving and Lifegiving Society, Kathmandu, Nepal. Fax: 977-1-416417. There is always a need of human contact between IDUs and needle exchange programs in a developing country to educate on the necessity and skills for sterilizing injecting equipment. Project: The primary objective of this programme is the prevention of AIDS among and from IDUs and their sexual partners. The metho |
| Mo.D.244 | HIV youth intervention: a school-based theatre performance and related intervention activities. Int Conf AIDS 1996 Jul 7-12; 11:45 (abstract no. Mo.D.244) Nordenberg DF, Bernstein CW; Egleston Children's Hospital at Emory University, Atlanta, GA. Fax: (404) 315-3850. Georgia s adolescents are engaging in behaviors which put them at risk for HIV. Approximately 66% of high school students reported ever having sex while condom use ranged from 37% to 74%. Approximately 50% of high school students have had more than one partner and 23% of high school students have had 5 or more p |
| Mo.D.246 | The female minstrels of Bobo-Dioulasso: use of a traditional channel for AIDS IEC. Int Conf AIDS 1996 Jul 7-12; 11:46 (abstract no. Mo.D.246) Yameogo V, Watts S, Devine J; PROMACO/PSI, Ouagadougou 03, Burkina Faso. Fax: 011-226-36-50-54. As part of a pilot IEC strategy, the Condom Social Marketing Project of Burkina Faso (PROMACO), implemented by Population Services International (PSI), used female minstrels called griottes as a vector for disseminating information on AIDS prevention in Bobo-Dioulasso, Burkina s second largest city. As tradition |
| Mo.D.247 | Wind blows at night and morning creating a research-based dramatic television serial for deep attitude change in Vietnam. Int Conf AIDS 1996 Jul 7-12; 11:46 (abstract no. Mo.D.247) Franklin BA, Ngo TK; The Care/AVC Television Project, Hanoi, Vietnam. Fax: (844) 527-962. Research shows that Vietnam has high levels of knowledge about HIV/AIDS, but many people remain at risk due to widespread, deeply-held attitudes about sex, gender and AIDS. Vietnamese media often portray HIV/AIDS dramatically, but portrayals are haphazard and often counterproductive. The power of popular televis |
| Mo.D.250 | Training in HIV/STD prevention education helps adolescents to sort out misconceptions about HIV/STD portrayed in films and T.V. shows. Int Conf AIDS 1996 Jul 7-12; 11:46 (abstract no. Mo.D.250) Hue L, Kauffman C, Clarke Y; Jamaica Red Cross Society, Central Village, St Catherine. Fax: 809 984 7863. Mixed messages in the media undermine HIV/STD prevention education. Project: Over 200 14 to 19 year olds participated in 27 hours of training to become HIV/STD Prevention Peer Educators in the Together We Can programme. Training included topics ranging from HIV/STD prevention to Living with HIV infection. It was |
| Mo.D.251 | The use of mass media for public education on AIDS through training of journalists as AIDS educators in Rwanda, Senegal and Zimbabwe. Int Conf AIDS 1996 Jul 7-12; 11:46 (abstract no. Mo.D.251) Makinwa B, Nkusi A, Dioume R, Odindo R; AIDSCAP, Arlington, VA, USA. Fax: (703) 516-9781. To enable journalists to combine information dissemination with role of educators on STD/HIV/AIDS through the mass media. Project: While journalism training seminars on STD/AIDS in Africa aim to improve the skills and knowledge of the participants in information dissemination through the mass media, it is genera |
| Mo.D.252 | Letra "S", a journalistic and cultural proposal against AIDS in Mexico. Int Conf AIDS 1996 Jul 7-12; 11:46 (abstract no. Mo.D.252) Brito A, Diaz A, Vazquez A, Bonfil C, Contreras A, Palacios M, Figueroa M; Del Valle, Mexico. Fax: 688.6581. Development of a critical journalism with a strong and steady influence on public opinion and official policies in order to cope with new aspects of the AIDS epidemic in Mexico. Project: Letra S is a monthly supplement in a nationwide newspaper and it welcomes a journalism of criticism and research on AIDS and i |
| Mo.D.253* | Int Conf AIDS 1996 Jul 7-12; 11:46 (abstract no. Mo.D.253) |
| Mo.D.254* | Int Conf AIDS 1996 Jul 7-12; 11:46 (abstract no. Mo.D.254) |
| Mo.D.255* | Int Conf AIDS 1996 Jul 7-12; 11:46 (abstract no. Mo.D.255) |
| Mo.D.256 | Dhaaley Dai speaks HIV/AIDS messages in Nepal. Int Conf AIDS 1996 Jul 7-12; 11:47 (abstract no. Mo.D.256) Basnyat A, Gauchan D, Lama R, Pollock J; AIDSCAP, Arlington, VA, USA. Fax: (703) 516-9781. Condoms are the most popular family planning method in Nepal . There were some initial fears that active promotion of condoms for disease prevention might damage the acceptance of Nepal s socially marketed condoms. Project: Nepal s first multimedia campaign for AIDS awareness and condom promotion was launched to |
| Mo.D.350 | AIDS prevention, testing and care in current military practice. Int Conf AIDS 1996 Jul 7-12; 11:47 (abstract no. Mo.D.350) Kingma SJ; AIDS in the Military, UNAIDS, Geneva, Switzerland. Fax: 41-22-791-4187. E-mail: kingmas@who.ch. Armed forces personnel constitute a population at special risk for infection with HIV. Studies show that military personnel on deployment regularly have sexual contacts with prostitutes and the local population. Infection rates of STDs among the military are 2 to 5 times higher than STD infection rates in compar |
| Mo.D.351 | HIV/AIDS vulnerability of the Armed Forces. Int Conf AIDS 1996 Jul 7-12; 11:47 (abstract no. Mo.D.351) Puta JC; Nursing (Army), Zambia Defence and Security Forces, Lusaka, Zambia. Fax: 260-1-264-643. From 1985 (when a number of HIV related cases were reported) up to 1992, the AIDS prevention programme was targeted to the civilian population only. This meant that all the donor resources meant for people living in Zambia to fight AIDS left out a large number of vulnerable men and women aged between 18-45 yrs. This ag |
| Mo.D.352 | The contribution of the military medical infrastructure for surveillance and monitoring of HIV and other emerging infections. Int Conf AIDS 1996 Jul 7-12; 11:47 (abstract no. Mo.D.352) D'Amelio R; Ministro della Difesa, Rome, Italy. Fax: 39 6 46 91 25 28. The world Health Organization (WHO) has recently turned its attention to the problem of Emerging and Reemerging Infectious Diseases, including HIV. The overall strategy includes the strengthening of surveillance for infectious diseases, through a network of national laboratories, able to diagnose the usual infectious d |
| Mo.D.353 | STD/AIDS intervention initiative among the Armed Forces and police in Cameroon. Int Conf AIDS 1996 Jul 7-12; 11:47 (abstract no. Mo.D.353) Mpoudi NE, Torimiro JN, Boupda A, Nkoue C; Service de Lutte contre le Sida, Cameroon. HIV sentinel surveillance among the military and police was first implemented in 1990 for voluntary testing, recording a prevalence of 3.2 % while the general population recorded 1.25 %. Two years later, it increased to 6.28%. Project: The program Prevention of Sexual Transmission of HIV in the Armed Forces and |
| Mo.D.354 | HIV exposure risk in military populations: an uncharted prevention frontier. Int Conf AIDS 1996 Jul 7-12; 11:48 (abstract no. Mo.D.354) Temoshok LR, Kingma SJ; UNAIDS, Geneve, Switzerland. Tel/Fax: +4122.788.0906. Objective: To apply the results of the first large-scale survey of HIV exposure risk-relevant factors in a military population (the US Army) to the development of targetted HIV behavioural prevention strategies for world-wide military populations. Methods: An anonymous self-administered survey of HIV exposure risk-rele |
| Mo.D.361 | Evaluation of the Baltimore needle exchange program: preliminary results. Int Conf AIDS 1996 Jul 7-12; 11:48 (abstract no. Mo.D.361) Vlahov D, Junge B, Beilenson P, Brookmeyer RS, Cohn S, Armenian H; Johns Hopkins SHPH, Baltimore, MD, USA. Fax: 410-614-9910. Objective: To evaluate the first year of the Needle Exchange Program (NEP) for injection drug users (IDUs). Methods: All participants between 8/12/94 and 8/11/95 who underwent enrollment interviews on sociodemographic and drug use practices. A systematic sample was interviewed at initial, two week and six month follow- |
| Mo.D.362 | AIDS prevention programme including needle distribution for female prisoners: the Hindelbank pilot project. Int Conf AIDS 1996 Jul 7-12; 11:48 (abstract no. Mo.D.362) Zeegers Paget D, Bernasconi S, Wasserfallen F, Rihs-Middel M, Nelles J, Burki B, Baechtold A; Federal Office of Public Health, Bern-Liebefeld, Switzerland. Fax: -31 -323 87 89. Due to high prevalences of HIV and hepatitis in prisons, there is a need for prevention programmes for prisoners who continue to inject drugs in prison. Project: Comprehensive AIDS and drugs prevention programme including needle distribution in the female prison of Hindelbank. The programme aimed at: 1) preventi |
| Mo.D.363 | Social determinants predict needle sharing behaviour among injection drug users in Vancouver. Int Conf AIDS 1996 Jul 7-12; 11:48 (abstract no. Mo.D.363) Strathdee SA, Patrick DM, Archibald C, Ofner M, Craib KJ, Cornelisse PG, Eades G, Schechter MT, Rekart M, O'Shaughnessy MV; BC Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC. Fax: (604) 631-5464. E-mail: steff@hivnet.ubc.ca. Objective: To identify determinants of needle sharing behaviour in Vancouver, where a recent outbreak of HIV infection occurred among injection drug users (IDUs) despite longstanding needle exchange and outreach services. Methods: A total of 281 IDUs participated in a case control study of risk factors for HIV infectio |
| Mo.D.364 | Limitations on the sale and possession of syringes; results of a national survey of laws and regulations. Int Conf AIDS 1996 Jul 7-12; 11:48 (abstract no. Mo.D.364) Lazzarini Z, Gostin LO, Flaherty KM, Jones TS; Harvard School of Public Health, Dept. Health Policy and Management, Boston, MA, USA. Fax: (413) 533-7550. Background: Legal provisions in many United States (U.S.) jurisdictions criminalize sale, possession, distribution or manufacture of hypodermic syringes and needles (drug paraphernalia laws); require a physician s prescription for legal sale (syringe prescription laws); or restrict sales by regulation. Objectives: 1. T |
| Mo.D.365 | Needle/syringe sources, reuse, and opinions toward "one set, one shot" among active injection drug users (IDUs) in six U.S. cities. Int Conf AIDS 1996 Jul 7-12; 11:49 (abstract no. Mo.D.365) Gleghorn AA, Wright-DeAguero L, Jones ST, Ogden L; Centers for Disease Control and Prevention, Atlanta, GA. Internet: Ixa3@oddhiv1.em.cdc.gov. Objectives: To determine differences in sources of needles and syringes (NS), and patterns of NS use and reuse among active injection drug users (IDUs) in 6 U.S. cities characterized by varied legal restrictions for NS acquisition and possession. We examined reasons for NS disposal and opinions toward single use of NS. |
| Mo.D.366 | New partners in HIV prevention: role of pharmacists in increasing drug users' access to sterile syringes. Int Conf AIDS 1996 Jul 7-12; 11:49 (abstract no. Mo.D.366) Wright-De Aguero LK, Weinstein B, Jones ST; Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA. Fax: 404-639-0929. E-mail: Ikw1@oddhiv1.em.cdc.gov. Objective: In July 1992, Connecticut legalized the sale of up to 10 needles and syringes without a prescription. The intent of the law change was to reduce sharing of blood-contaminated syringes by injecting drug users (IDUs). We assessed pharmacy policy and managers support for the sale of syringes and factors and neg |
| Mo.D.371 | Women living with HIV/AIDS: the dual challenges of being a medical patient and a primary family caregiver. Int Conf AIDS 1996 Jul 7-12; 11:49 (abstract no. Mo.D.371) Hackl KL, Somlai AM, Kelly JA, Kalichman SC; Center for AIDS Intervention Research (CAIR), Medical College of Wisconsin, Milwaukee, WI, USA. Fax: 414-287-4683. Over 60,000 women in the United States have been diagnosed with AIDS and millions of women worldwide are infected with HIV. Most of these women will die at an early age, orphaning their children. During their illness, women will often confront the challenge of being both patient and family caregiver. Little rese |
| Mo.D.372 | Parenting by HIV seropositive women. Int Conf AIDS 1996 Jul 7-12; 11:49 (abstract no. Mo.D.372) Hutton N, Anderson J, Gielen A; Johns Hopkins Hospital, Baltimore, MD, USA. Fax: 410-614-8821. E-mail: nhutton@welchlink.welch.jhu.edu. Objective: To determine the parenting experience of a cohort of HIV seropositive women. Methods: Three hundred twenty women, recruited to participate in a randomized intervention trial of peer advocacy and support, were interviewed at study entry regarding their childbearing and parenting experience. Frequency distribu |
| Mo.D.373 | The effects of an HIV-positive diagnosis on heterosexual womens' intimate relationships. Int Conf AIDS 1996 Jul 7-12; 11:49 (abstract no. Mo.D.373) Acosta AB; Albuquerque, NM, USA. Fax: 505-266-6010. An HIV-positive diagnosis stirs up many issues regarding one s sexuality; for heterosexual women, these may include dating, sex, and maintaining intimate relationships. Project: Eight HIV-positive heterosexual women were questioned using a moderately scheduled interview which lasted approximately 1 1/2 hours. Th |
| Mo.D.374 | Seriously seeking: the experiences and coping strategies of women living with HIV/AIDS in two Australian states. Int Conf AIDS 1996 Jul 7-12; 11:49 (abstract no. Mo.D.374) Lawless S, Greet B, Vivienne M; National Centre for HIV Social Research, Sydney, Australia. Fax: 61 02 850 8112. Objective: (a) to examine the coping strategies utilised by a diverse group of HIV+ women when attempting to access health care services, and support; and (b) to identify the implications for improving service provision. Methods: As part of the Women living with HIV/AIDS research project, in-depth interviews were condu |
| Mo.D.480 | Holistic approach to Native American case management. Int Conf AIDS 1996 Jul 7-12; 11:50 (abstract no. Mo.D.480) Bellymule-Zuniga G, Franklin VE, Armstrong D, Logston D; Ahalaya Project, Oklahoma City, OK. Fax: (405) 631-9989. Native Americans are often discriminated against based on thier HIV status. Project: Native Americans with HIV are often discriminated against based on their HIV status. The results are denial of adequate health care, support services, and other benefits. Resolving these problems often requires specialized and i |
| Mo.D.481 | Living with AIDS - a south Australian aboriginal perspective. Int Conf AIDS 1996 Jul 7-12; 11:50 (abstract no. Mo.D.481) Junga R; Blair Atol, South Australia. Telephone 08342 1248. Aboriginal people in South Australia make up 1% of the state population and 3% on a national level. Yet in South Australia we have the highest suicide rate (37%), not only nationally but one of the highest in the world. This combined with the poor health standards, lack of education and extremely low life expectancy ma |
| Mo.D.482 | Indigenous to indigenous outreach: a collaboration between Native Americans and Native Hawaiians. Int Conf AIDS 1996 Jul 7-12; 11:50 (abstract no. Mo.D.482) Green Rush A, Iinuma G; NNAAPC, Oakland, CA, USA. Fax: 510-444-1593. E-mail: andreagr@aol.com. In order to address the unique needs of indigenous populations, HIV/AIDS prevention education strategies must be developed by indigenous people that reflect their values and traditions. Further, a mechanism is needed for indigenous people to share successful approaches and strategies with one another. Project: I |
| Mo.D.483 | Unprotected intercourse and the meanings ascribed to sex by aboriginal people living on-reserve in Ontario, Canada. Int Conf AIDS 1996 Jul 7-12; 11:50 (abstract no. Mo.D.483) Bullock SL, Myers T, Calzavara LM, Cockerill R, Marshall VW, Burchell A; HIV Social Behavioral and Epidemiological Studies Unit, W. Toronto, ON. Fax: (416)971-2704. E-mail: sbullock@epas.utoronto.ca. Objective: To determine whether the meanings ascribed to sex by on-reserve Aboriginal people are associated with their reported use of condoms. Methods: A stratified random sample of 658 Aboriginal people was drawn from 11 reserve communities in the province of Ontario, Canada . Unprotected and protected intercourse we |
| Mo.D.484 | Feather of hope aboriginal AIDS prevention society (FOHAAPS): an oral tradition of "cultural sensitivity" and spiritually based process. Int Conf AIDS 1996 Jul 7-12; 11:50 (abstract no. Mo.D.484) Lennie EH, Daniels JA; Feather of Hope Aboriginal AIDS Prevention Society, Edmonton, AB. Aboriginal Elders prophesied The Shape Shifter known as the HIV virus. They said the Shapeshifter has the ability to destroy us or to teach us. Project: Aboriginal people have a unique process of healing and dealing with HIV/AIDS. Feather of Hope Community Development shares this process of healing through educa |
| Mo.D.490 | The influence of personal and generational factors on the incidence of HIV and STDs among young gay and bisexual men in France. Int Conf AIDS 1996 Jul 7-12; 11:50 (abstract no. Mo.D.490) Adam P, Schiltz MA; CAMS, Paris, France. Fax: 33-1-49 54 21 09. E-mail: schiltz@cams.msh-paris.fr. Objectives: Depending on the age group observed, there exist considerable differences in the incidence of HIV and of STDs among young French gay men. These variations will be put into perspective with the dissemination of prevention messages and with the establishment of familial separation and economic and sexual inde |
| Mo.D.491 | Factors associated with unprotected anal intercourse in positive and non-positive gay men's casual partnerships. Int Conf AIDS 1996 Jul 7-12; 11:51 (abstract no. Mo.D.491) Van de Ven PG, Campbell D, Kippax S, Prestage G, Crawford J, Baxter D, Cooper D; NCHSR, Macquarie University, Sydney, Australia. Fax: +61-2-850-8112. E-mail: paul.vandeven@mq.edu.au. Objective: To assess the factors associated with unprotected anal intercourse with casual partners among positive and non-positive gay men in Sydney, Australia . Methods: Participants were recruited through gay community and a variety of other sources and interviewed for the Sydney Men and Sexual Health studya longitud |
| Mo.D.492 | Men who have sex with men in public places are more likely to have unprotected anal intercourse. Int Conf AIDS 1996 Jul 7-12; 11:51 (abstract no. Mo.D.492) Coates TJ, Acree M, Stall R, Hoff C, Kegeles S, Ekstrand M, Paul J, Jinich S; Center for AIDS Prevention Studies (CAPS), University of California, San Francisco, CA, USA. Objective: To determine whether or not men who have sex with men who meet sexual partners in gay saunas or in public sex environments (PSEs) are more likely to engage in unprotected anal intercourse (UPI) with non-monogamous partners. Methods: We recruited a cohort of gay men in 1992 in Portland OR and Tucson AZ using |
| Mo.D.493 | Broadening the social base of AIDS prevention among men who have sex with men (MSM) in the Dominican Republic (DR). Int Conf AIDS 1996 Jul 7-12; 11:51 (abstract no. Mo.D.493) Sanchez L, Arredondo M; AIDSCAP, Arlington, VA, USA. Fax: (703) 516-9781. Objectives: Reorganizing and redirecting a gay outreach organization after the death of its charismatic leader to design more appropriate intervention strategies in a country where homosexuality still incurs significant social stigma. Methods: A cross-sectional study of 354 MSM from a variety of community settings was |
| Mo.D.494 | Post AIDS: assessing the long-term social impact of HIV/AIDS in gay communities. Int Conf AIDS 1996 Jul 7-12; 11:51 (abstract no. Mo.D.494) Dowsett GW, McInnes D; School of Behavioural Sciences, Macquarie University, Sydney, Australia. Fax: +61 2 850 9355. E-mail: Australian gay communities have been living with HIV/AIDS for 14 years and behavioural research has indicated a very high, sustained level of safe sex. However, the long-term impact of safe sex on gay sexual culture and the losses to AIDS on the social fabric of gay communities has not been assessed. Project: Th |
| Mo.D.495 | Radio AIDS prevention program targeting young homosexual men. Int Conf AIDS 1996 Jul 7-12; 11:51 (abstract no. Mo.D.495) Clouzeau F, Lamien E, Desclaux B, Debains J, Valentin B, Maurel H; Sida Info Service, PARIS, France. Fax: 1-44931649. Studies have shown that unsafe sex practices often increase among young homosexual men when they are unable to come to terms with their own homosexuality. Project: An AIDS prevention project intiated by RADIO FG and SIDA INFO SERVICE. RADIO FG is a gay community radio broadcasting 24/24 h on the greater Paris ar |
| Mo.D.580 | The AIDS community demonstration projects (ACDP): a successful multi-site community-level behavioral intervention. Int Conf AIDS 1996 Jul 7-12; 11:52 (abstract no. Mo.D.580) Fishbein M, Johnson WD; BIRB, DSTD, CDC, Atlanta, GA, USA. Fax: 404-639-8622. E-mail: mxf0@cpsstdl.em.cdc.gov. Objective: To evaluate a theory-based, community-level intervention designed to increase consistent condom and bleach use among populations at high risk for HIV infection (i.e., injecting drug users [IDU], female sex partners of IDU, commercial sex-workers, men who have sex with men but who do not gay identify, and str |
| Mo.D.581 | Community mobilization reduces HIV risk among young gay men: a two community study. Int Conf AIDS 1996 Jul 7-12; 11:52 (abstract no. Mo.D.581) Kegeles SM, Hays R, Pollack L, Coates T; Center for AIDS Prevention Studies (CAPS), University of California, San Francisco, USA. Fax: 415-597-9213. E-mail: Susan_Kegeles@quickmail.ucsf.edu. Objective: To evaluate an 8-month peer-led community-level HIV prevention program for young gay/bisexual men that we developed and implemented in 2 mid-sized U.S. communities. Methods: The intervention, based on diffusion of innovations theory, used 5 elements designed to increase support for safer sex and to change co |
| Mo.D.582 | Increased consistent condom use among students in a prevention study based on community organisation and action and the use of peer educators. Int Conf AIDS 1996 Jul 7-12; 11:52 (abstract no. Mo.D.582) Svenson GR, Johnsson K, Hanson BS; Dept. of Community Medicine, Malmo University Hospital, Malmo, Sweden. Fax: +46-40-336215. Objective: To develop and longitudinally evaluate a HIV-STD prevention approach based on community organisation and action, target group empowerment and the use of opinion leaders as peer educators. A study project modelled on the approach was initiated among the student body of Lund University (37,000 students) in 199 |
| Mo.D.583 | The women's safer sex hierarchy: initial responses to counseling on women's methods of STD/HIV prevention at an STD clinic. Int Conf AIDS 1996 Jul 7-12; 11:52 (abstract no. Mo.D.583) Gollub EL, French P, Latka M, Johns L, Blum L, O'Donnell J, Stein ZA; Philadelphia Dept. of Public Health/AIDS Activities Coordinating Office, Phila., PA. Fax: 215-685-6714. E-mail: 102027. 1445@compuserve.com. Objective: To measure differences in risk of reinfection with STD and unwanted pregnancy in a clinical trial of three different counseling messages: full choice ( hierarchy ) of women s barrier methods (female condom, diaphragm, spermicides, etc.); enhanced male condom counseling only, and female condom counseling only |
| Mo.D.600 | HIV/AIDS intervention among transsexuals in Bangalore. Medico - legal impediments for effective intervention. Int Conf AIDS 1996 Jul 7-12; 11:52 (abstract no. Mo.D.600) Sanjay G; "Royal Corner", Bangalore, India. Objective: To provide HIV/AIDS information/counselling/STD treatment and condom distribution among transsexuals in, Bangalore - INDIA. Methods: In Bangalore there are 7 families comprising of approximately 25 transsexuals each, they are a very closely knit community. After making the initial contact each group was educ |
| Mo.D.601 | AIDS prevention for transgender and transsexual persons: a collaborative community-based program. Int Conf AIDS 1996 Jul 7-12; 11:53 (abstract no. Mo.D.601) Warren BE, Capozuca J, Pols B, Otto B; The Center, NYC, NY. Fax: (212)924-2657. E-mail: lgcsc@aol.com. Transgender and transsexual populations, adult and especially adolescent, are at high risk for HIV/AIDS but have no access to relevant and appropriate prevention education and early intervention services. Project: An HIV/AIDS outreach and education program was developed by five community-based transgender servic |
| Mo.D.602 | Risk of HIV infection by transvestite sex workers in Brazil: prostitution, silicone and drugs. Int Conf AIDS 1996 Jul 7-12; 11:53 (abstract no. Mo.D.602) Mott L, Cerqueira M; Universidade Federal da Bahia, Salvador, Bahia, Brazil. Fax: 55-71-3223782. E-mail: luizmott@ufba.br. Project: In Brazil , it is estimated there are 6,000 to 8,000 transvestites, 90% of them living as prostitutes with bisexual clients. This very poor and marginalized population is concentrated in decadent prostitution areas. These breast boys receive average of 4 clients each night. As a result of financing from the Br |
| Mo.D.603 | Developing effective HIV/AIDS programs for transsexuals working as sex workers. Int Conf AIDS 1996 Jul 7-12; 11:53 (abstract no. Mo.D.603) Slamah D; IKHLAS Center, Kuala Lumpur, Malaysia. Fax: 603.4415699. HIV/AIDS Education & Awareness to transgendered sex workers community Projects: A transsexuals program targeting the transgendered sex workers reaching out to the transgendered community at brothels, back lanes, streets and homes of the transgendered sex workers. In bring discussions and retreat workshops is |
| Poster Abstracts - Monday, July 8 Track A: Basic Science Mo.A.1001 thru Mo.A.1117 |
|
| Mo.A.1001 | The dynamic expression of CD4 on cultured monocytes: implications for in vitro HIV infection. Int Conf AIDS 1996 Jul 7-12; 11:56 (abstract no. Mo.A.1001) Graziani GM, Filion LG; University of Ottawa, Department of Microbiology/Immunology, Faculty of Medicine, Ottawa, ON, CA. Fax: 613-562-5452. E-mail: g507794@labsunl.med.uottawa.ca. Introduction: Following overnight culture of purified monocytes, or monocytes in a PBMC (peripheral blood mononuclear cell) fraction, CD4 is down-regulated. However, within the PBMC cultures, CD4 on T cells continues to be expressed, suggesting that CD4 regulation is cell-specific. Whereas much work has been done on T |
| Mo.A.1002 | The implication of CD26 in HIV infection: viral entry and its cytopathic effect. Int Conf AIDS 1996 Jul 7-12; 11:56 (abstract no. Mo.A.1002) Callebaut C, Jacotot E, Krust B, Hovanessian AG; Institut Pasteur, UA CNRS Paris. Fax: 33 1 4061 3012. E-mail: chrcall@pasteur.fr. Objective: The T cell activation antigen CD26 is a cell surface serine-exopeptidase charaterized by a dipeptidyl peptidase IV (DPP IV) activity. We have previously reported that CD26 through a potential interaction with the V3 loop of HIV envelope gp120, could serve as a cofactor of CD4 in entry of lymphotropic HIV-1 L |
| Mo.A.1003 | Identification of the beta 2-m derived epitope responsible for neutralisation of HIV isolates. Int Conf AIDS 1996 Jul 7-12; 11:56 (abstract no. Mo.A.1003) Le Contel C, Galea P, Silvy F, Hirsch I, Chermann JC; Unite de Recherches sur les Retrovirus et Maladies Associees, Marseille, France. Fax: (33) 91 41 92 50. Objective: Specific antibodies against beta 2-microglobulin (beta 2-m) have been demonstrated to precipitate HIV-1 LAV showing that HIV virions carried beta 2-m on their surface. Such antibodies inhibit replication of HIV-1 LAV. We investigated whether beta 2-m could represent a target against all HIV strains and which |
| Mo.A.1004 | Differential course of HIV-1 infection in primary human monocytes and macrophages. Int Conf AIDS 1996 Jul 7-12; 11:56 (abstract no. Mo.A.1004) Schneider J, Bohuschke M, Kary B, Herchenroder O; Abt. Virologie, Freiburg, Germany. Fax: *49761 2036639. E- mail: schf@sun1.ukl.uni-freiburg.de. Objective: Blood monocytes can transport HIV from the blood into the organs. As a prerequisite to understand their potential role in the AIDS pathogenesis, we have studied the course of HIV-infection during differentiation of blood monocytes (MO) to adherent macrophages (MF) in vitro. Methods: MO from 34 healthy blood |
| Mo.A.1005 | Subtype identification and replication capacity of HIV-1 strains isolated in Hungary. Int Conf AIDS 1996 Jul 7-12; 11:56 (abstract no. Mo.A.1005) Nagy K, Barabas E, Varkonyi V, Horvath A; National Institute of Dermato-Venereology, Budapest, Hungary. Fax: +36 1 134 0566. E-mail: nagkar@bor.sote.hu. Objective: To identify HIV-1 envelope sequence subtype and characterise in vitro replication capacity of HIV strains from infected asymptomatic individuals. Methods: DNA samples derived from periferal blood mononuclear cells were analsed by sequencing of HIV-1 env region encoding V3-loop. A 211 nucleotide fragment (706 |
| Mo.A.1006 | Separation of gp120 and gp160 by Cibacron Blue 3GA. Int Conf AIDS 1996 Jul 7-12; 11:56 (abstract no. Mo.A.1006) Hattori T, Sato Y, Kubo T, Zhan X, Sakaida H, Nishikawa S, Uchiyama T; Institute for Virus Research, Kyoto Univer., Kyoto, Japan. Tel/Fax: 81-75-751-3986. E-mail: thattori@virusl.virus.kyoto-u.ac.jp. Objectives: We have attempted to separate gp120 from gp160 from the culture supernatants of gp120/gp160 secreting CHO cells to characterize the biological and biochemical features of both proteins. Methods: CHO-SEC cells were used for secreting cells (kindly provided from Dr. Weiss at FDA ). The cells are made by tr |
| Mo.A.1007 | Roles of sialic acid in HIV-1 infection. Int Conf AIDS 1996 Jul 7-12; 11:57 (abstract no. Mo.A.1007) Murakami T, Hamamoto Y, Asagami C, Yamamoto M, Handa S, Taki T, Mizuochi T, Yoshida K, Yamamoto N; Tokyo Medical and Dental University, Tokyo, Japan. Fax: 81-35803-0124. E-mail: murakami.mmb@med.tmd.ac.jp. Objective: To investigate the roles of sialic acid residues both on HIV-1 and target cells on the virus infectivity. Methods: HIV-1HTLV-IIIB and MT-4 or YAA cells (a non-tumorous monocyte/macrophage lineage cell line) were treated with a bacterial neuraminidase in the presence or absence of a specific inhibitor of the |
| Mo.A.1008 | Spectroscopic investigation of secondary structure change of a peptide from C4 region of HIV-1 gp120. Int Conf AIDS 1996 Jul 7-12; 11:57 (abstract no. Mo.A.1008) Chang DK, Chien WJ, Cheng SF, Chen ST; Institute of Chemistry, Academia Sinica, Taipei, Taiwan, ROC. Fax: 886-2-783-1237. E-mail: dkc@chem.sinica.edu.tw. Objective: To determine the secondary structure of the C4 region of HIV-1 gp120 and its change on CD4 binding to assist vaccine and inhibitor development. Methods: A 44-mer peptide encompassing a CD4-binding site was synthesized and its secondary structure determined by NMR, circular dichroism (CD) spectroscopies. Bind |
| Mo.A.1009 | Mechanisms of opsonized-HIV entry in normal B lymphocytes. Int Conf AIDS 1996 Jul 7-12; 11:57 (abstract no. Mo.A.1009) Legendre C, Gras G, Krzysiek R, Galanaud P, Richard Y, Dormont D; Service de Neurovirologie, IPSC, CEA and CRSSA, Fontenay aux Roses, France. Fax: (33 1) 46 54 77 26. E-mail: gras@dsv-idf.cea.fr. Objective: To determine the respective contributions of CD4, and complement receptors, to opsonized HIV entry into normal B lymphocytes. Methods: Normal tonsil B lymphocytes, in vitro stimulated or not, were used as target cells for infection by antibody and complement-opsonized HIV-1/LAI. The effect of CD4-HSA, and th |
| Mo.A.1010 | Antisense expression cloning of HIV host factor genes. Int Conf AIDS 1996 Jul 7-12; 11:57 (abstract no. Mo.A.1010) Schalk HJ, Scheinert P, Thiesen J, Bendrat E; Bernhard-Nocht-Institute for Tropical Medicine Virology, Hamburg, Germany. Fax: 49-70-31182309. Besides its receptor CD4 HIV presumably needs additional membrane bound and intracellular receptors. To isolate genes for essentially needed host factors, we developed a three step cell genetic screen based on the expression of antisense RNA libraries. 1.) We constructed very small cDNA antisense libraries of cellular |
| Mo.A.1011 | Adenine clustering, guanine to adenine hypermutation and secondary HIV-1 RNA structure. Int Conf AIDS 1996 Jul 7-12; 11:57 (abstract no. Mo.A.1011) Rabinovich RD, Ghiringhelli D, Gutson D, Fernandez D, Marquina S, Libonatti O; National Reference Centre for AIDS, Paraguay, Argentina. Fax: 54 1 962 5404. Objective: to study the possible relation among adenine accumulation, guanine to adenine hypermutation and RNA secondary structure in HIV-1 genomes. Methods: Fifteen HIV-1 and one HTLV-I sequences were obtained from Los Alamos data base. RNA folding (secondary structure) was predicted by using the FOLD program with upd |
| Mo.A.1012 | Anti-HIV action possessing a dual mechanism of masked alaninyl d4T-MP derivatives. Int Conf AIDS 1996 Jul 7-12; 11:57 (abstract no. Mo.A.1012) Balzarini J, Egberink H, Hartmann K, Karlsson A, Perno CF, Cahard D, Vahlenkamp T, Thormar H, De Clercq E, McGuigan C; Rega Institute for Medical Research, Leuven, Belgium. Fax: 32-16-33.73.40. Masked nucleoside phosphoramidate derivatives of stavudine ( d4T ) such as So324 were found to show a marked anti-HIV activity in cell culture. So324 proved more inhibitory to HIV replication in thymidine kinase-deficient CEM/TK- cells than in wild-type cells, whereas |
| Mo.A.1013 | Possible regulation of HIV replication by a cellular factor binding to the primer binding site. Int Conf AIDS 1996 Jul 7-12; 11:58 (abstract no. Mo.A.1013) Lai D, Guo HG, Gallo RC, Reitz M; UMBI, Baltimore, Maryland. Fax: 410-706-8184. Objective: The regulation of HIV replication has been intensively studied. One of the early steps is the reverse transcription of viral RNA into viral DNA, which is then integrated into the infected host cell genome. The natural primers for reverse transcription are the cell derived tRNAs. However, the exact interactio |
| Mo.A.1014 | Evaluation of anti-HIV-1 reverse-transcriptase (RT) antibody titer in HIV-infected subjects. Int Conf AIDS 1996 Jul 7-12; 11:58 (abstract no. Mo.A.1014) Meguro T, Yamazaki S, Takayama S, Shiga K, Takil M, Ito H, Sadamoto S, Koyanagi H, Kakishima H, Yamada K; Dept. of Pediatrics, Institute of Medical Science Division of Research Laboratory, St. Marianna Univ. School Med, Yokohama, Japan. Fax: 045-366-1190. We tried to study on the antibody titer against reverse-transcriptase (RT) of HIV and its clinical significance in 10 cases of HIV-infected hemophiliac patients, 4 cases of HIV-infected homo/heterosexual subjects and 51 uninfected volunteers. Methods: Using recombinant RT antigen of HIV-1, RT antibody in plasma or sear |
| Mo.A.1018 | Different viral variants in chromosomic and extra-chromosomic viral DNA in an in vitro superinfection with HIV-1. Int Conf AIDS 1996 Jul 7-12; 11:58 (abstract no. Mo.A.1018) Marquina S, Gomez CM, Galvan V, Libonatti O, Rabinovich RD; National Reference Centre for AIDS, Buenos Aires, Argentina. Fax: 54 1 962 5404. Objective: to study the viral DNA in the chromosomic and extrachromosomic fraction and the viral progenie in a superinfection, with another variant, of a cell line persistently infected with an HIV-1 strain. Methods: The superinfection system consisted in the H9HTLVIIIB cell line persistently infected, and the superinf |
| Mo.A.1019 | Assaying integration activity of HIV-1 integrase with DNA-coated plates. Int Conf AIDS 1996 Jul 7-12; 11:58 (abstract no. Mo.A.1019) Syu W Jr, Chang YC, Ching TT; National Yang-Ming University, Taipei, Taiwan. Fax: 886-2-821-2880. E-mail: wjsyu@ym.edu.tw. Objective: To simplify the measurement of integration reaction, an easy method mimicing enzyme-linked immunosorbent assay (ELISA) procedures was developed. Methods: Integration of reverse transcribed viral DNA of HIV into host chromosomes is mediated by the viral enzyme, integrase. This enzymatic activity can be monito |
| Mo.A.1020 | Isolation and characterization of a novel class of human immunodeficiency virus integrase inhibitors from natural product screening. Int Conf AIDS 1996 Jul 7-12; 11:58 (abstract no. Mo.A.1020) Hazuda D, Blau C, Felock P, Hastings J, Lineberger D, Wolfe A, Goetz M, Williams M, Zink D, Singh S; Merck Research Laboratories, West Point, PA, USA. Fax: 215-652-0994. E-mail: daria_hazuda@merck.com. Objective: Integration of a copy of the viral genome into the genome of the host cell is an essential and defining step in the replication of all retroviruses. Integration is catalyzed by a virally encoded enzyme, integrase. The absolute requirement for integrase activity in the propagation of HIV-1 in cell culture def |
| Mo.A.1021 | Int Conf AIDS 1996 Jul 7-12; 11:39 (abstract no. Mo.A.1021) Chen SS, Terwilliger E; Academia Sinica, Taipei, Taiwan, R.O.C. Fax: 02-782-5573. E-mail: schen@ibms.sinica.edu.tw. Objective: To determine whether an HIV-1 envelope (Env) variant lacking the gp41 cytoplasmic domain can function as an inhibitory mutant in the production of infectious virus, and to study the mechanism underlying the interference effect conferred by this mutant protein. Methods: The interference effect conferred by a |
| Mo.A.1022 | Targeted integration of HIV and HTLV-I proviral sequences into the human genome. Int Conf AIDS 1996 Jul 7-12; 11:59 (abstract no. Mo.A.1022) Rynditch AV, Zoubak SV, Bernardi G; Institute of Molecular Biology and Genetics, Kiev, Ukraine. Fax: +380-44-2663498. E-mail: rynditch@imbig.kiev.ua. Objective: The aim of present study was to assess if the regional specificity of HIV and HTLV-I integration exists and how it may contribute to explain some aspects of HIV and HTLV-I pathogenesis. Methods: The distribution of HIV and HTLV-I proviral sequences in DNA from cells in culture, asymptomatic carriers or patie |
| Mo.A.1023 | HIV-1 5'-LTRs from 42 patients representing all stages of infection, display a wide range of polymorphism in sequence, transcription potential and binding of factors but no clinical correlation. Int Conf AIDS 1996 Jul 7-12; 11:59 (abstract no. Mo.A.1023) Estable MC, Bell B, Merzouki A, Montaner JS, O'Shaughnessy MV, Sadowski IJ; Dept. Pathology, UBC, Vancouver, BC, Canada. E-mail: estable@hivnet.ubc.ca /ferrero@unixg.ubc.ca. Objective: Despite extensive in vitro studies identifying a myriad of cellular transcription factors that bind the prototypical HIV-1 5 -LTR, the relative contribution of these factors to HIV-1 replication in infected individuals remains obscure. We wished to determine what are the in vivo HIV-1 5 -LTR polymorphisms in |
| Mo.A.1024 | Protective effects of exogenous copper-zinc superoxide dismutase on the TNF-alpha induced oxidative stress and HIV replication. Int Conf AIDS 1996 Jul 7-12; 11:59 (abstract no. Mo.A.1024) Edeas M, Peltier E, Claise C, Khalfoun Y, Lindenbaum A; Laboratoire de Biochimie, Hopital Antoine Beclere, Clamart, France. Fax: 45 37 47 45. Objective: To examine the effects of exogenous copper-zinc SOD on HIV expression and TNF-induced oxidative stress. Methods: SOD effects (anti-HIV and oxidative stress) were studied: 1-on the TNFalpha induced redox alteration in chronically HIV-1 infected promonocytic U1 cell line, 2- on HIV replication in peripheral bl |
| Mo.A.1025 | Reactivation by Tat and TNF-alpha of integrated HIV-1 genomes inactivated in cell culture by CPG methylation. Int Conf AIDS 1996 Jul 7-12; 11:59 (abstract no. Mo.A.1025) Bergmann S, Marschall M, Frohlich U, Lower R, Lower J; Paul-Ehrlich-Institut, Langen, Germany. Fax: +496103-771252. E-mail: loewer@em.uni-frankfurt.de. Objective: To detect and to characterize intracellular mechanisms which inactivate already integrated HIV genomes. Methods: A cell clone (CBH) derived from the human T-cell line CEM-CM3 has been selected which contains a single copy of an HIV construct with a positively as well as negatively selectable marker gene (hyd |
| Mo.A.1026 | Influence of the HIV-1 leader sequence on mRNA stability. Int Conf AIDS 1996 Jul 7-12; 11:59 (abstract no. Mo.A.1026) Lenz C, Schaal H, Scheid A; Institut fur Medizinische Mikrobiologie und Virologie, Heinrich-Heine-Universitat, Dusseldorf, Germany. Fax: +49-211-81-12227. E-mail: clenz@rs6000.virol.uni-duesseldorf.de. Objective: Investigation of the influence of the authentic tat mRNA 1.4.7 leader sequence on human immunodeficiency virus type 1 (HIV-1) gene expression. Methods: An expression vector with the bacterial chloramphenicol acetyltransferase (CAT) open reading frame under transcriptional control of the HIV-1 promoter was co |
| Mo.A.1027 | Role of Vif in HIV-1 replication in non-permissive cells. Int Conf AIDS 1996 Jul 7-12; 11:59 (abstract no. Mo.A.1027) Yu XF, Dettenhofer M, Tang XB; Dept. Molecular Microbiology and Immunology, Jonhs Hopkins School of Hygiene, Baltimore, MD, USA. Fax: 410-955-0105. Objective: Replication of HIV-1 Vif mutants is cell type dependent. Vif is essential for HIV-1 replication in primary target cells and H9 CD4+ T cells (non-permissive cells). It is dispensable in many CD4+ T cell lines such as Jurkat (permissive cells). Vif function is required for generating infectious virus in the no |
| Mo.A.1028 | Induction of nitric oxide synthase (iNOS) gene in H9 by anti-HIV-1 compound 3-deaza-neplanocin A. Int Conf AIDS 1996 Jul 7-12; 11:60 (abstract no. Mo.A.1028) Chiang PK, Burke DS, Kutty RK, Mayers DL, Pardhasaradhi K; Division of Retrovirology, Walter Reed Army Institute of Research, Washington, DC, USA. Fax: 202-782-9040. 3-Deaza-naplanocin A (DZNep) has been shown to exhibit potent anti-viral activity against clinical strains of HIV-1 in phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear cells (PBMC) and other cell lines [Mayers DL et al. Proc. Natl. Acad. Sci. USA, 92, 215 (95)]. However, the mode of action of thi |
| Mo.A.1030 | Modification of the plasma membrane of cells induced by HIV-1. Int Conf AIDS 1996 Jul 7-12; 11:60 (abstract no. Mo.A.1030) Grigoriev VB, Kadochnicov UP, Vorcunova NK, Klimenko SM; The D.I. Ivanovsky Institute of Virology, RAMS, Moscow, Russia. Fax: (095) 1902867. Objective: The aim of present investigation was to study distribution of integral proteins in hidrophobic zone of the plasma membrane of HIV-1 infected cells. Methods: Important structural markers for membrane functions are the intramembrane particles (IPMs) seen on membrane fructure faces. The presence of IPMs correla |
| Mo.A.1032 | p15 RNA binding: a potential target in AIDS treatment. Int Conf AIDS 1996 Jul 7-12; 11:60 (abstract no. Mo.A.1032) Ozturk D, Erickson-Viitanen S; DuPont Merck Pharmaceutical Co., Wilmington, DE, USA. Introduction/objectives: One of the steps in HIV-1 virus replication is the cleavage of gag gene product Pr55 by HIV-1 protease. The Pr55 processive events by the protease are ordered and time dependent, and yield proteins necessary for infectious viral assembly. One of the Pr55 cleavage products is p15 protein, which |
| Mo.A.1033 | Genomic defects in attenuated HIV-1 from the Sydney bloodbank long-term non-progressors. Int Conf AIDS 1996 Jul 7-12; 11:60 (abstract no. Mo.A.1033) Solomon A, Smith K, Ludford-Menting M, Hooker D, Tsykin A, McPhee D, Chatfield C, Ellett A, Greenway A, Crowe S, Learmont J, Deacon N; Macfarlane Burnet Centre for Medical, Fairfield Vic., Australia. Fax: 03 9280 2561. E-mail: solomon@burnet.mbcmr.unimelb.edu.au. Objective: Between April 1981 and July 1984 seven people were infected with HIV-1 by transfusion of blood from a single HIV-1 infected donor. All cohort members (the Sydney Blood bank long-term non-progressor cohort) have remained free from AIDS or any HIV-1 related illness for up to 14 years. Since cohort members coul |
| Mo.A.1034 | PCR cloning and sequencing of three hybridoma cell lines producing monoclonal antibodies against the same region of nef protein. Int Conf AIDS 1996 Jul 7-12; 11:60 (abstract no. Mo.A.1034) Chang AH, Leslie K, Hoxie J, Cassol S; B.C. Center for Excellence in HIV/AIDS, Vancouver, BC, Canada. Fax: 604-631-5646. E-mail: achang@hivnet.ubc.ca. Objective: To determine the sequences of the antibody variable regions of three hybridoma cell lines, all of which produce monoclonal antibodies against the C terminus of Nef protein, and to construct anti-Nef single-chain antibodies (SFV) in order to study the intracellular role of Nef in HIV-1 infection. Methods: The |
| Mo.A.1035 | Molecular biology of the human endogenous retrovirus family HERV-K: transactivation by viral proteins. Int Conf AIDS 1996 Jul 7-12; 11:60 (abstract no. Mo.A.1035) Lower R, Thelen K, Hasenmaier B, Knobetal M, Kurth R, Lower J; Paul-Ehrlich-Institut, Langen, Germany. Fax: +496103-771252. E-mail: loewer@em.uni-frankfurt.de. Objective: To determine whether viral trans-activators (including HIV Tat) can modulate the expression of a human endogenous retrovirus family which gives rise to virus particles in teratocarcinoma cell lines. Methods: In the human genome, the endogenous retrovirus family HERV-K is represented by approximately 50 copie |
| Mo.A.1036 | Analysis of in vivo genetic variability of Vif from HIV-2. Int Conf AIDS 1996 Jul 7-12; 11:61 (abstract no. Mo.A.1036) Ribeiro AC, Santos Ferreira MO, Moniz Pereira J, Barahona I; Faculty of Pharmacy, Univ. of Lisbon, Lisbon, Portugal. Fax: 3511 7934212. Objective: To characterize Vif protein encoded by HIV type 2 from several AIDS patients. Identification of HIV-2 specific motifs in order to define putative functional motifs possibly involved in the differences of viral infectivity between HIV-1 and HIV-2. Methods: Fifteen blood samples have been obtained from HIV-2 i |
| Mo.A.1037 | Effect of tat-protein on T-cell expression of adhesion molecules. Int Conf AIDS 1996 Jul 7-12; 11:61 (abstract no. Mo.A.1037) Castanos-Velez E, Valancauskaite V, Patarroyo M, Fenyo EM, Biberfeld P; Immunopathology Laboratory, Karolinska Institute/Hospital, Stockholm, Sweden. Fax: 46-8-345820. E-mail: E.C-Velez@onkpat.ki.se. Objective: To analyze the effect of constitutively expressed tat-protein on the display of cell adhesion molecules (CAM) by T cells. Methods: The profile of expression of 40 different CAM was determined on Jurkat and on tattransfected Jurkat cells (J-tat) by FACS analysis using an indirect immunofluorescence method on |
| Mo.A.1038 | Down regulation of HIV-1 replication by wild type rev in RD131 cells. Int Conf AIDS 1996 Jul 7-12; 11:61 (abstract no. Mo.A.1038) Natarajan V, Bosche MC, Lane HC; NCI-FCRDC-SAIC, Frederick, MD. Objective: The aim of this work is to evaluate the impact of excess rev on HIV-1 replication. Methods: RD131 cells were transfected with the combination of either a wild type HIV-1 (pNL4-3) plasmid or a HIV-1 mutant (pVNL-4) plasmid containing a frame shift mutation in the rev gene and different quantities of a rev exp |
| Mo.A.1039 | Transactivating effect of Vpr on viral LTR and c-fos promoter. Int Conf AIDS 1996 Jul 7-12; 11:61 (abstract no. Mo.A.1039) Philippon V, Matsuda Z, Lee TH, Essex M; Department of Cancer Biology, Harvard School of Public Health, Boston, MA. Fax: 617-739-8348. Objective: To determine the ability of Vpr proteins of several primates lentiviruses to activate the expression of the viral LTR and cellular factors involved in cell cycle progression such as c-fos and c-jun. Methods: Fibroblastic, monocytic and T-cell lines were transfected with Vpr expression vectors and HIV LTR, c- |
| Mo.A.1040 | Identification of cellular receptors for HIV-1 viral protein r (Vpr). Int Conf AIDS 1996 Jul 7-12; 11:61 (abstract no. Mo.A.1040) Ayyavoo V, Mahalingam S, Phung MT, Williams WV, Weiner DB; University of Pennsylvania, Department of Pathology, Philadelphia, PA, USA. Fax: 215-573-9436. E-mail: velpandi@mail.med.upenn.edu. Objective: Identification of the host cellular proteins interacting with HIV-1 vpr using Yeast Two-Hybrid system. Methods: Vpr interacting proteins were identified using the Yeast Two Hybrid system and immunoaffinity colums. Two hybrid proteins were made; one is between the binding domain and the known protein Vpr and |
| Mo.A.1041 | SIV/Mne Nef interacts with Raf-1 kinase and interferes with its signal transduction. Int Conf AIDS 1996 Jul 7-12; 11:61 (abstract no. Mo.A.1041) Heidecker Gisela, Mood K, Ruscetti FW; SAIC-NCI/FCRDC, Frederick, MD, USA. Fax: 301 846 7034. E-mail: heidecke@fcrfv1.ncifcrf.gov. The nef gene of HIV and SIV has come into focus as a major contributor to the pathogenesis of primate immune deficiencies. Several lines of evidence suggest that Nef interferes with signal transduction in infected and possibly even in bystander cells. We have analyzed the interaction of SIV/Mne Nef protein with several |
| Mo.A.1042 | Anti-HIV homologous viral interference as a tool for gene therapy. Int Conf AIDS 1996 Jul 7-12; 11:61 (abstract no. Mo.A.1042) Federico M, Bona R, d'Aloja P, Olivetta E, Mavilio F, Verani P; Laboratory of Virology, Istituto Superiore di Sanita, Rome, Italy. Fax: 39-6-4453369. Objective: We propose an anti-HIV gene therapy approach based on the homologus viral interference induced by a non-producer HIV-1 variant (F12-HIV). Methods: The F12-HIV genome was inserted in the opposite orientation with respect to the N2 retroviral vector, after replacing the nef gene with the human nerve growth fac |
| Mo.A.1043 | The use of HIV vectors for AIDS gene therapy. Int Conf AIDS 1996 Jul 7-12; 11:62 (abstract no. Mo.A.1043) Matsukura M, Suzuki T, Shimada T; Dept. of Child Devel., Kumamoto Univ. School of Medicine, Kumamoto City, Japan. Fax: 96-373-5200. Objective: To examine the feasibility of the use of HIV vectors in AIDS gene therapy. Methods: The herpes simplex virus thymidine kinase (HSV-TK) suicide gene was inserted between the packaging signal and the neo gene of pHXN, yielding pHXTKN. The HSVTK gene is directed by the HIV-LTR, while the neo gene is by the inte |
| Mo.A.1044 | HIV-regulated luciferase and diphtheria toxin A fragment genes are expressed specifically in HeLa cells after transfection by cationic liposomes. Int Conf AIDS 1996 Jul 7-12; 11:62 (abstract no. Mo.A.1044) Konopka K, Harrison G, Slepushkin V, Felgner P, Duzgunes N; University of the Pacific, School of Dentistry, San Francisco, CA. Fax: (415) 929-6564. Objective: To determine whether HIV-regulated luciferase and diphtheria toxin A fragment (DT-A) genes are expressed in HeLa cells following transfection by cationic liposomes and whether expression of the DT-A gene in HeLa-T4 cells can protect against de novo HIV infection. Methods: HeLa/LAV and HeLa cells were transfe |
| Mo.A.1045 | Engineering T cells against HIV with human ScFvs selected from phage-antibody libraries. Int Conf AIDS 1996 Jul 7-12; 11:62 (abstract no. Mo.A.1045) Bitton N, Parizot C, Schindler D, Waks T, Debre P, Eshhar Z, Gorochov G; Immunologie Cellulaire, CERVI, CNRS, Paris, France. Fax: (33 1) 42 17 74 90. E-mail: gorochov@ccr.jussieu.fr. Objective: Engineering of T cells that express A): chimeric receptors with an antibody-type anti-HIV specificity that could eliminate infected cells in a non-MHc dependent fashion, or B): intracytoplasmic antibody fragments directed against the HIV-1 integrase. Methods: Human single chain Fvs (ScFvs) are selected from: |
| Mo.A.1046 | Antitat gene is a candidate for both T-cell and stem-cell gene therapy. Int Conf AIDS 1996 Jul 7-12; 11:62 (abstract no. Mo.A.1046) Lisziewicz J, Johnson P, Rosenzweig M, Sun D, Lori F; Research Institute for Genetic and Human Therapy, Gaithersburg, MD, USA. Fax: (301) 330-9458. E-mail: Liszi@eworld.cor. Objective: To determine the antiviral efficacy of the antitat gene in in vivo infected T-cells as well as in lymphocytes and macrophages differentiating from antitat-transduced stem-cells. Methods: Antitat is an autoregulated, dual function antiviral gene (polymeric-TAR and antisense-Tat combination) capable of inhibit |
| Mo.A.1047 | "Passive" intracellular immunization with an exonuclease specific for single stranded DNA. Int Conf AIDS 1996 Jul 7-12; 11:62 (abstract no. Mo.A.1047) Savarino A, Turco E, Sinicco A, Pugliese A; University of Turin, Torino, Italy. +39114393865. Objective: A new molecule for experimental gene therapy was sought. We hypothesized that an exonuclease specific for single-stranded DNA may inhibit HIV-1, since a single stranded DNA terminus (SSDT) extends from proviral DNA during its synthesis. An activity independent from a peculiar viral nucleotidic sequence was r |
| Mo.A.1049 | Human in vitro T-lymphopoiesis as a model for HIV gene therapy. Int Conf AIDS 1996 Jul 7-12; 11:63 (abstract no. Mo.A.1049) Zhu H, Freedman A, Kurtzman G, Scadden D; Massachusetts General Hospital, Charlestown, MA. Testing gene therapy strategies for AIDS requires the evaluation of transduced gene expression in cells differentiating along lines relevant to HIV infection. To further this end, we have developed a method of inducing CD34+, CD2- human adult bone marrow cells to develop functional and immunophenotypic characteristics |
| Mo.A.1050 | Anti-human immunodeficiency virus type 1 (HIV-1) activity of Achyrocline flaccida Wein DC and Gamochaeta simplicicaulis aqueous extracts. Int Conf AIDS 1996 Jul 7-12; 11:63 (abstract no. Mo.A.1050) Salomon H, Pampuro S, Libonatti O, Cavallaro L, Garcia G, Campos R, Coussio J; Departamento de Microbiologia, Facultad de Medicina. Fax: 54 1 962 5404. Objective: To study anti-HIV-1 activities of South American plant extracts from both Achyrocline flaccida Wein DC (AF) and Gamochaeta simplicicaulis (GS) on infected lymphocytes of primary origin. Methods: The plant extracts (aerial part) were extracted successively with solvents of increasing polarity: hexane, dichlor |
| Mo.A.1051 | Thiocarboxanilide derivatives: highly potent and selective HIV inhibitors with a broad activity spectrum against mutant HIV-1 strains resistant to other non-nucleoside reverse transcriptase inhibitors. Int Conf AIDS 1996 Jul 7-12; 11:63 (abstract no. Mo.A.1051) Balzarini J, Brouwer WG, Dao DC, Osika EM, Karlsson A, De Clercq E; Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium. Fax: 32-16- 33.73.40. A series of novel thiocarboxanilide derivatives have been synthesized and evaluated for their activity against human immunodeficiency virus type 1 (HIV-1) in cell culture. They are highly specifically inhibitory to HIV-1 strains and not active against other retroviruses including HIV-2 or other RNA or DNA viruses (i.e. |
| Mo.A.1052 | Design, synthesis and biological activity of aminoglycoside-like inhibitors of the Rev/RRE interaction. Int Conf AIDS 1996 Jul 7-12; 11:63 (abstract no. Mo.A.1052) Brown W, Cedergren R, Charron M, Duschene J, Ellington A, Falardeau G, Gillard JW, Hamel M, Leclerc F, Mansour T, Mounir S, Srinivasan J, Yuen L; BioChem Therapeutic Inc., Laval, QC, Canada. Fax: 514-978-7777. Objective: To identify inhibitors of HIV which function by disrupting the Rev/RRE(Rev responsive element) interaction, which were designed by using a proprietary molecular modelling docking program. Methods: Illustration of the use of a proprietary molecular modelling docking program of the RBE(Rev binding element) to |
| Mo.A.1053 | Efficacy of F-5 gel against HIV-1 and HIV-2 in infected human peripheral blood mononuclear cells (PBMC). Int Conf AIDS 1996 Jul 7-12; 11:63 (abstract no. Mo.A.1053) Wetherall NT, Hodges-Savola C, Werness L, Gosselin LF, Sauriol C, Colin P; Axcan Ltd., Mont-St-Hilaire, Quebec, Canada. Fax: (514) 464-9979. Objective: To determine the in-vitro cytotoxicity and antiviral efficacy of F-5 Gel (used in Protectaid sponge), on HIV-1 and HIV-2 infected PBMCs, which are involved in the heterosexual transmission of HIV. Methods: HIV-1 strain HTLV IIIB and HIV-2 strain CBL-20 were used in this study. PBMCs were obtained from an HIV |
| Mo.A.1054 | Entrapment of foscarnet in liposomes: a strategic approach for the treatment of HIV and CMV infections. Int Conf AIDS 1996 Jul 7-12; 11:63 (abstract no. Mo.A.1054) Dusserre N, Omar R, Desormeaux A, Tremblay M, Beauchamp D, Poulin L, Bergeron MG; Centre de Recherche en Infectiologie, Centre Hospitalier de l'Universite Laval, Quebec, Canada. Fax: (418) 654-2715. Objective: To evaluate the potential therapeutic applications of liposome-encapsulated foscarnet for the treatment of HIV and CMV infections. Methods: In vitro experiments have been performed to evaluate the accumulation and anti-HIV efficacy of free and liposome-encapsulated foscarnet in different cell lines. The phar |
| Mo.A.1055 | Inhibition of HIV infection by pseudopeptides blocking viral entry into CD4+ cells. Int Conf AIDS 1996 Jul 7-12; 11:64 (abstract no. Mo.A.1055) Hovanessian AG, Jacotot E, Guichard G, Krust B, Blanco J, Rey-Cuille MA, Muller S, Briand JP, Callebaut C; Unite VIC, Institut Pasteur, Paris, France. Fax: 33.1.4061 3012. E-mail: arahovan@pasteur.fr. Objective: The development of potent inhibitors of HIV entry into CD4+ T Lymphocytes. Methods: The RP dipeptide motif is highly conserved in the V3 loop of the extracellular envelope glycoprotein of different types of HIV isolates. In view of this, we have designed and synthesized a construction referred to as template |
| Mo.A.1056 | Nanoparticles as drug carriers for antiviral agents against HIV. Int Conf AIDS 1996 Jul 7-12; 11:64 (abstract no. Mo.A.1056) Bender A, Immelmann A, Kreuter J, Rubsamen-Waigmann H, von Briesen H; Analysis GmbH, Georg-Speyer-Haus, Frankfurt, Germany. Fax: +49.69-63395-211. Objective: In this study, nanoparticles (NP) as drug carriers loaded with different antiviral agents were tested in vitro for their activity in HIV-infected human monocytes/macrophages (MO/ MAC ). Methods: Polyhexylcyanoacrylate nanoparticles were prepared by emulsion polymerization of the monomer in acid medium. For p |
| Mo.A.1057 | BM 21.1290: in vitro evaluation of a potential new anti-AIDS compound. Int Conf AIDS 1996 Jul 7-12; 11:64 (abstract no. Mo.A.1057) Herrmann DB, Kucera LS, Zilch H, Mertens A, Opitz HG; Boehringer Mannheim GmbH, Dept. Molecular Pharmacology/New Indications, Mannheim, Germany. Objective: Determination of the anti-HIV activity and cytotoxicity of the new anti-AIDS compound BM 21. 1290 (INN: Fozivudine tidoxil) in different in vitro cell systems. Methods: 50% anti-HIV (IC50) and 50% toxic (TC50) concentrations were determined in several human T cell lines (CEM-SS, H9, H9IIIB) and in human peri |
| Mo.A.1058 | Blocking of HIV-1 envelope glycoprotein (gp120)-binding to CD4+ lymphocytes by anti-HIV monoclonal antibodies. Int Conf AIDS 1996 Jul 7-12; 11:64 (abstract no. Mo.A.1058) Kroepelin M, Suesal C, Daniel V, Opelz G; University of Heidelberg, Institute of Immunology Im Neuenheimer Feld 305, Heidelberg, Germany. Fax: (+49) 6221 56-4200. E-mail: marianne.kroepelin@krzmail.krz.uni-heidelberg.de. Objective: Our research aim was to characterize HIV-1 envelope glycoprotein (gp120)-binding to CD4+ lymphocytes and to block this interaction with monoclonal antibodies as a potential strategy for immunotherapy. Methods: CD4+ lymphocytes of healthy volunteers were isolated by Ficoll-Hypaque gradient centrifugation foll |
| Mo.A.1059 | Thiadiazole derivatives were highly potent inhibitors of HIV-1. Int Conf AIDS 1996 Jul 7-12; 11:65 (abstract no. Mo.A.1059) Fujiwara M, Ijichi K, Hanasaki Y, Ide T, Katsuura K, Takayama H, Aimi N, Shigeta S, Konno K, Yokota T, Baba M; Rational Drug Design Laboratories, Fukushima, Japan. Fax: 81-245-67-5554. E-mail: fuji@rdl.co.jp. Objective: To evaluate whether several thiadiazole (TDA) derivatives selectively inhibit the replication of HIV-1 in vitro. Methods: Anti-HIV-1 activities of TDA derivatives were examined in various cell lines. Inhibitory effects of the compounds on HIV-1 reverse transcriptase (RT) activity were determined by a standar |
| Mo.A.1060 | Allophenylnorstatine-containing peptidomimetic HIV protease inhibitors exhibit both in vitro and in vivo antiviral activities. Int Conf AIDS 1996 Jul 7-12; 11:65 (abstract no. Mo.A.1060) Kiso Y, Mimoto T, Kato R, Mitoguchi T, Nakata S, Kimura T, Ussery MA; Dept. Med. Chem., Kyoto Pharmac. Univ., Kyoto, Japan. Fax: 81-75-591-9900. E-mail: PXH00435@niftyserve.or.jp. Objective: To develop orally potent and small-sized HIV protease inhibitors as anti-HIV drugs. Methods: We designed and synthesized a novel class of substrate-based peptidomimetic HIV protease inhibitors containing allophenylnorstatine [Apns; (2S,3S)-3-amino-2-hydroxy-4-phenylbutyric acid] with a hydroxymethylcarbonyl |
| Mo.A.1061 | Potent activity of the extract of Geum japonicum Thunb. For the prophylaxis of cytomegalovirus infection in AIDS patients. Int Conf AIDS 1996 Jul 7-12; 11:65 (abstract no. Mo.A.1061) Kageyama S, Kurokawa M, Sato H, Yukawa T, Ohyama H, Kurimura T, Namba T, Shiraki K; Toyama Medical & Pharmaceutical University, Toyama, Japan. Fax: 0764-34-5020. E-mail: kageyama@toyama-mpu.ac.jp. Objective: A traditional herbal medicine extracted from Geum japonicum Thunb. (GJ) with hot water, which had exhibited antiviral activity against herpes simplex virus in a mouse model, was also examined for its prophylactic efficacy against cytomegalovirus ( CMV ) infection in im |
| Mo.A.1062 | Anti-HIV-1 activity of Labiatae plants, especially aromatic plants. Int Conf AIDS 1996 Jul 7-12; 11:65 (abstract no. Mo.A.1062) Yamasaki K, Nakano M, Otake T, Kawahata T, Mori H, Morimoto M, Ueba N; Osaka Prefectural Institute of Public Health, Osaka, Japan. Fax: 81-(0)6-972-2393. Object: We have screened and identified compounds that inhibit the replication of HIV-1 from natural products and defined the mechanisms of the anti-HIV-1 activity of the hit, we found some Labiatae plants exhibiting anti-HIV activity, we screened several aromatic plants(herbs) belonging to Labiatae, and searched for t |
| Mo.A.1063 | Anti-HIV activity of boromycin. Int Conf AIDS 1996 Jul 7-12; 11:65 (abstract no. Mo.A.1063) Kawahata T, Otake T, Mori H, Morimoto M, Ueba N, Kohno J, Nishio M, Kinumaki A, Komatsubara S; Osaka Prefectural Institute of Public Health, Osaka, Japan. Fax: 81-(0)6-972-2393. We have reported several natural products that have a potent inhibitory activity on HIV replication. The extracts of fermentation broth of microorganisms isolated from soil were tested for anti-HIV-1 activity by the screening assay using MT-4 cells. The product of Streptomyces sp. A-3376 was found to have anti-HIV-1 ac |
| Mo.A.1064 | Inhibition of cellular activation of latently HIV-infected peripheral blood mononuclear cells by traditional medicine. Int Conf AIDS 1996 Jul 7-12; 11:65 (abstract no. Mo.A.1064) Haruyo M, Inada Y, Otake T, Ueba N; Osaka Prefectural Institute of Public Health, Osaka, Japan. Fax: 81-6-972-2393. The majority of HIV-infected CD4+ lymphocytes and macrophages are in the latent state in vivo, particularly the early stage of infection. It is considered that these latent cells can be activated by several stimulants such as cytokines and start to produce HIV particles, resulting in the progression of disease.We have |
| Mo.A.1065 | Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture. Int Conf AIDS 1996 Jul 7-12; 11:66 (abstract no. Mo.A.1065) Yuasa S, Yamada K, Nakade K, Okamoto M, Makino M, Baba M; Mitsubishi Chemical Corp., Research Center, Pharmaceuticals Lab 2, Yokohama, Japan. Fax: +81-45-963-3890. Objective: To investigate whether the combination of nonnucleoside reverse transcriptase inhibitors (NNRTIs) and AZT is effective in inhibiting the emergence of HIV-1 mutants in vitro. Methods: 50% effective concentrations (EC50) of AZT and NNRTIs, such as MKC-442 (6-benzyl-1-ethoxymethyl-5-isopropyluracil), |
| Mo.A.1066 | Analysis of HIV-1 variants resistant to the irreversible protease inhibitors, LB71148 and LB71262. Int Conf AIDS 1996 Jul 7-12; 11:66 (abstract no. Mo.A.1066) Lee TG, Kwon YD, Choi HI, Chang HJ, Hwang SY, Kim SC, Yoo YJ; LG Chemical Ltd/Research Park, DaeJeon, Korea. Fax: (042) 862-0332. Objective: To investigate in vitro emergence of HIV-1 variants resistant to the irreversible protease inhibitors (LB71148, LB71262) containing cis-epoxide, and to analyze the effect of the mutations on the enzyme activity as well as on the virus. Methods: MT-2 cells infected with HIV-1 NL-4-3 were cultured in the prese |
| Mo.A.1067 | Significant delay of HIV-1 emergence after pretreatment with an irreversible protease inhibitor, LB71148. Int Conf AIDS 1996 Jul 7-12; 11:66 (abstract no. Mo.A.1067) Kwon YD, Lee TG, Kim SC; LG Chemical Ltd/Research Park, DaeJeon, Korea. Fax: (042) 862-0332. Objective: LB71148 containing cis-epoxide inhibits HIV-1 protease irreversibly. We determined whether the irreversible inhibitor had an advantage over the conventional reversible protease inhibitor. Methods: MT-2 cells infected with HIV-1 NL-4-3 were pretreated with the irreversible inhibitor, LB71148 or with the rever |
| Mo.A.1068 | Comparative study with two treatment schemes of ddC plus AZT in HIV infection. Int Conf AIDS 1996 Jul 7-12; 11:66 (abstract no. Mo.A.1068) Torres R, Villarreal C, Robles M, Terrazas J; Ajusco Del Coyoacan CP, Mexico, D.F. Objective: To compare efficacy and tolerance between two different treatment schemes with a double drug regimen ( AZT plus DDC) in patients with HIV infection. Group A included DDC 0.375 mg tid and three times a week, plus AZT 100 mg tid, three times a week in alternating days. Group B included DDC 0. |
| Mo.A.1069 | Negatively charged human serum albumins as inhibitors of HIV-1 replication: mechanism of action, in vitro activity against distinct HIV-1 isolates and in vivo efficacy in mice. Int Conf AIDS 1996 Jul 7-12; 11:66 (abstract no. Mo.A.1069) Kuipers ME, Swart PJ, Schutten M, Huisman JG, Schuitemaker H, Osterhaus AD, Meijer DK; University Centre for Pharmacy, Groningen, The Netherlands. Fax: #31-50-3633311. E-mail: M.E.Kuipers@farm.rug.nl. Objective: Negatively charged albumins (NCAs), with the prototypes Suc-HSA and Aco-HSA, are polyanionic proteins with a potent antiviral activity on HIV-1 laboratory strains. In the present study the mechanism of their antiviral action was studied. In addition we determined the in vitro antiviral activity of these NCAs |
| Mo.A.1070 | Antiviral effects of milk proteins: acylation results in polyanionic proteins with potent activity against HIV type I and II in vitro. Int Conf AIDS 1996 Jul 7-12; 11:66 (abstract no. Mo.A.1070) Huisman H, Kuipers ME, Smit C, De Clercq E, Meijer DK, Swart PJ; Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Dept. of Developmental Research, Amsterdam, The Netherlands. Fax: 20-5123474. Objective: A number of native and modified milk proteins from bovine or human sources were analyzed for their anti-HIV and anti-HIV-2 effect in vitro. Methods: The proteins investigated were lactoferrin, alpha-lactalbumin, beta-lactoglobulin A and beta-lactoglobulin B. The capability to inhibit viral infectivity was as |
| Mo.A.1071 | Inhibiton of acute HIV-1 infection of CD4+ T cells by lithium gamolenate. Int Conf AIDS 1996 Jul 7-12; 11:67 (abstract no. Mo.A.1071) Randall S, Winther MD, Horrobin DF, Chan WL; Dept. of Virology, St. Bartholomew's Hospital Medical College, West Smithfield, London, UK. Objectives: The fatty acid metabolism of T cells has been shown to be altered in HIV-1 infection. We are investigating the possible development of a new therapeutic approach to HIV-1 infection by targeting fatty acid metabolism in the host cell. Syncytium formation, which plays an important role in the mediation and sp |
| Mo.A.1072 | Assessment of antiretroviral therapy on activation-induced cell death in HIV-positive individuals. Int Conf AIDS 1996 Jul 7-12; 11:67 (abstract no. Mo.A.1072) Johnson N, Stone J, Pinching AJ, Parkin JM; Dept. of Immunology, St. Bartholomews Hospital, London, UK. Fax: 0171 6060845. E-mail: n.johnson@mds.qmw.ac.uk. Objectives: To assess the effect of antiretroviral therapy on in vitro lymphocyte activation-induced cell death (AICD) in HIV-infected patients. Compare this to changes in CD4 cell numbers and assess AICD as a means of monitoring antiretroviral therapy. Methods: Eight patients were sampled before and after initiation o |
| Mo.A.1073 | Assessment of HIV inhibitory activity in saliva and other body fluids. Int Conf AIDS 1996 Jul 7-12; 11:67 (abstract no. Mo.A.1073) Kazmi SH, Mullen JE, O'Shea S, Banatvala JE, Challacombe SJ, Sweet SP; Dept. Oral Medicine, Guy's Hospital, London, UK. Fax:(44) 0171 955 4455. Objectives: To perform a comparative evaluation of the HIV inhibitory activity of a number of body fluids including saliva, breast milk and seminal plasma. This was done in parallel with a gp120 binding plant lectin from Galanthus nivalis which was used as a positive control. Methods: HIV inhibitory activity was evalua |
| Mo.A.1074 | Inhibition of HIV replication by the plant Phylanthus amarus. Int Conf AIDS 1996 Jul 7-12; 11:67 (abstract no. Mo.A.1074) Mullen JE, O'Shea S, Rostron T, Houghton PJ, Woldermariam TZ, Walker E, Banatvala JE, Thyagarajan SP; Dept. of Virology, United Medical and Dental Schools of Guys and St. Thomas's Hospitals, London, United Kingdom. Fax: 44-171-922-8387. Objective: Plants of the genus Phyllanthus are widely used by traditional medical practitioners for the treatment of jaundice and other diseases and are very well tolerated. Phyllanthus amarus (PA) inhibits the DNA polymerase of hepatitis B virus and chronic carriers treated with the plant extract clear hepatitis B sur |
| Mo.A.1075 | Discovery of potent, orally bioavailable, non-peptidic, cyclic sulfones as HIV protease inhibitors. Int Conf AIDS 1996 Jul 7-12; 11:67 (abstract no. Mo.A.1075) Kim CU, McGee L, Krawczyk S, Harwood E, Harada Y, Swaminathan S, Bischofberger N, Chen MS, Cherrington JM, Xiong SF, Mulato A, Flores C, Cundy KC, Griffin L, Oliyai R, Erickson JW; Gilead Sciences Inc., Foster City, CA, USA. Fax: 415-573-4899. A rational drug design strategy using crystallographic information generated from several HIV Protease-inhibitor complexes has led to the discovery of a novel series of highly potent, non-peptidic and cyclic inhibitors of the HIV protease. The new structure of these compounds possesses a C2 symmetric diol which resembl |
| Mo.A.1076 | 2'-beta-fluoro-2',3'-dideoxyadenosine (F-ddA): a new anti-HIV clinical drug candidate. Int Conf AIDS 1996 Jul 7-12; 11:68 (abstract no. Mo.A.1076) Johns DG, Driscoll J; Laboratory of Medicinal Chemistry, NCI, Nat. Institutes of Health, Bethesda, MD, USA. Fax: 301-496-5839 or 301-402-2275. Objective: To characterize the pharmacological, toxicological and chemical properties of the 2 -beta-fluoro analog of the anti-HIV agent 2 ,3 -dideoxyadenosine. Methods: F-ddA was synthesized in this laboratory and its anti-HIV activity determined in a variety of in vitro assay systems, including ATH8 cells, monocyte/m |
| Mo.A.1077 | L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Int Conf AIDS 1996 Jul 7-12; 11:68 (abstract no. Mo.A.1077) Young SD; Merck Research Laboratories, West Point, PA. The clinical benefit of the human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase (RT) inhibitors (NNRTI s) is limited by the rapid selection of inhibitor-resistant viral variants. We believe the clinical utility of this class of anti-HIV agents may be enhanced if a compound expressing both hi |
| Mo.A.1078 | Suppression of both wild-type and drug-resistant HIV-1 by combination of thymidylate synthase inhibitors with AZT or d4T. Int Conf AIDS 1996 Jul 7-12; 11:68 (abstract no. Mo.A.1078) Gao WY, Tanaka M, Ahluwalia GS, Johns DG, Mitsuya H; Lab. Med. Chem., Nat. Cancer Inst., NIH, Bethesda, MD, USA. Fax: 301-402-0709. Objective: To develop a non-discriminative strategy for the inhibition of replication of both wild-type and drug-resistant HIV-1. Methods: The dependence of proviral DNA replication by all HIV-1 strains on host-cell dNTPs, including dTTP, was selected as the target. The antiviral activities of combinations of low conce |
| Mo.A.1079 | Lymphatic distribution of 2',3'-dideoxyinosine (ddI) after administration of phospholipid prodrug in mice. Int Conf AIDS 1996 Jul 7-12; 11:68 (abstract no. Mo.A.1079) Manouilov KK, Xu ZS, Boudinot FD, Schinazi RF, Chu CK; Med. Chem. College of Pharmacy, University of Georgia, Athens, GA. Fax: (706) 542-5381. E-mail: DChu@rx. UGA.edu. Objective: Previously, it was shown that administration of phospholipid prodrugs of AZT and AZdU resulted in increased exposure of the nucleosides in the lymphatic system compared to administration of parent compounds (Manouilov et al. 1995, Antiviral. Chem. Chemother. 6, 230). In the search for prodrugs of |
| Mo.A.1080 | Antiviral activity and pharmacokinetics of T-20, an amphipathic helical peptide derived from gp41. Int Conf AIDS 1996 Jul 7-12; 11:68 (abstract no. Mo.A.1080) Lambert DM, Johnson MR, Black PL, Ussery MA, Venetta T, DiMassimo E, Barney S, et al; Trimeris, Inc., Research Triangle Park, North Carolina, USA. Fax: 919-419-1816. T-20 (pentafuside, DP-178), a 36-mer synthetic peptide derived from the HIV-1 gp41 transmembrane protein, is a selective and potent inhibitor of HIV-1 infection (IC50=80ng/ml) and fusion (IC50=lng/ml) in vitro. T-20 appears to block the transition of gp41 to it fusogenic state during the infection process and during ce |
| Mo.A.1081 | Design, synthesis and SAR of dihydropyrone sulfonamide non-peptidic HIV protease inhibitors. Int Conf AIDS 1996 Jul 7-12; 11:68 (abstract no. Mo.A.1081) Skulnick HI, Johnson PD, Aristoff PA, Turner SR, Strohbach JW, Tommasi RA, Thaisrivongs S, Skaletzky LL, Judge TM, Morris JK, Castle TM, Seest EP, Dolak LA, Horng MM, Lynn JC, Tomich PK, Hinshaw RR, Pagano PJ, Chong KT; Pharmacia & Upjohn, Inc., Kalamazoo, MI, USA. Fax: 616-385-5232. E-mail: hiskulni@pwinet.upj.com. Objectives: To design and synthesize a series of dihydropyrone sulfonamides with improved HIV antiviral and protease inhibition based on the previously disclosed pyrone templates U-99499 and U-103017. Methods: The reaction between a heteroaromatic sulfonyl chloride and a chiral amino dihydropyran-2-one gave an enantiom |
| Mo.A.1082 | GEM 91, a gag-antisense phosphorothioate: mechanisms of inhibition of HIV replication and attempts to generate HIV resistance in vitro. Int Conf AIDS 1996 Jul 7-12; 11:69 (abstract no. Mo.A.1082) Yamaguchi K, Papp B, Zhang D, Agrawal S, Byrn RA; Deaconess Hospital, Boston, MA, USA. Fax: 617-424-6237. E-mail: rbyrn@nedhmail.nedh.harvard.edu. Objective: To examine the mechanisms of the inhibitory activity of GEM 91 (Gene Expression Modulator 91), a 25-mer antisense phosphorothioate designed to interact with the conserved gag initiation site of HIV-1, against HIV replication in vitro and to generate and characterize GEM-91 resistant strains of HIV-1. Methods |
| Mo.A.1083 | Effects of reverse transcriptase inhibitor therapy on HIV-1 viral burden in semen. Int Conf AIDS 1996 Jul 7-12; 11:69 (abstract no. Mo.A.1083) Gilliam BL, Dyer J, Cohen MS, Fiscus S, Eron JJ Jr; University of North Carolina at Chapel Hill, Div. of Infect. Dis., Chapel Hill, NC. Fax: 919-966-6714. E-mail: bgilliam@med.unc.edu. Previous studies have suggested that AZT may reduce the concentration of HIV in semen. In order to more fully evaluate the effects of reverse transcriptase inhibitors on the HIV concentration in semen, we recently studied semen donated from 12 men participating in a clinical trial with AZT or DDI +/- |
| Mo.A.1084 | Application of a fluorescent based particle concentration HIV protease assay in the identification of third-generation nonpeptidic dihydropyrone HIV protease inhibitors as clinical candidates. Int Conf AIDS 1996 Jul 7-12; 11:69 (abstract no. Mo.A.1084) Tomich PK, Thaisrivongs S, Aristoff P, Romines K, Howe J, Watenpaugh K, Chong KT, Kezdy F, Tomich CS, Tomasselli A, Tarpley G; Chemical & Biological Screening, Upjohn Laboratories, Pharmacia & Upjohn, Inc., Kalamazoo, MI. Fax: 616-385-5225. Objectives: Having previously introduced two generations of orally bioavailable, nonpeptidic HIV protease inhibitors (the pyrone U-96988 and the cyclooctylpyrone U-103017) into phase I clinical trials (in 1993 and 1994, respectively), the next goal was to design and optimize orally bioavailable third-generation nonpept |
| Mo.A.1085 | An efficient asymmetric synthesis of dihydropyrone HIV protease inhibitors. Int Conf AIDS 1996 Jul 7-12; 11:69 (abstract no. Mo.A.1085) Chrusciel RA, Romines KR, Morris JK, Judge TM, Lovasz KD, Tulinsky J, VanderVelde SL, Morris J, Luke GP, Chrusciel RA, Tustin JM, Dolak LA, Seest EP, Watt W, Mizsak SA, Gammill RB; Pharmacia & Upjohn, Inc., Kalamazoo, MI, USA. Fax: 616-385-4500. E-mail: rachrusc@pwinet.upj.com. Objectives: Several dihydropyrone structures containing one or two chiral centers had been identified as potent HIV protease inhibitors . Initially, these compounds were synthesized as mixtures of two enantiomers or four diastereomers and separated using chiral HPLC techniques to provide small quantities for testing. T |
| Mo.A.1086 | Drug safety evaluation of dihydropyrones, non-peptidic HIV protease inhibitors, in rats and dogs. Int Conf AIDS 1996 Jul 7-12; 11:69 (abstract no. Mo.A.1086) Kakuk TJ, Cole SL, Zaya RM, Schwende FJ, Howard GM, Zhao Z, Koeplinger KA, Zipp GL, Ishii W, Mitsui T; Pharmacia & Upjohn, Inc., Kalamazoo, MI. Fax: 616-385-7629. Objectives: To aid in prioritizing these dihydropyrone compounds on a safety basis and to provide safety data to support clinical development in the second half of 1996. Methods: Oral single-day and multi-dose (up to 14 days) preclinical studies for these dihydropyrones have either been completed or are in progress in |
| The pharmacokinetics and oral bioavailability of three dihydropyrone non-peptidic HIV protease inhibitors in rats and dogs. Int Conf AIDS 1996 Jul 7-12; 11:69 (abstract no. Mo.A.1087) Schwende FJ, Howard GM, Wilkinson KF, Wilson GJ, Rush BD, Chong KT, Zipp GL, Possert PL, Shiou L; The Pharmacia & Upjohn Co., Inc., Kalamazoo, MI, USA. E-mail: fjschwen@pwinet.upj.com. Objective: To characterize the pharmacokinetics and oral bioavailabilities (%F) of three dihydropyrone, non-peptidic HIV- protease inhibitors in rats and dogs. Methods: Rats were surgically implanted with superior vena cava cannula to facilitate intravenous dosing and serial blood sampling. Test compounds were administ |
|
| Mo.A.1088 | The role of chiral chromatography in the discovery of a non-peptidic, HIV protease inhibitor development candidate. Int Conf AIDS 1996 Jul 7-12; 11:70 (abstract no. Mo.A.1088) Seest EP, Dolak L, Castle T; Chemical & Biological Screening, Upjohn Laboratories, Pharmacia & Upjohn, Inc., Kalamazoo, MI. Fax: 616-385-5225. Objectives: We initiated the work described to speed the lead finding process for a new generation of orally active, non-peptidic HIV protease inhibitors . We supplied synthetic chemists with pure stereoisomers and devised analytical methods for the monitoring of enantiomeric purity of the candidate molecule in stereos |
| Sequence determination and chemical characteristics of a novel anti-HIV protein, cyanovirin-N, isolated from the cyanobacterium, Nostoc ellipsosporum. Int Conf AIDS 1996 Jul 7-12; 11:70 (abstract no. Mo.A.1089) Gustafson KR, Sowder R 2d, Henderson L, Pannel L, Cardellina J 2d, McMahon J, Shoemaker R, Boyd M; NCI-FCRDC, Frederick, MD, USA. Fax: 301-846-6177. Objective: To chemically characterize cyanovirin-N (CV-N), a novel anti-HIV agent recently selected by the U.S. National Cancer Institute (NCI) for preclinical development as a potential prophylactic virucide. Methods: CV-N was initially isolated from an aqueous cellular extract of the cyanobacterium Nostoc ellipsospor |
|
| Mo.A.1090 | Analysis of sequence requirements for biological activity of recombinant cyanovirin-N, a novel anti-HIV virucidal protein. Int Conf AIDS 1996 Jul 7-12; 11:70 (abstract no. Mo.A.1090) Mori T, Shoemaker R, McMahon J, Gustafson K, Boyd M; NCI-FCRDC, Frederick, MD, USA. Fax: 301-846-6177. Objective: To evaluate amino acid sequence requirements for bioactivity of recombinant cyanovirin-N (r-CV-N), a novel protein currently undergoing high priority preclinical development by the U.S. National Cancer Institute as a potential prophylactic anti-HIV virucide. Methods: Site-directed mutagenesis of a synthetic |
| Mo.A.1091 | Mechanism of action of the potent anti-HIV virucidal protein cyanovirin-N. Int Conf AIDS 1996 Jul 7-12; 11:70 (abstract no. Mo.A.1091) McMahon JB, O'Keefe B, Buckheit R, Nara P, Gustafson K, Shoemaker R, Boyd M; NCI-FCRDC, Frederick, MD, USA. Fax: 301-846-6177. Objective: To investigate the mechanism of action of cyanovirin-N (CV-N), a novel anti-HIV protein currently undergoing high priority development by the U.S. National Cancer Institute as a potential virucide for prophylactic applications against HIV. Methods: Cell- and virus-based bioassays were used to ascertain the m |
| Mo.A.1092 | Construction and expression in E. coli of a synthetic gene coding for cyanovirin-N, a novel anti-HIV protein originally isolated from a cultured cyanobacterium. Int Conf AIDS 1996 Jul 7-12; 11:70 (abstract no. Mo.A.1092) Shoemaker RH, Wu L, Smythe A, Gulakowski R, McMahon J, Gustafson K, Boyd M; NCI-FCRDC, Frederick, MD, USA. Fax: 301-846-6177. Objective: To develop recombinant DNA methods for characterization and production of cyanovirin-N, a novel anti-HIV protein recently selected by the U.S. National Cancer Institute for high priority preclinical development as a potential virucide for prophylaxis against HIV infection. Methods: The unique 101 residue ami |
| Mo.A.1093 | Discovery of cyanovirin-N, a novel HIV-inactivating protein from Nostoc ellipsosporum that targets viral gp120. Int Conf AIDS 1996 Jul 7-12; 11:71 (abstract no. Mo.A.1093) Boyd MR, Gustafson K, McMahon J, Shoemaker R; NCI-FCRDC, Frederick, MD, USA. Fax: 301-846-6919. There is an urgent international priority for discovery and development of female-controllable measures against HIV transmission. The viral-gp120/cellular-CD4 interaction remains an especially attractive target both for developmental therapeutics and for prophylaxis against HIV infection. Project: As a part of t |
| Mo.A.1094 | Effect of the tat inhibitor, 7-chloro-5-(2-pyrrl)-3h-1,4-benzodiazepin-2-(H)-one, in in vitro reconstituted and cell-based transactivation systems. Int Conf AIDS 1996 Jul 7-12; 11:71 (abstract no. Mo.A.1094) Tomassini J, Blau C, Byrnes V, Flores O, Graham P, Hazuda D, Yang L; Merck Research Laboratories, West Point, PA, USA. Fax: 215-652-0994. Objective: The benzodiazepine compound, 7-chloro-5-(2-pyrrl)-3H-1,4-benzodiazepin-2-(H)-one, was previously identified as an inhibitor of TAT-activated HIV transcription and of HIV replication in acute and chronically infected cells (1). Although the mechanism of action of this inhibitor is not completely understood, s |
| Mo.A.1095 | Synthesis and biological evaluation of cyclic phospholipid analogues targeting HIV-1. Int Conf AIDS 1996 Jul 7-12; 11:71 (abstract no. Mo.A.1095) Ishaq KS, McLean JW, Morris-Natschke SL, Iyer N, Kucera LS; Wake Forest University Medical Center, Winston-Salem, North Carolina, USA. Fax: 910-716-9928. E-mail: lkucera@bgsm.edu. Objectives: The major objectives are to synthesize and evaluate membrane interactive cyclic phospholipid analogues and to conjugate them with AZT to enhance anti-HIV-1 selectivity. Methods: We have synthesized conformationally constrained phospholipid analogues with heteroalkyl chains and a phosphocholine moiety incorp |
| Mo.A.1096 | HIV-1 load is decreased in chronic infected ACH-2 cell line by successive in vitro hyperthermia treatment. Int Conf AIDS 1996 Jul 7-12; 11:71 (abstract no. Mo.A.1096) Lee MH, Schick PM, Hsu MY, Ly H; Harbor-UCLA Medical Center, Torrance, CA, USA. Fax: 10-782-8776. E-mail: moonlee@harbor2.humc.edu. Objective: Extracorporeal whole body hyperthermia is currently in clinical trials for treating AIDS patients in the USA. Since efficacy of this treatment is not well established, we studied the effects of hyperthermia treatment (42 degrees C) in the HIV-1 chronically infected T cell line (ACH-2). Methods: Uninfected pa |
| Mo.A.1097 | Open-label sorivudine (BV-araU) for the treatment of varicella zoster virus (VZV) infections in pediatric AIDS patients who failed or were intolerant of intravenous acyclovir. Int Conf AIDS 1996 Jul 7-12; 11:71 (abstract no. Mo.A.1097) Oshana S, Brennan-Rowe N, Denisky G, Thomis J, DeHertogh D, Smaldone L, Freifeld A; Bristol-Myers Squibb, Wallingford, CT. Fax: (203) 284-7698. Objective: To determine efficacy and safety of oral sorivudine (BV-araU) in pediatric AIDS patients with cutaneous, visceral or ocular VZV disease who had failed or were intolerant of intravenous acyclovir . Methods: Patients were evaluated at entry, during treatment and at post-treatment. The oral sorivudine dose appr |
| Mo.A.1098 | The compromised membrane: a target for HIV drug design. Int Conf AIDS 1996 Jul 7-12; 11:71 (abstract no. Mo.A.1098) Gatti PJ, Haislip AM, Plymale DR, Makutonina A, Choi B, Garry RF; Dept. Micro/Immunol, Tulane Medical School, New Orleans, LA, USA. Fax: 504-588-5144. Objective: HIV infection alters permeability of the plasma membrane to ions and other small molecules. The objective of this study was to identify molecules that can selectively enter HIV-infected cells and inhibit progeny virus expression. Methods: CD4+ T-lymphoblastoid cells (RH9) and peripheral blood mononuclear cel |
| Mo.A.1099 | Proteolytic fragments of anti-HIV proteins MAP30 and GAP31 are biologically active. Int Conf AIDS 1996 Jul 7-12; 11:72 (abstract no. Mo.A.1099) Lee-Huang S, Huang PL, Huang PL, Bourinbaiar A, Chen HC, Kung HF; Biochemistry Department, NYU Medical School, New York, NY, USA. Objective: The plant sources of anti-HIV proteins MAP30 and GAP31 have been used in traditional medicine by oral administration. Thus the bioavailable form of these anti-HIV agents may be proteolytic fragments. The objective of this study is to determine whether proteolytic fragments of MAP30 and GAP31 are biologically |
| Mo.A.1100 | Anti-HIV effect of pregnancy hormone, human chorionic gonadotropin (hCG) and beta hCG in vitro. Int Conf AIDS 1996 Jul 7-12; 11:72 (abstract no. Mo.A.1100) Bourinbaiar AS, Fruhstorfer EC; Metatron, Inc., New York, NY, USA. Fax: 212-598-0074. E-mail: emballon@pipoline.com. Objective: To identify further the anti-HIV mechanism of human chorionic gonadotropin (hCG) in vitro with the goal of using this pregnancy hormone in AIDS prevention and therapy. Methods: The scrial ten-fold dilutions of alpha and beta subunits (range 100 micrograms - 100 pg per ml) and the intact hCG as a control (100 |
| Mo.A.1101 | Lithium gamma-linolenic acid (LiGLA)-associated cytotoxicity in acute and chronic HIV infection models in vitro. Int Conf AIDS 1996 Jul 7-12; 11:72 (abstract no. Mo.A.1101) Mpanju O, Manning J, Randall S, Winther M, Montaner J, O'Shaughnessy M, Conway B; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada. Fax: (604) 631-5527. E-mail: ompanju@hivnet.ubc.ca. Objective: To carry out a comparative study of LiGLA - associated cytotoxicity in chronic and acute models of HIV infection. Methods: (i) PHA-stimulated PBMCs were infected with HTLV-IIIB or G910-6 isolates of HIV (MOI=0.0001-0.05). Cells were then cultured in the presence of 0-20 micrograms/mL LiGLA. Viable cells were |
| Mo.A.1102 | Antiviral profile of HBY097, a nonnucleosidic inhibitor of HIV-1 RT in a phase I study. Int Conf AIDS 1996 Jul 7-12; 11:72 (abstract no. Mo.A.1102) Rubsamen-Waigmann H, Wainberg MA, Huguenel E, Shah A, Paessens A, Kleim JP, Rosner M; Institute of Virology, Bayer Pharma Research Center, Wuppertal, Germany. Fax: 0049-202-364162. Objective: This study was designed to characterize viral load and viral characteristics during a 14 day treatment of HIV-1-positive individuals with HBY 097. Method: Blood was drawn from the patients at day 0, 14 and 21 (i.e. 7 days after the last day under treatment with HBY 097). Viral load determinations were done b |
| Mo.A.1103 | Synergistic inhibition of human immunodeficiency type 1 replication in vitro by two- and three-drug combination of delavirdine, lamivudine and zidovudine. Int Conf AIDS 1996 Jul 7-12; 11:72 (abstract no. Mo.A.1103) Chong KT, Pagano PJ; Cancer & Infectious Diseases Research, Pharmacia and Upjohn, Inc., Kalamazoo, MI, USA. Fax: 616-385-6492. Objective: To evaluate combination therapy involving delavirdine (DLV), a non-nucleoside reverse transcriptase inhibitor, in two- and three-drug combination with lamivudine ( 3TC ) and zidovudine (ZDV). |
| Mo.A.1104 | Anti-HIV activity by MGN-3 in vitro. Int Conf AIDS 1996 Jul 7-12; 11:72 (abstract no. Mo.A.1104) Ghoneum M; Drew University of Medicine and Science, L.A., CA. Fax: (310) 474-6724. Objective: To examine the effect of MGN-3 on HIV induced syncytia formation (SF) In Vitro. MGN-3 is an arabinoxylane from rice bran, that is enzymatically treated with an extract from basidiomycetes mycelia. Method: Peripheral Blood Lymphocytes (PBL) from AIDS patients were cultured with PHA in the presence or absence |
| Mo.A.1105 | Quantitative NASBA and competitive PCR and RT-PCR can rapidly monitor in vitro the effect of antiretroviral drugs on HIV replication. Int Conf AIDS 1996 Jul 7-12; 11:73 (abstract no. Mo.A.1105) Debiaggi M, Carlevari M, Brerra R, Zara F, Bruno R, Achilli G, Giacobone E, Romero E, Filice G; Istituto di Microbiologia, via Brambilla, Universita Studi di Pavia, Pavia, Italy. Objective: We have applied a quantitative NASBA and competitive PCR to examine the kinetics of HIV-1 replication in vitro and to assess the effect of antiviral drugs on the accumulation of HIV gag RNA and DNA. Methods: H9 cells (1x106/ml) were infected with HTLV IIIB (100 TCID50). Cell cultures were treated with |
| Mo.A.1106 | Comparative study with ddC plus AZT in HIV infection: early vs later: preliminary report. Int Conf AIDS 1996 Jul 7-12; 11:73 (abstract no. Mo.A.1106) Dominguez CC, Villarreal C, Torres R, Robles M, Terrazas J, Blanno V; Hospital de Infectologia, Centro Medico Nacional La Raza IMSS, Mexico D.F. Objective: To compare efficacy and tolerance with a double drug regimen ( AZT plus DDC) in HIV patients infection: early vs later. Gruop A included DDC 0.750 mg tid plus AZT 100 mg tid, lymphocites CD4 counts greater than 300/mm3. Group B DDC plus AZT at same doses but lymphocites CD4 counts less than 300/mm3. |
| Mo.A.1107 | Factor(s) active against human immunodeficiency virus, cytomegalovirus and Herpes simplex virus. Int Conf AIDS 1996 Jul 7-12; 11:73 (abstract no. Mo.A.1107) Nosik DN, Vainberg Y, Nossik N, Kaplina E, Kalnina L; D.I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, Moscow, Russia. Fax: (095) 190-74-85. Objective: To study an antiviral activity of agents against Human Immunodeficiency Virus, Cytomegalovirus ( CMV ) and Herpes Simplex Virus ( HSV ). Methods: The antiviral activity of soluble low weight factor(s) (m.m. around 5 kD) (named AVF) produced in T-cells was studied in the model system of human PBMCs and T-cell |
| Mo.A.1109 | Cystamine inhibits HIV-1 replication in cord blood-derived mononuclear phagocytes and lymphocytes. Int Conf AIDS 1996 Jul 7-12; 11:73 (abstract no. Mo.A.1109) Ho WZ, Kaufman D, Song L, Douglas SD; Immunology Dept., The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, PA, USA. Fax: 215-590-2025. E-mail: Ho@e-mail.CHOP.Edu. Objective: To determine the effects of cystamine on HIV expression in cord blood monocytes derived macrophages (CBMDM) and lymphocytes in vitro. Methods: Cord blood were obtained from the umbilical vein of healthy term newborn infants after uncomplicated pregnancies and deliveries. Cord monocytes and lymphocytes were i |
| Mo.A.1110 | Detection of mutant viruses at codon 215 in the HIV reverse transcriptase gene in untreated patients. Int Conf AIDS 1996 Jul 7-12; 11:73 (abstract no. Mo.A.1110) Picard H, Binet D, Burghoffer B, Kirstetter M, Frottier J, Petit JC, Morand-Joubert L; Service de Bacteriologie-Virologie; Hopital Saint-Antoine; Paris, France. Fax: 33 (1) 49 28 24 72. Objective: to determine the prevalence of mutant viruses at codon 215 in the reverse transcriptase gene, in HIV-1 positive patients who have never received antiretroviral drugs. Methods: forty-three HIV-infected patients were included in this study between April 1994 and January 1996, in Saint-Antoine hospital. The pat |
| Mo.A.1111 | Genotype resistance at codon 215 and SI-NSI phenotype long-term evolution of HIV-1. Correlation to clinical outcome in a cohort of 21 AZT-treated patients. Int Conf AIDS 1996 Jul 7-12; 11:74 (abstract no. Mo.A.1111) Arvieux C, Ruffault A, Michelet C, Renard I, Jacquelinet C, Colimon R, Cartier F; Departement de Virologie, Hopital Ponchaillou, Rennes, France. Fax: 33 99 28 41 59. Objectives: to evaluate the association between (1) genotypic resistance to AZT (codon 215) of HIV-1, (2) SI-NSI phenotype and clinical evolution in a cohort of 21 patients treated with AZT. Patients and Methods: Patients were enrolled in a first prospective study to determine the correlation between viral load (Plasma |
| Mo.A.1112 | Reverse transcriptase (RT) gene analysis of HIV-1 mutants dually resistant to AZT and ddI. Int Conf AIDS 1996 Jul 7-12; 11:74 (abstract no. Mo.A.1112) Kondo M, Saito T, Ito A, Akagi K, Nishioka K, Imai M; Kanagawa Prefectural Public Health Laboratory, Yokohama, Japan. Fax: 81-45-363-1037. Objective: To study the relation between drug susceptibility and amino acid mutation in reverse transcriptase (RT) coding region of HIV-1 isolates. Methods: We isolated HIV-1 mutants dually resistant to AZT and ddI from patients who received ddI treatment longer than one year after switching |
| Mo.A.1113 | Zidovudine resistance and HIV-1 load in multiple autopsy tissues of AIDS patients. Int Conf AIDS 1996 Jul 7-12; 11:74 (abstract no. Mo.A.1113) Emery VC, Aitkins M, Strappe P, Kaye S, Loveday C, McLaughlin JE, Johnson MA, Tedder RS, Griffiths PD; Department of Virology, Royal Free Hospital, London, UK. Fax: 0171 830 2854. Objective. This study aims to investigate the relationship between the quantitative prevalence of ZDV resistance in peripheral blood and lymphoid organs to that present in multiple other organs of the same individual. Methods Proviral HIV-1 load was measured by quantitative-competitive PCR in multiple organs of 11 pati |
| Mo.A.1114 | Differential plaque assay for studying population dynamics of wild-type and drug-resistant mutant HIV in mixed infections. Int Conf AIDS 1996 Jul 7-12; 11:74 (abstract no. Mo.A.1114) Rayner MM, Jackson DA; DuPont Merck Pharmaceutical Company, Wilmington, DE, USA. Objective: We wished to develop a sensitive assay that would differentially detect wild-type (WT) and drug-resistant HIV in a mixed infection for the purpose of studying HIV population dynamics in response to drug selective pressure. Methods: As a model system we studied mixtures of WT HIV and the mutant virus containi |
| Mo.A.1115 | HIV-1 isolates from subjects on prolonged stavudine therapy remain sensitive to stavudine. Int Conf AIDS 1996 Jul 7-12; 11:74 (abstract no. Mo.A.1115) Deminie C, Bechtold C, Riccardi K, Lin PF, Colonno RJ; Bristol-Myers Squibb Co., Wallingford, CT, USA. Fax: 203-284-6088. Objective: To determine if stavudine-resistant variants arise following prolonged therapy, and to identify a genetic marker for any resistance observed. Methods: Nineteen matched pairs of pre- and post-treated samples were obtained from subjects on stavudine therapy. Two approaches were employed to obtain viruses for s |
| Mo.A.1116 | Hydroxyurea as antiviral drug against HIV-1 resistant mutants. Int Conf AIDS 1996 Jul 7-12; 11:74 (abstract no. Mo.A.1116) Lori F, Malykh A, Wainberg M, Villani P, Maserati R, Gallo RC, Lisziewicz J; Research Institute for Genetic and Human Therapy (RIGHT), Gaithersburg, MD, USA. Fax: +1 (301) 3309458. Objective: To assess the sensitivity to nucleoside analogues ( AZT , ddI ) of nucleoside resistant variants of HIV-1 in the presence of Hydroxyurea at concentrations achievable in vivo. Methods: In vitro. Peripheral blood mononuclear cells were infected with high multiplicity of infection with H |
| Mo.A.1117 | In vitro resistance to HIV in PBMC cultures from recently infected participants in HIV vaccine trials is CD8 dependent. Int Conf AIDS 1996 Jul 7-12; 11:75 (abstract no. ) Schwartz DH, Arrango-Jaramillo S, Castillo R, Sridharan G, Clements ML; Johns Hopkins University Center for Immunization Research, Baltimore, MD. Fax: 410/955-2791. Objective: To longitudinally assess the in vitro susceptibility or resistance of PBMCs from recent seroconverters who had received two or more injections of HIV-1 envelope based vaccine products. Methods: Individuals who had participated in various Phase I or II trials of envelope based HIV vaccines were monitored for |
| Poster Abstracts - Monday, July 8 Track B: Clinical Science Mo.B.1120 thru Mo.B.1397 |
|
| Mo.B.1121 | A randomized, double-blind, dose-ranging phase II European study of the safety and efficacy of chronically administered butanoyl-castanospermine (MDL 28,574A) HIV-infected patients. Int Conf AIDS 1996 Jul 7-12; 11:75 (abstract no. Mo.B.1121) Arasteh K, Czerwinska R, Schlote F, Fatkenheuer G, Jessen H, Moll A, Gehring P, Ulmer A, Hamedani P, McPherson M; Auguste-Viktoria-Hospital, Berlin, Germany. Fax: .49.30.7903.2005. Study Drug: MDL 28,574A is a derivate of castanospermine, a naturally occuring plant alkaloid of the Australian chestnut. It is inhibiting the activity of alpha-glucosidase, a host cell enzyme, resulting in a diminished amount of gp 120 in the viral envelope, which may lead to reduced infectivity of the HIV virus. Obje |
| Mo.B.1122 | Stavudine (d4T)-HIV 1 viral load and CD4 positive cell count in HIV+ individuals pretreated with zidovudine. Int Conf AIDS 1996 Jul 7-12; 11:75 (abstract no. Mo.B.1122) Mauss S, Adams O, Willers R, Haussinger D, Jablonowski H; Klinik fuer Gastroenterologic und Infektiologic, Universitat Duesseldorf, Duesseldorf, Germany. Fax: +49 1211 1811-8752. Objective: To determine HIV 1 viral load and the course of CD4-positive (CD4+) cells in HIV-seropositive (HIV+) individuals treated with stavudine ( d4T ) after prolonged pretreatment with zidovudine (ZDV). Methods: HIV+ individuals with less than 350 CD4+ cells/micro |
| Mo.B.1123 | Defined manipulation of mutational pathways of the HIV-1 RT gene with the nonnucleoside reverse transcriptase inhibitor (NNRTI) HBY 097. Int Conf AIDS 1996 Jul 7-12; 11:75 (abstract no. Mo.B.1123) Kleim JP, Winkler I, Rosner M, Kirsch R, Rubsamen-Waigmann H, Paessens A, Rie G, Hoechst AG; Frankfurt, Germany. Fax: +49-69-305-81908. Objective: HBY 097 is a second-generation NNRTI oF HIV-1 replication and is at present undergoing phase I/II clinical trials. In vitro, HBY 097 causes the appearance of characteristic RT G190-E viral variants, which are resistant to the drug but display a crippled RT polymerase function and retarded growth properties. |
| Mo.B.1124 | Long term outcome of ZDV/ddC treatment in ZDV-experienced patients. Int Conf AIDS 1996 Jul 7-12; 11:76 (abstract no. Mo.B.1124) Banhegyi D, Gerlei Z, Szlavik J, Miskovits E, Ujhelyi E, Toth FD, Fust G; Saint Laszlo Hospital, Dept. of Immunology, Budapest, Hungary. Fax: (36)-1217-1422. E-mail: immunol@datanet.hu. Objective: To evaluate the long term outcome of zidovudine/ zalcitabine ZDV/DDC treatment in heavily ZDV-pre-treated patients (pts) in survival, HIV related diseases and surrogate markers. Methods: 28 ZDV-experienced (mean 19,2 month, 6 - 40) pts were involved into this study. Mean CD4+cell count was 174/mm3 (42 - 320) |
| Mo.B.1125 | From monotherapy to the multidrug combination era: a case of sustained response to addition of nevirapine to continued zidovudine. Int Conf AIDS 1996 Jul 7-12; 11:76 (abstract no. Mo.B.1125) Tumietto F, Costigliola P, Moroni Marco, Colangeli V, Borderi M, Venturi C, Spinosa S, Chiodo F; Boehringer Ingelheim, Milano, Italy. Background and introduction: Recently, trials have demonstrated that multidrug treatment based on concurrent administration of at least two antiretrovirals is more effective than monotherapy in the treatment of HIV infection. Nevirapine (NVP), a new antiretroviral drug of the non-nucleoside reverse transcriptase inhibi |
| Mo.B.1126 | A multicentric, prospective, randomized trial of IFN+ ddI versus ddI monotherapy in HIV patients. A preliminary report. Int Conf AIDS 1996 Jul 7-12; 11:76 (abstract no. Mo.B.1126) Casari S, Orani A, Scalzini A, Donisi A, Gregis G, Gattuso G, Carosi G; Clinica di Malattie Infettive e Tropicali, Brescia, Italy. Fax: .39.30.303061. Objectives: To evaluate tolerability and efficacy of the combined therapy with IFN-DDI versus DDI monotherapy. Methods: Naive ARC pts with CD4+ less than 350/cmm were randomized to receive IFNalpha-2b MU 3x3/week + DDI mg 200x2/day for 12 months (GR 1) versus DDI mg 200x2/day for 12 months (GR 2), followed by 12 months |
| Mo.B.1127 | Anti-HIV activity and mechanism of nicked and circular dumbbell RNA/DNA chimeric oligonucleotides. Int Conf AIDS 1996 Jul 7-12; 11:76 (abstract no. Mo.B.1127) Yamakawa H, Hosono K, Inagawa T, Singh R, Takai K, Takaku H; Chiba Institute of Technology, Chiba, Japan. Fax: +81-474-71-8764. Objective: We have studied a new type of antisense oligonucleotide, with RNA-DNA base pairs (sense (RNA) and antisense (DNA)) in the double helical stem (nicked and circular dumbbell DNA/RNA chimera oligonucleotides). Methods: The circularization of the 40 mer DNA/RNA chimeric oligonucleotide was carried out by enzymat |
| Mo.B.1128 | Plasma viral load (VL) and CD4 cell count changes in naive patients at 3 months after initiation of combined therapy with zidovudine (ZDV) and zalcitabine (ddC). Int Conf AIDS 1996 Jul 7-12; 11:76 (abstract no. Mo.B.1128) Ibanez A, Ruiz L, Puig T, Gutierrez C, Sanchez I, Clotet B; Retrovirology Lab, IRSI-Caixa and AIDS Unit, Hospital Universitari Germans Trias i Fuojol, Badalona, Spain. Fax: .34-3-465 7602. Objective: To examine the plasma viral load (RNA HIV-1 copies) at baseline, 4 and 12 weeks and to compare these values with CD4 cell counts in naive patients that initiated antiretroviral therapy with ZDV+ ddC . Methods: We studied 31 HIV seropositive patients not previously exposed to antiretroviral therapy ( naive pa |
| Mo.B.1129 | Safety and efficacy of zalcitabine (ddC) and zidovudine (ZDV) combination in HIV-positive persons with CD4 cell counts less than or equal to 300/mm3: an international open label evaluation (Roche study M50002). Int Conf AIDS 1996 Jul 7-12; 11:77 (abstract no. Mo.B.1129) Walker M, Moyle GJ, Harris R, Warburg M; Hoffmann La Roche, Basel, Switzerland. Fax: 41 61 6881820. Objective. This study was initiated prior to the commercial availability of ddC to both provide ddc in countries where access was limited ( Spain , Italy , Mexico , South America, Benelux) and to collect well-controlled safety data |
| Mo.B.1130 | Zidovudine prophylaxis for the prevention of HIV vertical transmission in the hospital clinic of Barcelona. Int Conf AIDS 1996 Jul 7-12; 11:77 (abstract no. Mo.B.1130) Martinez-Tejada B, Coll O, Zamora L, Fortuny C, Ravenau W, Lonca M, Lopez A; Hospital Clinic of Barcelona, Spain. Fax: 641-5290. E-mail: tejada+@pitt. edu. Objective: To assess the efficacy, evaluate the acceptability and monitor the compliance and side effects of zidovudine (ZDV) prophylaxis in HIV-infected pregnant women. Methods: Since June 1994, all HIV-infected pregnant women have been offered ZDV prophylaxis for the prevention of HIV vertical transmission. All women |
| Mo.B.1131 | Lamivudine (3TC) therapy for patients with advanced AIDS and less than 50 CD4 cells. Int Conf AIDS 1996 Jul 7-12; 11:77 (abstract no. Mo.B.1131) Sha BE, Pottage JC Jr, Benson CA, Agnoli MM, Haas A, Kessler HA; Section of Infectious Disease, Rush Medical College, Chicago, IL. Objective: To characterize the clinical and virologic response and tolerability of 3TC in patients with advanced AIDS. Methods: From March 1995 to December 1995 patients with AIDS and CD4 less than 50 cells/mm3 were enrolled, evaluated, and treated according to the 3TC compassionate treatment IND protocol. |
| Mo.B.1132 | A phase I trial of HIV protease inhibitor KNI-272 in patients with AIDS or symptomatic HIV infection. Int Conf AIDS 1996 Jul 7-12; 11:77 (abstract no. Mo.B.1132) Humphrey RW, Nguyen BY, Wyvill KM, Shay LE, Lietzau J, Ueno T, Fukasawa T, Hayashi H, Mitsuya H, Yarchoan R; NIH, Bethesda, MD, USA. Fax: (301) 402-3645. Objectives: KNI-272, a novel transition-state mimetic tripeptide HIV protease inhibitor, was previously shown to have potent activity against HIV in vitro at concentrations of approximately .008 - 2 micromolar and to have reasonable oral bioavailibility in animals (Kageyama et al., AAC 1994; 38: 1107). The present stud |
| Mo.B.1133 | Persistence of CD4 lymphocyte increases at 18 months of treatment with lamivudine. Int Conf AIDS 1996 Jul 7-12; 11:77 (abstract no. Mo.B.1133) Wiewora RJ, Landvay K; Stratogen of the Palm Beaches, Palm Beach Gardens, FL, USA. Fax: 407-775-8711. Objective: Lamivudine has been shown to increase CD4 counts. This increase has been shown to persist for at least 12 months. We sought to determine if this increase persists for 18 months. Method: Seventy-seven patients in a community practice setting had received lamivudine since it became available through compassion |
| Mo.B.1134 | Surrogate marker responses from an open-label, extended use delavirdine mesylate (DLV) treatment in triple combination (ZDV+DLV+ddI or ZDV+DLV+ddC) for HIV-1+ patients. Int Conf AIDS 1996 Jul 7-12; 11:78 (abstract no. Mo.B.1134) Freimuth WW, Wang Y, Docsa SR, Greenwald CA, Wathen LK, Batts DH, Peel BG; Pharmacia & Upjohn, Inc., Kalamazoo, MI. Fax: (616) 329-8593. About 200 patients have entered this clinical trial from other phase II/III DLV protocols who have completed the original protocol, or who have had an AIDS defining illness or 50% decline in CD4 since entry into their respective protocol. This ongoing protocol permits the study of the effect of switching patients to DL |
| Mo.B.1135 | Early zidovudine treatment extends AIDS-free time. Int Conf AIDS 1996 Jul 7-12; 11:78 (abstract no. Mo.B.1135) Detels R, Munoz A, Peng Y, Graham N, Phair J, Mellors JS; UCLA, Dept. of Epidemiology (CHS), Los Angeles, CA, USA. Fax: (310) 206-6039. E-mail: detels@admin.ph.ucla.edu. Objectives: To compare time to AIDS between men receiving zidovudine before or not before the diagnosis of AIDS, and time to death for men receiving zidovudine before or only after AIDS. Methods: For the time to AIDS, 821 men receiving zidovudine prior to AIDS were pair matched to men not treated on level of CD4+ cells |
| Mo.B.1136 | Survey of antiretroviral selection by physicians and HIV-infected persons. Int Conf AIDS 1996 Jul 7-12; 11:78 (abstract no. Mo.B.1136) Dong BJ, Luber AD; University of California, San Francisco, CA, USA. Fax: (415) 476-6632. E-mail: bjdong@itsa.ucsf.edu. Objective: To describe the selection of antiretoviral agents by physicians and HIV-infected persons located in 3 different geographic regions, the information sources that influence decision making, and whether the 1993 NIAID guidelines represent the current standard of practice. Methods: A survey depicting 5 different |
| Mo.B.1137 | Clinical and virological responses to ritonavir, an inhibitor of HIV protease. Int Conf AIDS 1996 Jul 7-12; 11:78 (abstract no. Mo.B.1137) Korneyeva M, Molla A, Kempf D, Vasavanonda S, Chernyavskia T, Boucher C, Schipper P, Lyons N, Gao Q, Norbeck D, Leonard J; Abbott Laboratories, Abbott Park, IL. Fax: (847) 938-1021. Objectives: Ritonavir , a potent and selective peptidomimetic inhibitor of HIV protease, exhibits high oral bioavailability and demonstrates profound antiviral and immunologic activity in HIV-infected humans. Methods: In Phase II studies, maximum declines (more than 1 order of magnitude) in plasma viral RNA were observ |
| Mo.B.1138 | Efficacy and safety of MDL 28,574A in HIV-positive patients with baseline CD4 values of 100 - 300. Int Conf AIDS 1996 Jul 7-12; 11:78 (abstract no. Mo.B.1138) Zolnouni P, Berger DS, Perez G, Hamedani P, Frampton M, Gibson C, Sidarous E, Stoltz M; California Clinical Trials, Beverly Hills, CA, USA. Fax: (310) 854-5419. Introduction: MDL28,574A (MDL) is a butanoyl derivative of castanospermine (CAST), a naturally occurring plant alkaloid, with 30-fold greater anti-HIV activity in-vitro than CAST. MDL is under development for delay of the progression of disease in HIV-positive patients. MDL is an alpha-glucosidase I inhibitor which act |
| Mo.B.1139 | An evaluation of the effect of Invirase (saquinavir) HIV proteinase inhibitor on plasma HIV-1 RNA: a substudy of the Invirase open-label compassionate treatment program (SV 14974). Int Conf AIDS 1996 Jul 7-12; 11:78 (abstract no. Mo.B.1139) Torres R, Barr MR, Weber PF, Siemon-Hryczyk M, Salgo MP, Yucaitis J, Lam WS, Busa MS; AIDS Center, St. Vincent's Hospital and Medical Center, New York, NY. Fax: (212) 353-3056. E-mail: gabrieltop@AOL.com. Objective: To study the effects of saquinavir on plasma HIV-1 RNA viral load using quantitative polymerase chain reaction (PCR) assays and to correlate the effect of these changes with clinical outcome and survival in HIV-1 infected patients with CD4 cell counts less than or equal to 300 cells/mm3 who have previously b |
| Mo.B.1140 | Single-dose and steady-state pharmacokinetics of escalating regimens of 1592U89 with and without zidovudine. Int Conf AIDS 1996 Jul 7-12; 11:79 (abstract no. Mo.B.1140) McDowell JA, Symonds WT, LaFon SW; Glaxo Wellcome, Inc., Research Triangle Park, NC. Fax: 919-315-0440. E-mail: jim_mcdowell@us.wfl.com. Objective: To determine the single dose and steady-state pharmacokinetics (PK) of escalating regimens of 1592U89, a new purine-based nucleoside analog with significant in vitro anti-HIV activity, and to evaluate possible effects of concomitant zidovudine (ZDV) capsules upon the PK of 1592U89. Methods: 1592U89 was admin |
| Mo.B.1141 | Acyclovir in combination with zidovudine does not prolong survival in advanced HIV disease. Int Conf AIDS 1996 Jul 7-12; 11:79 (abstract no. Mo.B.1141) Erbelding EJ, Moore RD, Chaisson RE; Johns Hopkins University School of Medicine, Baltimore, MD, USA. Fax: (410)955-7889. E-mail: eerbeldi@welchlink.welch.jhu.edu. Objective: To evaluate the association between combination acyclovir (ACV) and zidovudine (ZDV) use and survival in a cohort of HIV-infected patients receiving care at an urban HIV clinic. Methods: We measured survival in a cohort of HIV-infected patients who had CD4 cell counts of 500 per cubic millimeter or less and |
| Low dose AZT in combination with ddC in HIV+ patients (pts) with hematological intolerance (HI) or failure to AZT (FA). Final report. Int Conf AIDS 1996 Jul 7-12; 11:79 (abstract no. Mo.B.1142) Lupo S, Bortolozzi R, Taborda M, Fernandez E, Kneitschel R, Santarelli MT; University of Rosario, Santa Fe, Argentina. Fax: (54) (41) 248045. Objective: the primary objective is to evaluate tolerance and toxicity associated with low dose of AZT in combination with ddC in pts previously treated with AZT with HI and FA. The secondary objective is to assess the efficacy of this association. |
|
| Mo.B.1143 | Anti-HIV activity after 24 weeks of the didanosine and hydroxyurea combination in HIV-1 infected patients with CD4+ mean value below 200/mm3. Int Conf AIDS 1996 Jul 7-12; 11:79 (abstract no. Mo.B.1143) Ruiz L, Clotet B, Cabrera C, Ibanez A, Puig T, Sirera G; Retrovirology Lab IRSI-Caixa, Hospital Universitari Germans Trias I Pujol, Barcelona, Spain. Fax: 3-34-465 7602. Hydroxyurea (HU) has shown to potentiate the anti-HIV-1 effect of didanosine ( ddI ) in vitro. We report 24 weeks follow-up of the anti-HIV activity of the ddI+HU combination administered to patients with CD4 mean value below 200/mm3. Our first objective was to assess the anti-HIV activity thro |
| Mo.B.1144 | Crixivan: summary of 24-week experience with Crixivan at 2.4g/d in phase II trials. Int Conf AIDS 1996 Jul 7-12; 11:79 (abstract no. Mo.B.1144) Chodakewitz JA, Leavitt R, Massari F, Hildebrand C, Arcuri K, Gilde L, Nessly M, Meibohm A, Ghosh K, Radkowski R, Getson A, Rockhold F; Merck Research Laboratories, West Point, PA. Fax: 610-834-0586. Objectives: To integrate information regarding the efficacy and safety of CRIXIVAN ( indinavir sulfate, CXN), an oral HIV protease inhibitor, as assessed in multiple phase II clinical trials.Methods: Information from 3 different phase II clinical trials in which CXN therapy was initiated at the phase III dose (2. |
| Mo.B.1145 | Efficacy and safety of MDL 28,574A in HIV-positive patients with baseline CD4 values of 301-500. Int Conf AIDS 1996 Jul 7-12; 11:80 (abstract no. Mo.B.1145) Richmond GJ, Zolnouni P, Stall J, McPherson M, Hamedani P, Cross V, Sidarous E, Stoltz M; Ft. Lauderdale, FL. Fax: (305) 524-5833. Objective: MDL28,574A (MDL), a butanoyl derivative of castanospermine, a naturally occurring plant alkaloid, is under development for use in the delay of the progression of disease in HIV-positive patients. MDL is an alpha-glucosidase I inhibitor which acts in the latter phases of viral replication by altering glycopro |
| Mo.B.1146 | Does legislation improve the safety of banked blood in Singapore? The experience with HIV and Hepatitis B. Int Conf AIDS 1996 Jul 7-12; 11:80 (abstract no. Mo.B.1146) Kan E, Ong D; Action for AIDS, Singapore. Fax: (65) 463-1220. E-mail: ogytt@sgh.gov.sq. Singapore detected its first case of HIV in 1985. All banked blood has since been serologically screened for HIV. Screening also includes a 1 to 1 interview using a donor health assessment questionnaire modified since 1986 to include risk factors for HIV. Since 1989, donors have been further required to sign a statut |
| Mo.B.1147 | Evaluation of rapid HIV 1/2 double spot and STAT PAK tests. Int Conf AIDS 1996 Jul 7-12; 11:80 (abstract no. Mo.B.1147) Kohreanudom S, Kunanusont C, Phoolcharoen W; AIDS Division, Dept of Communicable Disease Control, Ministry of Public Health, Nonthaburi, Thailand. Fax: [66]-(2)-5903210. Background: More HIV rapid test kits are commercially distributed in Thailand because of increasing awareness of HIV transmission risk. The major application is to test emergency donated blood especially in community hospitals where standard safe blood supply system is not well institutionalised. Objective: To evaluate |
| Mo.B.1148 | Training for safe blood programmes in sub-saharan Africa. Int Conf AIDS 1996 Jul 7-12; 11:80 (abstract no. Mo.B.1148) Goddard JM, Kataaha PK, Ssenyonga P; Nakasero Blood Bank, Kampala, Uganda. Fax: 256-41-257484. E-mail: nbb@mukla.gn.apc.org. Blood transfusion in sub-saharan Africa carries a high risk of transmission of HIV, Hepatitis B and C, Malaria and other infections. Prevention is by deferral of high-risk donors, testing of blood for infection markers and restricting blood transfusion to life-threatening situations. Implementation requires comp |
| Mo.B.1149 | Prevalence of HIV in different categories of blood donors attending a fixed site in Kampala. Int Conf AIDS 1996 Jul 7-12; 11:80 (abstract no. Mo.B.1149) Opollo MS, Aciro B, Goddard JM; Nakasero Blood Bank, Kampala, Uganda. Fax: 256 - 41 - 257484. Objective: To analyze the prevalence of HIV in different categories of blood donors. Method: Everyone coming to donate blood at the fixed site at Nakasero Blood Bank were counseled prior to donating blood, this included interviews and physical observations to try and exclude blood from people in the window period or wh |
| Mo.B.1150 | Evaluation of encouragement strategies for regular voluntary donors to ensure an adequate supply of safe blood. Int Conf AIDS 1996 Jul 7-12; 11:80 (abstract no. Mo.B.1150) Stein MF, Nyamgenge M, Kataaha PK; UBTS, Kampala, Uganda. Fax: 256 - 41 - 257484. Objectives: 1. To obtain a supply of safe blood. 2. To increase awareness of the dangers of HIV infection in blood donated. 3. To educate the public on how best to obtain safe blood, that is through the practice of self-deferment after unsafe sexual activity. Methods: 1. Re-organization of mobile teams to specific area |
| Mo.B.1151 | Confirmation testing of HIV p24+ seroconversion panel samples: application to blood supply testing. Int Conf AIDS 1996 Jul 7-12; 11:81 (abstract no. Mo.B.1151) Toedter GP, Brewer K, Hofheinz D; Coulter Corporation, Miami, FL, USA. Fax: 305-380-3699. Objective: To determine the specificity of confirmation testing of HIV-1 p24 positive samples in the pre-seroconversion window period. Methods: Twelve HIV-1 seroconversion panels, Panels A, C, E, G, I, J, L, P, R, V, Z, AD (Boston Biomedica, Boston, MA) were tested using the Coulter HIV-1 p24 Antigen Assay. Samples fou |
| Mo.B.1152 | Detection of HIV genome using nested RT-PCR in blood products in Japan. Int Conf AIDS 1996 Jul 7-12; 11:81 (abstract no. Mo.B.1152) Namiko Y, Suzuki H, Fukushima K, Matsuo M, Hashimoto N; AIDS Research Center, NIH, Tokyo, Japan. Fax:(81)-3-5285-1150. Objective: To determine HIV genome in blood products in Japan . Because, thirty percent of Japanese hemophiliacs have been infected with HIV, which contaminated the coagulation factor concentrates (blood products) they used in their treatment largely. We compared with unheated blood products since produced in 1985 and |
| Mo.B.1153 | Proposal of a new model of hospital care in HIV/AIDS. Int Conf AIDS 1996 Jul 7-12; 11:81 (abstract no. Mo.B.1153) Bevacqua AN, Maglio F, Barreda V; San Martin Hospital, Parana, Entre Rios, Argentina. Fax: 54-43-23-0523. Incorporation of patients pertaining to self- help-groups in the assistance strategy of an Infections- Diseases Service. Project: The functions of self-help groups are: administrative, companion of patients, participation in medical functions, social support, education and prevention. Professionals and technicia |
| Mo.B.1154 | Home care for HIV + patients in Brazil. Int Conf AIDS 1996 Jul 7-12; 11:81 (abstract no. Mo.B.1154) Zajdenverg R, Giordani ML, Raimundo PA; Affiliated Physicians of Golden Cross, Rio de Janeiro, Brazil. Fax: +55 21 267-0920. E-mail: Betode@ax.apc.org. Objective: To determine length of stay, prevalence of opportunistic infections and causa mortis in HIV+ pts in a private home care service (Golden Cross) in Brazil . Methods: Retrospective study of 61 charts from September 5,1994 to Feb 2,1995. Results: 327 pts had been followed and 61 (18.6%) were HIV+. The average du |
| Mo.B.1155 | The development and implementation of a seamless pharmaceutical care program for HIV patients. Int Conf AIDS 1996 Jul 7-12; 11:81 (abstract no. Mo.B.1155) Foisy M, Tseng A, Blaikie N; The Wellesley Hospital, C/O Pharmacy Department, Toronto, Ontario, Canada. Fax: 416-926-5050. Due to the complex and progressive course of HIV disease, patients will require varying types and intensities of medical care. Throughout a patient s illness, ambulatory, community, and hospital pharmacists can all play key roles in assisting patients with their medication-related concerns. There is a need for i |
| Mo.B.1156 | Improving, enriching and enabling appropriate home-based care for people with HIV and AIDS. Int Conf AIDS 1996 Jul 7-12; 11:81 (abstract no. Mo.B.1156) Walker D; The Canadian Association for Community Care (formerly HomeSupport Canada and the Canadian Long Term Care Association), Ottawa, Ontario. Fax: 613-241-5923. Face-to-face networking and collaboration at the local level improves and enriches the training of the homecare/home support sector. Project: There have been various models of training targeting the home care sector providing care to people living with AIDS. These sessions have been held in a number of regions: |
| Mo.B.1157 | Development of an occupational therapy role to provide a continuum of care across institution and community. Int Conf AIDS 1996 Jul 7-12; 11:81 (abstract no. Mo.B.1157) Thomas S; The Wellesley Health Centre, Toronto, Ontario, Canada. Fax: 416-926-4911. Occupational therapy (OT) services are traditionally provided in the hospital or in the community setting depending on the current health status or location of the person living with HIV/AIDS. People with HIV/AIDS lack continuity of care as their disease progresses because they do not see the same therapist when |
| Mo.B.1158 | Compliance to the medical service on HIV-positive patients in Japan. Int Conf AIDS 1996 Jul 7-12; 11:82 (abstract no. Mo.B.1158) Ajisawa A, Negishi M, Masuda G; Department of Infectious Diseases, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan. Fax: (81)-03-3824-1552. Objective: To investigate compliance to the medical service on HIV-positive patients and describe factors related to the compliance. Methods: Four hundred and thirty four HIV+ persons had visited to Tokyo Metropolitan Komagome Hospital by the end of 1994. We reviewed the records of the 434 HIV+ persons and took age, se |
| Mo.B.1159 | Epidemiological, clinical, psychological and social features of the first hospice created in the west part of Mexico for people living with HIV/AIDS. Int Conf AIDS 1996 Jul 7-12; 11:82 (abstract no. Mo.B.1159) Aguiniga-Sanchez MA, Hernandez-Chavez A, Ramirez-Rodriguez JM, Amaya-Tapia G, De Luna-Lopez A, Valadez-Casillas A, Lopez-Guillen P; Ser Humano A. C. Guadalajara, Jalisco, Mexico. Fax: 8253965. Introduction: AIDS is a disease that is distributed all around the world. In Mexico , AIDS has the sixth place of death rate. There are 24,843 reported cases until October 1st 1995. In Jalisco, there are 2,913 reported cases. Objetive: To value the epidemiological, clinical, psychological and social characteristics of |
| Mo.B.1160 | HIV care standards equivalent regardless of type of outpatient practitioner. Int Conf AIDS 1996 Jul 7-12; 11:82 (abstract no. Mo.B.1160) van den Berg-Wolf MG, Moyer D, Tedaldi E, Shah S, Yim R, Galloni T; Temple University, Philadelphia, PA, USA. Fax: 215-707-3644. Objective: To determine practitioner adherence to CDC guidelines for comprehensive and appropriate care of HIV- infected outpatients in an urban academic medical center. Methods: The encounters of all HIV-infected outpatients (17 females, 53 males) who presented to HIV clinic, between July 1, 1994 and July 1, 1995 were |
| Mo.B.1161 | AIDS drug assistance programs in 42 U.S. states: characteristics of clients served, drugs dispensed, and the role of Federal funding. Int Conf AIDS 1996 Jul 7-12; 11:82 (abstract no. Mo.B.1161) Eichler A, Baitty R; Division of HIV Services, Health Resources and Services Administration, Department of Health and Human Services, Rockville, MD, USA. Objectives: To describe the numbers and characteristics of clients served, drugs dispensed, and annual funding levels of AIDS drug assistance programs in the USA. Methods: Data were collected from 45 States including the Commonwealth of Puerto Rico , and the District of Columbia on clients served and drugs dispensed fo |
| Mo.B.1162 | Long-term care for people with HIV/AIDS in a dedicated skilled nursing facility. Int Conf AIDS 1996 Jul 7-12; 11:82 (abstract no. Mo.B.1162) Selwyn PA, Molde S, Constantino J, Demarinis J, Lesnick N, Costello G, Wetherill P, Kennedy C; AIDS Program, Yale School of Medicine, New Haven, CT. Fax: (203) 737-4051. Background and Rationale: As AIDS becomes more of a chronic disease, and with the changing dynamics of managed care and health care delivery, a growing need has arisen for long-term, non-hospital-based care. In October, 1995, in response to this need, Leeway, a freestanding, 30-bed skilled nursing facility for people w |
| Mo.B.1163 | Primary care vs. subspecialists' questions of an HIV telephone consultation service. Int Conf AIDS 1996 Jul 7-12; 11:83 (abstract no. Mo.B.1163) Liljestrand P, Goldschmidt R, Balano K, Moy A, Legg J, Dong B, Leoung G; CPAT, SF General Hospital, San Francisco, CA. Fax: (415) 476-3454. E-mail: petral@itsa.ucsf.edu. Objective: To compare primary care vs. subspecialists usage of the National HIV Telephone Consultation Service. Methods: The HRSA/AIDS ETC National HIV Telephone Consultation Service provides HIV education and clinical consultation for health-care providers. Data on physician callers (N=2,292), calls (N=4,486), encount |
| Mo.B.1164 | Occupational therapy: bedside evaluation and treatment of dysphagia for people with HIV disease in the hospital. Int Conf AIDS 1996 Jul 7-12; 11:83 (abstract no. Mo.B.1164) Chan R, Ilaria G, Jacobs J; New York Hospital, Center for Special Studies, New York, NY, USA. Fax: (212)746-8415. Patients hospitalized with HIV disease present with a variety of conditions resulting in dysphagia. Project: Diagnoses such as progressive multifocal leukoencephalopathy (PML), toxoplasmosis, cerebrovascular accidents, central nervous system lymphoma , and encephalitis can lead to cognitive changes, decreased or |
| Mo.B.1165 | Medication adherence to long-term therapy in HIV disease. Int Conf AIDS 1996 Jul 7-12; 11:83 (abstract no. Mo.B.1165) Eldred LJ, Wu A, Chaisson RE, Moore RD; Johns Hopkins University School of Medicine, PA-C, Baltimore, MD, USA. Fax: (410)955-0740. E-mail: leldred@welchlink.welch.jhu.edu. Objective: To determine the extent of adherence to long-term therapy in HIV-infected patients engaged in medical care. Methods: Adherence to therapy was determined by interview of a cohort of patients attending an urban HIV hospital-based clinic. All patients had been prescribed at least six months of anti-retroviral t |
| Mo.B.1166 | Home care for persons living with AIDS: a nursing care perspective. Int Conf AIDS 1996 Jul 7-12; 11:83 (abstract no. Mo.B.1166) Portillo CP, Holzemer W, Dawson C, Henry S; School of Nursing, University of California, San Francisco, CA, USA. E-mail: nursing c/o carmen_portillo@ccmail.ucsf.edu. Objectives: The three objectives of this study were: 1) to describe the numbers and types of patient problems and nursing interventions received by a sample of patients receiving home care for an AIDS-related problem; 2) to compare (after controlling for prognosis rating) differences in numbers of patient problems and |
| Mo.B.1167 | Institutional care (inpatient/outpatient/day care). Int Conf AIDS 1996 Jul 7-12; 11:83 (abstract no. Mo.B.1167) Ong D, Verghese I, Leo YS, Teh AC; Communicable Disease Centre, Republic of Singapore. Fax: 286-5801. E-mail: lynnho@pacific.net.sg. Objectives: 1) To reduce patients hospitalisation to save cost and patients can return home to be with family. 2) To create an affordable and conducive day treatment centre which is easily accessible. 3) To have a one-stop outpatient facilities. Patients were fearful of the disease and feel insecure staying at h |
| Mo.B.1168 | HIV/AIDS knowledge, attitudes and practices of community-based primary care physicians and dentists. Int Conf AIDS 1996 Jul 7-12; 11:83 (abstract no. Mo.B.1168) Baldwin HD, El-Sadr W, Ellis C, Francis C; Division of Infectious Diseases and Dept. of Medicine, Harlem Hospital and Columbia University, New York, NY, USA. Fax: 212-939-2968. E-mail: hdb8@columbia.edu. Objective: Primary care physicians and dentists are likely to play an increasingly prominent role in the counseling and care of HIV-infected individuals. The role of these clinicians is of even greater importance in communities with high rates of HIV infection. We conducted an assessment of HIV/AIDS knowledge and the p |
| Mo.B.1169 | The costs and effectiveness of combination therapy with epivir (lamivudine)/retrovir (zidovudine) vs. retrovir. Int Conf AIDS 1996 Jul 7-12; 11:84 (abstract no. Mo.B.1169) Kempel A, Dickinson P, Morris S, Lacey L, Mauskopf J; Pharmametrics GmbH, Freiburg, Germany. Fax: 49-761-71520. E-mail: kit@pharmiq. freinet.de. Objective: To evaluate the cost and effectiveness of combination therapy with Epivir (lamivudine)/Retrovir(zidovudine), compared with Retrovir alone, using Markov modelling. Methods: The clinical superiority of combination anti-retroviral therapy over monotherapy has been demonstrated using d |
| Mo.B.1170 | Influence of CMV disease in the hospitalary direct pharmaceutical cost of HIV patient. Int Conf AIDS 1996 Jul 7-12; 11:84 (abstract no. Mo.B.1170) Serrais J, Mallolas J, Ribas J; J. Mallolas Hospital Clinic I, Provincial, Barcelona, Spain. Fax: 34 3 2275457. Objective: To estimate the difference of pharmaceutical cost in hospitalary HIV patient with or without CMV disease and his relation with CD4 cell count. Methods: This study was conducted on patients who were admitted to hospital between 1/1/93 and 12/12/94. We collected for each patient: 1) Major discharge Diagnosis ( |
| Mo.B.1171 | Evaluation of asymptomatic eosinophilia in HIV-positive patients: is it really necessary? Int Conf AIDS 1996 Jul 7-12; 11:84 (abstract no. Mo.B.1171) Tietz A, Sponagel Lucas, Battegay M, Erb P, Gyr K, Zimmerli W; Medical Outpatient Clinic University Hospital Basel, Basel, Switzerland. Fax: 41-61-2654604. Objective: To examine the necessity and cost-effectiveness of laboratory tests in caucasian HIV-positive patients with blood eosinophilia. Methods: We investigated 125 HIV-positive caucasian patients for the occurrence of blood eosinophilia. Patients with absolute and relative eosinophilia were screened for conditions |
| Mo.B.1172 | The effect of income on the utilization of alternative therapies by HIV-positive individuals. Int Conf AIDS 1996 Jul 7-12; 11:84 (abstract no. Mo.B.1172) Paterson MA, Carwein VL, Sabo CE; University of Nevada-Las Vegas, College of Health Sciences, Las Vegas, NV. Fax: 702-895-1356. E-mail: csabo@ccmail.nevada.edu. Objective: To determine the effect of income on the utilization of alternative therapies (AT) in a cohort of HIV-positive individuals. Methods: A self-selected sample of 127 HIV-positive individuals completed a questionnaire designed to gather information on the frequency and reasons for use of alternative therapies. T |
| Mo.B.1173 | Hospital utilization by HIV+ and HIV-injection drug users before and during methadone treatment. Int Conf AIDS 1996 Jul 7-12; 11:84 (abstract no. Mo.B.1173) Batki SL, Sorensen JL, Young V; UCSF Dept. of Psychiatry, Div. of Substance Abuse & Addiction Med., SF General Hosp-Ward 93, San Francisco, CA, USA. Fax: (415) 206-6875. E-mail: atki93@itsa.ucsf.edu.usa. Objectives: To determine the effect of enriched substance abuse treatment on hospital utilization by injection drug users (IDUs) with human immunodeficiency virus (HIV) disease. Methods: Subjects were 96 IDUs, whose San Francisco General Hospital (SFGH) medical records were examined for the study period 7/1/92-9/30/94. |
| Mo.B.1174 | Cost of medication therapy in ambulatory HIV-infected patients. Int Conf AIDS 1996 Jul 7-12; 11:84 (abstract no. Mo.B.1174) Fernandez E, Lago M, Nykamp D, Barnett CW; HRSA/BHPr, Rockville, MD. Fax: 301-443-8890. E-mail: efernand@hrsa.ssw.dhhs.gov. Objectives: To examine the utilization and cost associated with the use of prescribed medications among ambulatory HIV-infected persons at primary health care centers funded by Ryan White Health Care Act, Title III(b). Methods: Participants (=223) were enrolled nationally from eight primary health care centers. Data wa |
| Mo.B.1175 | Diagnosis of HIV-1 infection in children born to HIV-1 infected mothers. Int Conf AIDS 1996 Jul 7-12; 11:85 (abstract no. Mo.B.1175) Liberatore D, Avila MM, Martinez PL, Libonatti O; Department of Microbiology, School of Medicine, National Reference Centre for AIDS, Buenos Aires, Argentina. Fax: 54-1-962-5404. Objectives: Laboratory diagnosis of HIV infection in pediatric patients represents a major challenge because of transplacentary transmission of maternal antibodies. The aim of this work was to develop a test for early diagnosis of HIV-1 in children by detection of specific IgA antibodies. Methods: We have evaluated the |
| Mo.B.1176 | A new generation of HIV-diagnostic assay: testing for anti-HIV and HIVAg in one determination. Int Conf AIDS 1996 Jul 7-12; 11:85 (abstract no. Mo.B.1176) Faatz E, Upmeier B, Hoss E, Louwagie J, Ofenloch B; Boehringer Mannheim GmbH, Penzberg, FRG. Fax: 08856-60-3131. Introduction: Even with the best anti-HIV diagnostic assays the early detection of seroconversion is on the average 5 to 7 days later than the detection by HIVAg-assays. Since performing HIV-screening with HIVAg assays in addition to anti-HIV assays is very expensive, we tried to combine both types of assay in one dete |
| Mo.B.1177 | Characteristics of a stabilization assay to detect specific antibodies to reverse transcriptase of HIV. Int Conf AIDS 1996 Jul 7-12; 11:85 (abstract no. Mo.B.1177) Morita M, Yoshida H, Suzuki T, Hoshino H; The Kitasato Institute, Tokyo, Japan. Fax: (81)-3-3443-4298. Objective: We developed a stabilization assay to detect antibodies against reverse transcriptase (RT) of HIV-1. We examine the specificity and clinical significance of this assay. The specificities of stabilization and neutralization assays against RTs of HIV-1, HIV-2 and SIV are examined comparatively. Methods: Human |
| Mo.B.1178 | False positive rates of anti-HIV antibody tests, EIA and PA. Int Conf AIDS 1996 Jul 7-12; 11:85 (abstract no. Mo.B.1178) Osato K, Matsubayashi T, Nagao T, Inuzumi K, Araki H, Kawai K; Osaka Prefectural Bandai Clinic for STD, Osaka, Japan. Fax: 06-693-7501. Objective: To investigate the false positive rates of anti-HIV antibody tests, EIA and PA. Methods: Enzyme linked immuno-sorbent assay (EIA) and particle agglutination (PA) were used for screening tests of anti-HIV antibodies and WB was used for comfirmatory test. Results: Eleven false positive cases were found in 4687 |
| Mo.B.1179 | Fully automated chemiluminescence assay for the detection of antibody to human immunodeficiency virus type-1 (HIV-1)/type-2(HIV-2). Int Conf AIDS 1996 Jul 7-12; 11:85 (abstract no. Mo.B.1179) Matsuda J, Tsukamoto M, Gohchi K, Kawasugi K, Gotoh M, Kawamoto M, Takizawa N, Kanno T; Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan. Fax: 03-5375-0272. Objective: We developed a new and fast automated chemiluminescence assay for the detection of antihuman immunodeficiency virus type-1 (HIV-1)/-type-2 (HIV-2) antibody and evaluated this assay system as a screening test. Methods & Results: Firstly, we tested commercially available panel sera, including 39 anti-HIV-1 |
| Mo.B.1180 | Earlier patient identification through anonymous CD4 service. Int Conf AIDS 1996 Jul 7-12; 11:85 (abstract no. Mo.B.1180) Nookhai S, Phanuphak P, Hanvanich M; Program on AIDS, Thai Red Cross Society, Bangkok, Thailand. Fax: 662-254-7577. Objective: To study the benefit of the new concept of having an anonymous CD4 service to patients with HIV infection as compared to the conventional CD4 service at an AIDS clinic Method: Demographic and clinical data of 249 HIV-infected patients who had their first CD4 cell count at the newly established Thai Red Cross |
| Mo.B.1181 | A strategic approach to the implementation of HIV/STD lab quality assurance (QA) in a resource limited setting. Int Conf AIDS 1996 Jul 7-12; 11:86 (abstract no. Mo.B.1181) Kitson-Piggott W, Tillett T, Gayle C, Wilson V; CAREC/PAHO, Federation Park, Port of Spain, Trinidad. Fax: 809-622-2792. E-mail: cec_mail@paho.org. Issues: The introduction of structural adjustment measures as well as the high incidence of AIDS are threatening the many advances made in primary health care in Caribbean territories. Regional governments are however advocating for health reform and improved health care delivery in the face of limited resources and de |
| Mo.B.1182 | Change of strategies HIV antibody testing in certain groups' population of Ukraine. Int Conf AIDS 1996 Jul 7-12; 11:86 (abstract no. Mo.B.1182) Ivasyuk VP, Tchentsova KE, Kislykh E, Maximenok E, Vatamanyuk M, Kobyshcha U; The President's National anti-AIDS Committee, National Reference Laboratory, Kyiv, Ukraine. Fax: + 380(44) 244-3811. Objective: To evaluate different HIV antibody testing strategies (with Western Blot (WB) and without WB) for IDUs. Methods: Two algorithms (one ELISA - ABBOTT HIV 1/2 3 rd Generation as screener, second ELISA - Vironostika Uniform II (Organon Teknika) and WB - New Lav Blot I (Sanofi Diagnostics Pasteur) as confirmatory |
| Mo.B.1183 | Home HIV testing and counseling: an application of telemedicine. Int Conf AIDS 1996 Jul 7-12; 11:86 (abstract no. Mo.B.1183) Frank AP, Wandell MG, Headings HD, Conant MA, Woody GE, Michel C; Hoffman Estates, IL. Objective: To evaluate the utility of HIV-1 home specimen collection kits with telephone counseling in persons at normal or increased risk for HIV-1 infection. Methods: 1255 subjects were given a home collection kit to obtain their own lancet-drawn blood spot sample for laboratory analysis. Subjects received counseling |
| Mo.B.1184 | Testing of commercial HIV low titer and seroconversion panels with Empyrean HIV-1,2 test. Int Conf AIDS 1996 Jul 7-12; 11:86 (abstract no. Mo.B.1184) Babu UM, Kouyate Y, Jacob S, Desai M, Veltema S, Beal C, Bland D; Empyrean Diagnostics, Inc., Mountain View, CA, USA. Objective: A double blind study was conducted to determine the ability of Empyrean HIV-1,2 Test to detect antibodies to HIV-1 and HIV-2 in low titer and seroconversion panels. Methods: Empyrean HIV-1,2 Test, developed by Empyrean Diagnostics, Inc., is a visual ELISA that uses a combination of recombinant HIV-1 protein |
| Mo.B.1185 | The detection of HIV serological variants using a synthetic peptide-based, indirect EIA. Int Conf AIDS 1996 Jul 7-12; 11:86 (abstract no. Mo.B.1185) Coleman PF, Monji N, Montana J, Cole CA, Higgs M, Mercier D, Shores P, Su PC, Ferrera C, Jinneman C; Genetic Systems - Sanofi Diagnostics Pasteur, Inc., Redmond, WA. Fax: 206-861-5011. Objective: To evaluate the capacity of a synthetic peptide, microwell EIA based on epitope regions derived from env and pol gene products to detect the presence of HIV-1 and HIV-2 antibodies in confirmed HIV-1 and HIV-2 positive sera, in well-characterized group O sera and in a BBI Panel (AfrRB1(M)) of partially charac |
| Mo.B.1186 | Performance evaluation of four Western Blot criteria to be used in clinical laboratories in a developing country. Int Conf AIDS 1996 Jul 7-12; 11:86 (abstract no. Mo.B.1186) Muchinik G, Juncos G, Munne M, Zapiola I, Bouzas MB, Andmejian G, Multare S, Wainstein C, Calello M; Unidad de Virologia, Hospital "F.J.Muniz", Buenos Aires, Argentina. Fax:(54-1) 806-2078. Objective: To evaluate four different criteria to interpret commercial Western Blots and to choose the one that can interpret more accurately the necessities of the clinical laboratories in developing countries Methods: Sera collected from patients requiring HIV testing were studied for HIV-1/2 using third generation t |
| Mo.B.1188 | Drug interactions & adverse drug reactions in HIV: chapters in "HIV infection: A Clinical Approach, 2nd ed." Int Conf AIDS 1996 Jul 7-12; 11:87 (abstract no. Mo.B.1188) Tseng AL, Foisy M; The Wellesley Health Centre, Toronto, Ontario, Canada. Fax: 416-926-5115. Human immunodeficiency virus (HIV) infected patients often require drug therapy with multiple agents, especially in the later stages of illness. Polypharmacy is often associated with complex drug interactions and additive drug toxicities, which may adversely affect patient morbidity and/or mortality. However, sp |
| Mo.B.1189 | Relapse of pentamidine-induced diabetes in AIDS patient. Int Conf AIDS 1996 Jul 7-12; 11:87 (abstract no. Mo.B.1189) Ravaux I, Rihet P, Quinson AM, Mars ME, Sellier P, Gallais H; Pr Gallais Unit Hopital de la Conception, Marseille, France. A 34 years old HIV-infected patient, diagnosed in 1988 (CD4 less than 50/mm3) treated with AZT 500 mg/day during 6 months, then by DDI 100mg bid since 12/93 and primary prophylaxis by aerosolized Pentamidine isethionate (AePi) (Quincke s edema due to Cotrimoxazole) presented a insulinopenic diabetes mellitus after intr |
| Mo.B.1190 | Nephrogenic diabetes insipidus related to foscarnet and thirst loss related to CMV encephalitis in AIDS patient. Int Conf AIDS 1996 Jul 7-12; 11:87 (abstract no. Mo.B.1190) Force Gilles, Blanchard A, Leviel F, Tugler MH, Champetier de Ribes D; Hopital du Perpetuel Secours, Levallois-Perret, France. Fax: (33) 1 47 59 59 60. Introduction: Nephrogenic diabetes insipidus (NDI) is known to occur as a rare complication of several drugs. An AIDS patient with CMV disease developed NDI with foscarnet (PFA) therapy. A relative thirst loss was associated. Case record: A 43-year-old african HIV-infected woman was evaluated for polydipsia and polyuri |
| Mo.B.1191 | Zidovudine-induced pure red cell aplasia. Int Conf AIDS 1996 Jul 7-12; 11:87 (abstract no. Mo.B.1191) Gohchi K, Gotoh M, Kawasugi K, Tsukamoto M, Saitoh N, Matsuda J; The First Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan. Fax: 03-5375-0272. Zidovudine ( AZT ) is a well known drug to be beneficial for the treatment of HIV-infected patients. However, AZT is also known to cause haematological toxicity such as megaloblastic anemia. We experienced a case of pure red cell aplasia induced by AZT. Case: The patient was 25-year old male with Hemophilia A. |
| Mo.B.1192 | Pharmacoepidemiology and drug interactions in ambulatory HIV-positive patients with less than 100 CD4+ cells. Int Conf AIDS 1996 Jul 7-12; 11:87 (abstract no. Mo.B.1192) Meister TH, Ledergerber B, Merk B, Opravil M, Luthy R; Div. of Infectious Diseases, Department of Medicine, University Hospital, Zurich, Switzerland. Fax: 41 1 255 3291. E-mail: tme@uszsira.unizh.ch. Objective: To determine the patterns of drug use and the frequency of possible drug interactions in prescriptions of ambulatory HIV-positive patients with less than 100 CD4+ cell counts. Methods: Two hundred and fifteen patients were seen at least once between January 1st and June 30th 1995 in our AIDS outpatient clini |
| Mo.B.1193 | Drug reactions to co-trimoxazole in HIV infection possibly not due to hydroxylamines. Int Conf AIDS 1996 Jul 7-12; 11:88 (abstract no. Mo.B.1193) Koopmans PP, van der Ven A, Vree T, van der Meer JW; Department of General Internal Medicine, University Hospital St. Radboud Nijmegen, Netherlands. Objective: To test the hypothesis that the increased incidence of drug reactions to cotrimoxazole (CTR) in HIV infection is due to the metabolite of sulphamethoxazole (SMZ), especially the hydroxylamine (HYD) of SMZ Methods: Co-soltrim(CSM) is a combination of sulfametrole(SMT) and trimethoprim. The pharmacokinetics of |
| Mo.B.1194 | Drug interactions with d4T phosphorylation in vitro. Int Conf AIDS 1996 Jul 7-12; 11:88 (abstract no. Mo.B.1194) Back D, Haworth S, Hoggard P, Khoo S, Barry M; Dept of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK. Fax: 44 151 794 5540. E-mail: daveback@liverpool.ac.uk. Objective: The dideoxynucleoside analogue d4T (2 ,3 -dideoxy-2 ,3 -didehydrothymidine; Zerit (), in common with other nucleoside analogue reverse transcriptase inhibitors, requires intracellular phosphorylation to the active triphosphate anabolite for inhibition of H |
| Mo.B.1195 | A case of isoniazid (INH) induced optic neuropathy in an asymptomatic HIV-infected woman and review of the literature. Int Conf AIDS 1996 Jul 7-12; 11:88 (abstract no. Mo.B.1195) Martin SG, Weidle PJ, Rismondo V, Bever S, Wheeler DA; University of Maryland Medical Center, Baltimore, MD. Issues: INH is frequently prescribed for HIV-infected individuals with a reactive tuberculin skin test (+PPD) or with active tuberculosis . Optic neuropathy is a rare complication associated with INH. Project: We report the first case of INH induced optic neuropathy in an HIV-infected adult. Results: A 35-year-old woma |
| Mo.B.1196 | The effect of fluconazole on the clinical pharmacokinetics of methadone. Int Conf AIDS 1996 Jul 7-12; 11:88 (abstract no. Mo.B.1196) Cobb M, Desai J, Brown LS, Zannikos P, Trapnell C, Rainey P; Addiction Research and Treatment Corporation, Brooklyn, NY. Fax: 718-522-3186. Objective: To evaluate the possibility of a drug-drug interaction between fluconazole (FLU) and methadone (METH) in METH-maintained patients. Methods: Twenty-five METH-maintained patients were enrolled into the study. The study was a randomized, double-blinded, placebo-controlled, pharmacokinetic and safety study in wh |
| Mo.B.1197 | Effect of ritonavir on the pharmacokinetics of trimethoprim/sulfamethoxazole. Int Conf AIDS 1996 Jul 7-12; 11:88 (abstract no. Mo.B.1197) Bertz RJ, Cao G, Cavanaugh JH, Hsu A, Granneman GR, Leonard JM; Abbott Laboratories, Abbott Park, IL. Fax: (847) 938-5193. E-mail: g.richard.granneman@abbott.com. Objective: To evaluate the pharmacokinetic effects of concomitant administration of multiple doses of the HIV-1 protease inhibitor ritonavir on single doses of the antiinfective combination of trimethoprim and sulfamethoxazole (TMP/SMX). Methods: This was an open label study during which each of 15 healthy male and fem |
| Mo.B.1198 | Effect of ritonavir on the pharmacokinetics of ethinyl estradiol in healthy female volunteers. Int Conf AIDS 1996 Jul 7-12; 11:88 (abstract no. Mo.B.1198) Ouellet D, Hsu A, Qian J, Cavanaugh J, Leonard J, Granneman GR; Abbott Laboratories, Abbott Park, IL, USA. Fax: 847-938-5193. E-mail: daniele.x.ouellet@abbott.com. Objective: To investigate the effects of the HIV-1 protease inhibitor ritonavir on the pharmacokinetics of ethinyl estradiol (EE). Methods: This was an open-label, single-center study in 23 healthy female volunteers. Subjects received the first dose of oral contraceptive (OC) containing 50 micrograms of EE and 1 mg of |
| Mo.B.1199 | Assessment of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Int Conf AIDS 1996 Jul 7-12; 11:89 (abstract no. Mo.B.1199) Cato A, Cavanaugh JH, Shi H, Hsu A, Granneman GR, Leonard J; Abbott Laboratories, Abbott Park, IL. Fax: (847) 938-5193. E-mail: Allen.E.Cato@Abbott.com. The pharmacokinetics of the antimycobacterial rifabutin (Mycobutin) and its active metabolite 25-O-desacetyl-rifabutin were assessed with concurrent administration of the HIV-1 protease inhibitor ritonavir or placebo in 24 healthy males and females in a double-blind, parallel group study. After a 14-day lead-in period |
| Mo.B.1200 | Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline. Int Conf AIDS 1996 Jul 7-12; 11:89 (abstract no. Mo.B.1200) Hsu A, Granneman GR, Witt G, Cavanaugh JH, Leonard J; Abbott Laboratories, Abbott Park, IL. Fax: (847) 935-3503. E-mail: Ann.Hsu@Abbott.com. Objective: To assess the effect of ritonavir (an HIV-1 protease inhibitor) coadministration on the steady-state pharmacokinetics of theophylline. Study Design: Twenty-seven subjects (3 female) completed the 5-day theophylline lead-in period (3 mg/kg q8h). On Day 6, subjects were randomized in a 2:3 ratio to receive Reg |
| Mo.B.1201 | Effect of ritonavir on the pharmacokinetics of desipramine. Int Conf AIDS 1996 Jul 7-12; 11:89 (abstract no. Mo.B.1201) Bertz RJ, Cao G, Cavanaugh JH, Hsu A, Granneman GR, Leonard JM; Abbott Laboratories, Abbott Park, IL. Fax: (847) 938-5193. E-mail: richard.j.bertz@abbott.com. Objective: To evaluate the potential for concurrent dosing of the HIV-1 protease inhibitor ritonavir to have a clinically significant effect on the pharmacokinetics of the tricyclic antidepressant (TCA) desipramine (DMI). Methods: This was an open label study during which each of 14 healthy male and female volunteers r |
| Mo.B.1202 | Cutaneous eruptions associated with nevirapine (NVP) therapy in HIV-1 infected individuals. Int Conf AIDS 1996 Jul 7-12; 11:89 (abstract no. Mo.B.1202) Kohlbrenner V, Dransfield K, Cotton D, Robinson P, Myers M; Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA. Objective: A descriptive study of HIV-1 infected persons taking NVP with identification of risk factors for the development of cutaneous eruptions. Methods: A retrospective analysis of all patients enrolled into NVP clinical trials. Those patients experiencing cutaneous eruptions, defined as any occurrence of erythemat |
| Mo.B.1204 | A comparison between the respective in vitro toxicities of sulphametrole and sulphamethoxazole. Int Conf AIDS 1996 Jul 7-12; 11:89 (abstract no. Mo.B.1204) Coleman MD, Kohl C; Pharmaceutical Sciences Institute, Aston University, Birmingham, UK. Fax: 44 121 359 0733. E-mail: m.d.coleman@aston.ac.uk. Objectives: to determine if sulphametrole (SMT) is less toxic in vitro compared with sulphamethoxazole (SMX). Methods: three toxicity tests have been used, all of which depended on rat liver microsomes (with or without the necessary NADPH for oxidative metabolism) to generate cytotoxic metabolites of SMX and SMT. They |
| Mo.B.1205 | A national study of access to dental care for HIV-infected patients in Canada. Int Conf AIDS 1996 Jul 7-12; 11:90 (abstract no. Mo.B.1205) McCarthy GM, MacDonald JK; Faculty of Dentistry, The University of Western Ontario, London, Ontario, Canada. Objective: To investigate dentists refusal to treat patients with HIV in Canada . Methods: A confidential mailed survey including items on sociodemographics, knowledge, attitudes and infection control was distributed to a random sample of all licensed dentists in Canada (n=6444). Follow-up included a reminder postcard |
| Mo.B.1206 | Compassionate access to experimental therapies: the Canadian saquinavir compassionate release programme. Int Conf AIDS 1996 Jul 7-12; 11:90 (abstract no. Mo.B.1206) Brabazon CJ, Kreppner J, Sussel R, De Haa L, Oza K, Moore W, Roy D, Conway D, Fauchere S; CAC, CTN, Vancouver, B.C. Fax: 604-631-5464. Many people living with HIV/AIDS view compassionate access to experimental therapies as an ethical responsibility, while manufacturers see it as discretionary. Project: A committee of PLWHIV/AI, ethicists, and staff from the Canadian HIV Trials Network and industry representatives from Roche Canada |
| Mo.B.1207 | Psychological issues affecting physician's communications to patients about first AIDS defining diagnoses. Int Conf AIDS 1996 Jul 7-12; 11:90 (abstract no. Mo.B.1207) Henshaw P, Petrak J, Hedge B; St. Bartholomew's Hospital, London, UK. Fax: 0171 601 8057. Objective: To evaluate the extent doctors delay telling patients they have AIDS and factors that determine what the patient is told about the significance of the diagnosis. Method: Medical notes of 50 patients with AIDS (reported to UK CDC) were reviewed. Dates of AIDS Defining Illnesses (ADI), dates patients were info |
| Mo.B.1208 | Clinical features of HIV-1/2-seroprevalence among surgical and internistic cases at a health clinic in western Uganda. Int Conf AIDS 1996 Jul 7-12; 11:90 (abstract no. Mo.B.1208) Schmalzbauer E, Tibananuka S, Bronn C, Froesner GG; Max von Pettenkofer-Institute, Munich, Germany. Fax: 0049/89/5380584. E-mail: ediths@m3401.mpk.med.unimuenchen.de. Objective: Determination of HIV-1/2-Seroprevalence, risk factors and clinical features among Surgical and Internal Cases at a Health Station in Western Uganda . Methods: Altogether 243 (162 Trauma- and 81 General/Abdominal-) Surgical outpatients and 671 Internistic in-and outpatients were examined, registered and scree |
| Mo.B.1209 | Natural history of dual infection with HIV-1 and HIV-2. Int Conf AIDS 1996 Jul 7-12; 11:90 (abstract no. Mo.B.1209) Dattatray S, Maniyar JK, Kurimura T, Curmally F; G.T.Hospital, Grant Medical College, Bombay University, Mahim, Bombay, India. Fax: 91-22-4379604, 2083184, 2062847. Aims: Dual infection with HIV-1 and HIV-2 is well known to occur. There is however very little literature on its natural history in India . To study natural history of dual infection with HIV-1 and HIV-2 in Bombay. Methods: All subjects were selected from patients presenting with STDs or skin and/or systemic markers of |
| Mo.B.1210 | Clinical profile of persons with single and dual HIV-1/2 infections in Bombay. Int Conf AIDS 1996 Jul 7-12; 11:90 (abstract no. Mo.B.1210) Hira S, Oberoi C, Gharpure H, Dupont H; AIDS Research & Control Centre (ARCON), Bombay, Mahim, Bombay, India. Fax: 91-22-444 0378. E-mail: subhash hira@lwbom.nandanet.com. Objectives: To determine prevalence of single and dual HIV-1/2 infections and their clinical profiles. Methods: One hundred and eighty consecutive patients attending ARCON referral outpatient service at JJ Hospital in Bombay were recruited in the study in October 1995. Those testing HIV-1/2 reactive with ELISA were cla |
| Mo.B.1211 | Bacteremia in a cohort of 1164 patients with AIDS: incidence, species distribution and outcome. Int Conf AIDS 1996 Jul 7-12; 11:91 (abstract no. Mo.B.1211) Grossi P, Corona A, Dalla Gasperina D, Marone P, Minoli L; Infectious Diseases Department, IRCCS San Matteo-University of Pavia, Pavia, Italy. Fax: 39-382-423320. Objective: To determine the characteristics of all bacteremic episodes in a cohort of patients with AIDS followed at a single Institution in northern Italy . Methods: From February 1984 through December 1995 a total of 1164 patients with AIDS (273 females, 891 males, mean age 32.2, range 0.3-79.7 years) have been admit |
| Mo.B.1212 | A comparative study of Staphylococcus aureus endocarditis in HIV-positive and negative patients. Int Conf AIDS 1996 Jul 7-12; 11:91 (abstract no. Mo.B.1212) Gorgolas M, Blanco A, Fernandez Guerrero ML; Division de E. Infecciosas, Fundacion Jimenez diaz, Universidad Autonoma de Madrid, Madrid, Spain. Objective: To determine the clinical characteristics and mortality associated risk-factors in patients with S. aureus endocarditis with and without HIV infection. Methods: Seventy five cases diagnosed since 1985 were evaluated according to a established protocol. Routine laboratory test, blood cultures, chest X-ray and |
| Mo.B.1213 | Uncommon Campylobacters are not so uncommon in stool of HIV-infected patients. Int Conf AIDS 1996 Jul 7-12; 11:91 (abstract no. Mo.B.1213) Snijders F, Kuijper EJ, Danner SA, Dankert J; Division of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center (AMC), Amsterdam, The Netherlands. Fax: -31-20-6972286. Objectives: Uncommon Campylobacters (other than C. jejuni, C. coli, and C. lari) have sporadically been isolated from humans with diarrhoea. Little is known about the incidence of uncommon C. s in stool of HIV-infected patients. Our objectives were to evaluate: the occurrence of uncommon C. s in HIV-infected patients, |
| Mo.B.1214 | Frequency and microbial etiology of sinusitis in Chilean HIV-positive patients. Int Conf AIDS 1996 Jul 7-12; 11:91 (abstract no. Mo.B.1214) Noriega LM, Vial PA, Rosenblut A, Gonzalez P, Perez J, Henriquez A, Michaud P; Hospital Sotero del Rio and Universidad Catolica, Santiago, Chile. In a previous cohort study of Chilean patients with CD4 counts over 400 cells/mm3 sinusitis was detected with a frequency of 10% patient/year of follow up. Objective. To characterize clinical, radiologic and microbiological aspects of sinusitis in Chilean HIV+ patients. Methods. Among a cohort of 100 HIV+ patients, 12 |
| Mo.B.1215 | Bacteremia and sepsis in HIV-seropositive patients. Int Conf AIDS 1996 Jul 7-12; 11:91 (abstract no. Mo.B.1215) Gritti FM, Guerra L, Fasulo G, Mazzetti M, Raise E; Di Pede B. Div. of Infectious Diseases, Dept. of Clinical Pathology, Ospedale Maggiore, Bologna, Italy. Objectives. To evaluate: prevalence/incidence of bacteremia (B) and sepsis (S) in HIV+ patients (Pts) in retrospective (RsP) and prospective (PsP) periods; clinical features of S by SAPS and APACHE II; cytokines, IL-1 beta, IL-2 , IL-6, IL-8, TNF-alpha, and INF-gamma in prospective cases of S. Methods: Incidence of B w |
| Mo.B.1216 | Bacterial pneumonia in HIV-infected patients: clinical and epidemiological study. Int Conf AIDS 1996 Jul 7-12; 11:92 (abstract no. Mo.B.1216) Baril L, Astagneau P, Mengual X, Nguyen J, Caumes E, Bricaire F, Katlama C; Departement des Maladies Infectieuses Hopital Pitie-Salpetriere,Paris, France. Fax: (33) 144240450. To determine the clinical and microbiological features of bacterial pneumonia (BP), all HIV-infected patients who consecutively presented clinical and radiological BP in our service from January to July 1994 underwent a protected specimen brush using fiberoptic bronchoscopy, blood cultures and serum collection for labo |
| Mo.B.1217 | Salmonella group D parotitis in an HIV-infected individual. Int Conf AIDS 1996 Jul 7-12; 11:92 (abstract no. Mo.B.1217) Hatcher J, Schranz J; Dept. of Medicine, Division of Infectious Diseases, SUNY Stony Brook, Stony Brook, New York. We describe a 44 year old HIV-infected male; CD4 lymphocyte count 540 cells/mm3, with bilateral parotid lymphoepithelial hyperplasia. The parotid gland hyperplasia intermittently required fine needle aspiration with prompt resolution of swelling and pain. This patient developed acute onset of fever (104 degrees F), rig |
| Mo.B.1218 | CMV retinitis treatment in AIDS patients in Argentina. Int Conf AIDS 1996 Jul 7-12; 11:92 (abstract no. Mo.B.1218) Perez H, Puente S, Mestre C, Casiro A; Cahn P-Hospital Fernandez, Buenos Aires, Argentina. Fax: (541) 983-7774. Objective: To study effect of treatment on CMV retinitis (CMV-R) in AIDS patients in Argentina . Methods: We studied 122 AIDS cases who met diagnostic criteria for CMV-R (11.6%), 109 were followed for at least 1 month, while the other 13 pts discontinued controls after diagnosis. Gancyclovir (GCV) was the initial choic |
| Mo.B.1219 | Early detection of CMV retinitis relapse in HIV patients and antiviral monitoring by CMV antigenemia, DNA hybridization and DNA PCR on sera. Int Conf AIDS 1996 Jul 7-12; 11:92 (abstract no. Mo.B.1219) Riss JM, Zandotti C, Petit N, Moreau J, Dhiver C, Gastaut JA, Bourgeade A; Service D'ophtalmologie, Marseille Cedex, France. Fax: 91.38.70.79. Objective: To determine virological markers of Cytomegalovirus ( CMV ) retinitis relapse and virological markers for antiviral monitoring in HIV patients under anTI CMV therapy. Methods: Fifteen HIV patients have been followed from 3 to 9 months after diagnosis of CMV retinitis. All were on maintenance therapy with int |
| Mo.B.1220 | Safety profile of foscarnet administered by portable infusion device in combination with oral hydration (OH) in cytomegalovirus (CMV) infections in patients with AIDS. Int Conf AIDS 1996 Jul 7-12; 11:92 (abstract no. Mo.B.1220) Obadia M, Bicart-See A, Gonzalez C, Averous S, Maurette M, Auvergnat JC; Hopital De Jour, Toulouse, France. Fax: 3361772138. Objective: High frequency of CMV infections, necessity of burdensome maintenance therapy for patients more and more often in good general condition, has comitted us to propose infusion of foscarnet by means of a portable infusion device with concomittant OH to improve the quality of life in these patients. Methods: Fos |
| Mo.B.1221 | Improved surgical technique for implantation of the intraocular sustained-release ganciclovir implant reduce postoperative complications in patients with AIDS and CMV-retinitis. Int Conf AIDS 1996 Jul 7-12; 11:92 (abstract no. Mo.B.1221) Guembel HO, Rosenkranz C, Mauck K, Fries U, Schnaudigel OE, Even van G, Ohrloff C; University Eye Clinics, Hessen, Germany. Fax: 06103-63015233. Objective: Cytomegalovirus ( CMV ) retinitis could be a main problem because of a long term venous access for administration of any antiviral therapy (ganciclovir, foscarnet) and its side effects. Direct ocular treatment with an intraocular sustained release ganciclovir implant is known as very effective in delaying th |
| Mo.B.1222 | Causes of death in a cohort of patients with advanced HIV disease enrolled in an international cytomegalovirus prophylaxis study. Int Conf AIDS 1996 Jul 7-12; 11:93 (abstract no. Mo.B.1222) Hurwitz S, Holland F, Owens S, Coakley D, Fry J, Feinberg J; Harvard School of Public Health, Boston, MA, USA. Fax: (617) 432-3163. Objective: To describe the causes of death in a clinical trial cohort of patients (pts) with advanced HIV disease receiving aggressive medical management. Methods: We evaluated and categorized the causes of death among 1227 participants with CMV IgG+ and CD4+ less than 100 in a CMV prophylaxis study comparing valaciclo |
| Mo.B.1223 | High dose (4 mg/0.1cc) intravitreal ganciclovir for zone 1 CMV retinitis. Int Conf AIDS 1996 Jul 7-12; 11:93 (abstract no. Mo.B.1223) Lieberman RM, Orellana J, Chatterjee R, Velez W, Dauhajre J, Adelson K; Mount Sinai School of Medicine, New York, NY, USA. Objective: To determine the safety and efficacy of high dose (4.0 mg / 0.1 cc) intravitreal ganciclovir. Methods: Ten patients (10 eyes) with progressing persistent Cytomegalovirus ( CMV ) retinitis in zone 1 were treated with a combination of systemic antivirals and intravitreal ganciclovir. The intravitreal dose was |
| Mo.B.1224 | Human cytomegalovirus, human herpesvirus-6 and human herpesvirus-7 DNA in colonic mucosa from HIV-seropositive patients with diarrhea. Int Conf AIDS 1996 Jul 7-12; 11:93 (abstract no. Mo.B.1224) Gautheret A, Monfort L, Poirel L, Desire N, Nicolas JC, Agut H, Beaugerie L; Service d'Hepato-Gastroenterologie et Nutrition, Hopital Rothschild, Paris, France. Fax: 33 (1) 40 19 34 36. Objectives: To study the presence of HCMV, HHV-6 and HHV-7 in the colonic mucosa of HIV-seropositive subjects with diarrhea. Methods: Thirty two HIV-seropositive patients with diarrhea were explored. Left-sided colonoscopy with intestinal biospy, cultures of stool and intestinal biopsy samples, and anatomopathological |
| Mo.B.1225 | Frequency of CMV-infection of the lung in AIDS-patients and its pathogenic impact. Int Conf AIDS 1996 Jul 7-12; 11:93 (abstract no. Mo.B.1225) Bieniek BJ, Arasteh K, Heise W, Futh U, Averdunk R, Grosse, L'age M; Auguste-Victoria Hospital, Berlin, Germany. Fax: 030-79032005 Objective: To evaluate the role of CMV-infection of the lung in severe therapy-resistant pneumonia or spontaneous pneumothoraces in AIDS-patients. Method: Fifteen HIV-infected men with symptoms of severe pneumonia have been observed: Detection of cytomegalo-virus-cells and CMV-immuno-histochemistry in lung tissue. Resu |
| Mo.B.1226 | Predictive values of CMV-pp65 antigenemia for the diagnosis of CMV disease in HIV-infected adults. Int Conf AIDS 1996 Jul 7-12; 11:93 (abstract no. Mo.B.1226) Reynes J, Montes B, Atoui N, Segondy M; Centre Hospitalier Universitaire de Montpellier, Montpellier, France. Fax: 33 67 33 77 60. Objective: To establish the diagnostic value of the cytomegalovirus ( CMV )-pp65 antigenemia in CMV disease occuring in HIV-infected patients. Methods: CMV-pp65 antigen in polymorphonuclear leukocytes (PMNLs) was assayed in 373 samples from 138 randomly-included adults followed up for a symptomatic HIV-1 infection (71, |
| Mo.B.1227 | Fungemia in patients with AIDS: etiological aspects. Int Conf AIDS 1996 Jul 7-12; 11:93 (abstract no. Mo.B.1227) Silva ML, Melhem M, Orozco SF, Ninomiya A, Palhares MC; Instituto Adolfo Lutz-Secretary of Health, Brazil. Fax: 55 11 853 3505. Objective: To determine the etiological agents responsible for fungemia occurring in patients with AIDS. Methods: From 1989 to 1995, 2884 samples from 1628 febrile patients clinically assessed by CDC AIDS case-definition criteria were analysed. Blood samples were directly inoculated onto brain heart infusion (BHI) medi |
| Mo.B.1228 | Primary fluconazole prophylaxis of invasive fungal infections in patients with advanced HIV disease. Int Conf AIDS 1996 Jul 7-12; 11:94 (abstract no. Mo.B.1228) Manfredi R, Chiodo F; Dept. of Clinical and Experimental Medicine, Division of Infectious Diseases, University of Bologna, Bologna, Italy. Fax: +39 51 34.35.00. Objective: To assess the efficacy of oral fluconazole (flu) in the prevention of systemic AIDS-related fungal diseases. Methods: All clinical records of HIV-infected patients (p) followed during the last 6 years were evaluated retrospectively, in order to identify p with a CD4+ cell count less than 200/microliter and n |
| Mo.B.1229 | Antifungal activities of antifungals against clinically isolated Candida species from oral cavities in HIV carriers / AIDS patients. Int Conf AIDS 1996 Jul 7-12; 11:94 (abstract no. Mo.B.1229) Ito A, Kawata K, Mitsuda T, Ichikawa S, Kawasaki K, Sudo T, Ikedo M, Yamaguchi H; Yokohama City Univ. Hospital Clinical Laboratory, Yokohama, Japan. Fax: 81-45-787-2915. Objective: To compare the isolated positive rate of Candida species in 31 HIV/AIDS patients with that in 64 healthy individuals and evaluate antifungal activities of various antifungal agents against isolated Candida species from oral cavities. Methods: Clinical isolates were collected repeatedly by swabbing oral cavit |
| Mo.B.1230 | Scedosporium prolificans infection in an AIDS patient. Int Conf AIDS 1996 Jul 7-12; 11:94 (abstract no. Mo.B.1230) De Pablos M, Aldamize M, Portu JJ, Soto MJ, Michaus L, Lezaun MJ, Jimenez JC; Hospital Txagorritxu, Microbiologia, Vitoria, Spain. Objective: To describe pulmonary infection due to Scedosporium prolificans in a patient with AIDS. Clinical Case: 37 year old male, HIV infection known for 9 years. He had developed extrapulmonary tuberculosis , latent syphilis, herpes zoster, and HIV encephalopathy. His CD4+ cell count was 27/mm3 (13.4%). He developed |
| Mo.B.1231 | Ventricular shunting in patients with cryptococcal meningitis and uncontrollable intracranial hypertension. Int Conf AIDS 1996 Jul 7-12; 11:94 (abstract no. Mo.B.1231) Bach MC, Tally PS; University of South Florida,Bradenton, Florida, USA. Objective: To demonstrate the therapeutic value of CNS shunting to correct severe intracranial hypertension associated with cryptoccal meningitis. Methods: Surgically placed lumbar-peritoneal (1) or ventriculo-peritoneal (4) shunts were placed in five patients with AIDS and acute cryptococcal meningitis. Their severe i |
| Mo.B.1232 | Extrapulmonary invasive aspergillosis in AIDS patients. Int Conf AIDS 1996 Jul 7-12; 11:94 (abstract no. Mo.B.1232) Mylonakis EE, Kwakwa H, Flanigan T, Mileno M; Brown University, Providence, RI, USA. Fax:(401) 331-8501. E-mail: Eleftherios Mylonakis@Brown.EDU. Objective: HIV-positive patients have a frequency of invasive aspergillosis (IA) that varies between 0.9 and 8.6%. Pulmonary aspergillosis (PA) is the most frequent clinical presentation representing greater than 70% of cases. Methods: Retrospective review of the cases of IA that occured between HIV(+) patients in a ho |
| Mo.B.1233 | Clinical characteristics and management responses in 85 HIV-infected patients with positive oral candida cultures. Int Conf AIDS 1996 Jul 7-12; 11:94 (abstract no. Mo.B.1233) Silverman S Jr, Gallo JW, McKnight ML; Priscilla Mayer University of California-San Francisco, San Francisco, CA, USA. Fax: 415-476-4204. Objective: To evaluate clinical responses to a systemic antifungal drug in HIV-positive patients with untreated oral candidiasis and compare with patient signs, symptoms, staging and fungal quantitation. Methods: Eighty-five consecutively seen HIV-positive individuals with oral candidiasis were evaluated for clinical c |
| Mo.B.1234 | Infection with hepatitis B(HBV) and hepatitis C(HCV) in patients HIV + in Buenos Aires, Argentina. Int Conf AIDS 1996 Jul 7-12; 11:95 (abstract no. Mo.B.1234) Lopez G, Russ C, Garcia MO, Cisneros JC, Gonzalez Blanco JC, Sicca G, Gonzalez S; Area Infectologia Policlinico Bancario, Buenos Aires, Argentina. Aims: To determine the incidence of infection through Hepatitis B (HBV) and C (HCV) in patients infected with HIV, analysing their distribution according to risky behaviour. To study the relation HbsAg and antiHbs in those infected with HBV. Material And Method: Out of the 262 patients (M/F 217/45) which compose our po |
| Mo.B.1235 | Prevalence of hepatitis E virus (HEV) antibodies according to HIV status. Int Conf AIDS 1996 Jul 7-12; 11:95 (abstract no. Mo.B.1235) Bissuel F, Houhou N, Leport C, Brun-Vezinet F, Vilde JL; Infectious and Tropical Unit,Bichat-Claude Bernard Hospital, Paris, France. Fax: 33-1-40-25-88-60. Objective: To assess the prevalence of Hepatitis E, a enterically transmitted hepatitis which resembles hepatitis A, according to HIV status in patients hospitalized in a french infectious diseases department. Methods: One hundred consecutive hospitalized patients were tested for anti-HEV IgG (HEV-EIA, Abbott), regardl |
| Mo.B.1236 | Interference between HBV and HCV viraemias among patients with and without HIV infection. Int Conf AIDS 1996 Jul 7-12; 11:95 (abstract no. Mo.B.1236) Chossegros P, Trepo C, Chevalier P, Guichard S, Vullo V, DeSanctis GM, Errera G, Chircu LV; Unite d'Hepatologie, Hotel Dieu Place de l'Hopital, Lyon, France. Fax: 0033/72413140. Objective: It is assumed that coexisting viral infections may influence the course of chronic hepatitis. Patients: We have studied 148 patients, with chronic HBs Ag (HBs Ag quantification, Imx ABBOTT) and anti-HBe carriers. 39% HBV DNA+ (Dot-Blot), 62 were anTI HCV+ (27% HCV RNA+, by PCR), 58 were anTI HD+ (20% HDV RNA |
| Mo.B.1237 | Red fingers syndrome in patients with HIV and hepatitis C. Int Conf AIDS 1996 Jul 7-12; 11:95 (abstract no. Mo.B.1237) Pechere M, Hirschel B, Krischer J, Spahr L, Rosay A, Van Delden C, Perrin L, Harms M, Saurat JH; DMI, Geneva University Hospital, Geneva, Switzerland. Fax: +41 22 372 98 20. E-mail: pechere@dminov1.hcuge.ch. Introduction: Specific cutaneous manifestations of systemic diseases can provide useful clues for clinical diagnosis. We observed a new cutaneous sign involving hands and feet in more than 1% of HIV-infected patients in our clinic. Case report: Well-delimited and striking periungueal and pulpar erythema with telangiect |
| Mo.B.1238 | Hepatitis C virus antibodies (HCV-Ab) prevalence in HIV-infected people from AIDS referral center, Montevideo. Int Conf AIDS 1996 Jul 7-12; 11:95 (abstract no. Mo.B.1238) Cardozo A, Savio E, Russi-Cahill J, Lowinger M, Cappuccio P; Hospital Italiano, Montevideo, Uruguay. Fax: (598)-2-801854. E-mail: gus@cs. cs. com.uy. Background: The prevalence of HCV infection is low in the Uruguayan general population. This prevalence increases among haemophiliacs or people under hemodyalisis (23%, range 5 - 65%). There were not national references related to HCV infection in other exposed to blood or sexual viral transmitted diseases groups such |
| Mo.B.1239 | Reactivation vs reinfection of hepatitis B in HIV seropositive individuals with previous natural immunity to hepatitis B. Int Conf AIDS 1996 Jul 7-12; 11:96 (abstract no. Mo.B.1239) Rusnak JM, Hong G; PSMI, Lackland AFB, TX. Fax: 210-675-0173. Objective: While loss of anti-HBs may occur in 8% of HIV patients with natural immunity to hepatitis B (HBV), the development of subsequent HBs Ag seropositivity is uncommon. Following identification of an HIV-positive patient with natural immunity to HBV, who then had isolated anti-HBc seropositivity, and subsequently |
| Mo.B.1240 | Recurrent hepatitis B infection in previously immune HIV-infected patients. Int Conf AIDS 1996 Jul 7-12; 11:96 (abstract no. Mo.B.1240) Merrick ST, Boyle BA, Jacobs JL; New York Hospital, NY, NY. Fax: 212-746-8415. New York Hospital-Cornell Medical Center, Center for Special Studies, New York, NY, USA Objective: We report three cases of recurrent, symptomatic hepatitis B in HIV-infected patients with serologic immunity. Methods: Biochemical and serologic testing of three patients who developed symptoms consistent with acute hepat |
| Mo.B.1241 | HCV viremia in HIV-positive patients negative for HBs Ag. Int Conf AIDS 1996 Jul 7-12; 11:96 (abstract no. Mo.B.1241) De Sanctis Giuseppe M, Chossegros P, Chircu LV, Chevalier P, Guichard S, Errera G, Falciano M, Trepo C; Dept. Infectious and Tropical Diseases, La Sapienza University Policlinico Umberto I, Rome, Italy. Fax: 39 6 4958919. Aim: To study if HCV viremia may be influenced by immune status versus HBV among HIV+ cases Patients: We have studied 153 patients positive for anti HIV (full-blown AIDS: 23%, mean CD4; AIDS + 76/mm3, AIDS- 368/mm3) and anti HCV (HCV RNA+: 45%). They were all HBs Ag- (anti HBc 60, anti HBs and HBc 47, no HBV 46). Histo |
| Mo.B.1242 | Hepatitis C prevalence, demographics and selection criteria for interferon therapy in an urban HIV-positive cohort. Int Conf AIDS 1996 Jul 7-12; 11:96 (abstract no. Mo.B.1242) Spencer MH, Ross JW; Adult Ambulatory Health Center, Hartford Hospital, Hartford, CT, USA. Fax: (860) 545-4256. Objective: To determine the seroprevalence of hepatitis C , to describe the demographics of the seropositive individuals and to propose selection criteria for alpha-interferon therapy in an urban HIV-positive population. Methods: Retrospective chart review was done on 131 HIV + patients with CD4 counts greater than 200 |
| Mo.B.1243 | When to prescribe available prophylactic treatments or to begin a systematic surveillance? Int Conf AIDS 1996 Jul 7-12; 11:96 (abstract no. Mo.B.1243) Costagliola D, Krause MM; INSERM, Faculte de Medecine Saint-Antoine, Paris, France. Fax: 33 1 43 07 39 57. E-mail: costagli@b3e.jussieu.fr. Objective: To estimate the risk of first occurrence of HIV-related diseases, for which prophylaxis are available, depending on the CD4 count level Methods: The French Clinical Epidemiology Database on HIV seropositive subjects followed in hospitals was started in 1989 in more than 50 hospitals in France . |
| Mo.B.1244 | Epidemiology and pathogenesis of plantar warts in HIV-infected patients. Int Conf AIDS 1996 Jul 7-12; 11:97 (abstract no. Mo.B.1244) Barbosa P, Loveland L, Kilpatrick R, Kenyon E; California College of Podiatric Medicine, San Francisco, California. Fax: (415) 292-0439. As the management of some of the more serious complications of HIV disease continues to improve, the podiatric manifestations become of greater significance for patient care. Plantar verrucae caused by human papillomavirus have been reported to be among the most commonly observed conditions in this patient population ( |
| Mo.B.1245 | Prevalence of HIV and HTLV infections in selective ethnic groups in Honduras. Int Conf AIDS 1996 Jul 7-12; 11:97 (abstract no. Mo.B.1245) Dubon JM, Garcia Saiz A, Klaskala W, Baum MK; U of Miami, Dept. Epidemiology & Public Health, Miami, FL. Objective: To determine the prevalence of HIV and HTLV infections in two different ethnic groups in Honduras : black Carribs (Garifunas)descendants of the African slaves and mestizo women. Methods: A total of 114 serum samples were tested for HTLV antibodies using particle agglutination and ELISA; then confirmed by mod |
| Mo.B.1246 | Parvovirus B19 infection in AIDS patients. Int Conf AIDS 1996 Jul 7-12; 11:97 (abstract no. Mo.B.1246) Barriga GA, Castillo TN; Hospital de Infectologia, Centro Medico "La Raza", I.M.S.S., Mexico City, Mexico. Fax: 525 556 6156. Objective: To determine the prevalence and the influence of Parvovirus B19 infection in the clinical outcome in AIDS and non AIDS patients. Methods: 116 persons with clinical syndromes suggestive of Parvovirus B19 infection, 100 AIDS patients and 100 healthy persons were studied using two EIA methods (PV-B19-IgG; PV-B1 |
| Mo.B.1247 | Evaluation of frequency of Mycobacterium avium complex (MAC) colonization and correlation with the development of disseminated disease in HIV-positive adult and pediatric patients. Int Conf AIDS 1996 Jul 7-12; 11:97 (abstract no. Mo.B.1247) Gori A, Rossi MC, Vezzoli S, Massironi E, Tornaghi R, Marchetti G, Franzetti F, Moroni M, d'Arminio MA; Clinic of Infectious Diseases, Milano, Italy. Fax: ++39 2 3560805. Objectives: To evaluate the frequency of MAC colonization of the gastro-enteric and respiratory tracts in HIV-positive patients; to correlate the role of the colonization with the development of acute infection. Methods: In a prospective study we included asymptomatic adult HIV-positive patients with CD4+ less than 150 |
| Mo.B.1248 | Detection of herpesvirus-like DNA sequence (KSHV) in HIV-positive patients with and without Kaposi's sarcoma (KS). Int Conf AIDS 1996 Jul 7-12; 11:97 (abstract no. Mo.B.1248) Jauregui RH, Rosetti S, D'Alessandro L, Lewi D, Monticelli A; FAIVIH/S Bs. As., Argentina. Fax: 962-8927. Objectives: 1) To detect the presence of KSVH in serum from HIV+ patients with and without KS. 2) To evaluate risk behaviours in HIV+ patients with KSHV+. 3) To determine in the studied KS population the existence of differences in the CD4 count and the clinical KS stage in relation with the detection or not of KSHV. M |
| Mo.B.1249 | Bleomycin + vincristine/VP16 with or without G-CSF in AIDS patients with Kaposi's sarcoma. Int Conf AIDS 1996 Jul 7-12; 11:97 (abstract no. Mo.B.1249) Routy JP, MacLeod J, Urbanek A; Immunodeficiency Program, Montreal Chest Institute, Montreal, Que. Fax: 514 843-2092. Objective: 1) To evaluate the efficacy and toxicity of bleomycin with vincristine or VP16 as a chemotherapeutic regimen for Kaposi s sarcoma (KS) in patients (pts) with extensive, progressive mucocutaneous and/or visceral disease. 2) To evaluate the usefulness of G-CSF (Filgrastim) in preventing severe neutropenia and |
| Mo.B.1250 | Extra-cutaneous manifestations of AIDS-related Kaposi's sarcoma: a retrospective study of 80 cases. Int Conf AIDS 1996 Jul 7-12; 11:98 (abstract no. Mo.B.1250) Nouts C, Morlat Ph, Dequae L, Pellegrin JL, Ragnaud JM, Dupon M, Bernard N, Doutre MS, Dabis F, Beylot J; Hospital St Andre, Bordeaux, France. Fax: (33) 56.79.58.22. Objective: To describe extra cutaneous AIDS-related Kaposi s sarcoma (ECKS) and its prognostic factors. Methods: We conducted a retrospective study within the Bordeaux University Hospital Cohort of all HIV-infected patients having presented at least one ECKS between January 1986 and February 1995. Results: Eighty cases |
| Mo.B.1251 | Topical photodynamic therapy (TPDT) of AIDS-associated Kaposi's sarcoma. Int Conf AIDS 1996 Jul 7-12; 11:98 (abstract no. Mo.B.1251) Beier C, Schofer H, Kaufmann R; Univ. Clinic Frankfurt, ZDV, Frankfurt, Germany. Fax: 4969 6301 5981. Objective: To determine the efficacy and tolerance of TPDT with the porphyrin precursor delta-aminolaevulinic acid (5-ALA) in the treatment of AIDS-associated Kaposi s sarcoma (KS). Methods: We performed topical photodynamic therapy in 4 HIV+ patients with 7 lesions of epidemic Kaposi s sarcoma (Table 1). An ointment c |
| Mo.B.1252 | HIV-related Kaposi's sarcoma associated with severe thrombocytopenia. Int Conf AIDS 1996 Jul 7-12; 11:98 (abstract no. Mo.B.1252) Sterrantino G, Trotta M, Milo D, Dionisio D, Leoncini F; Department of Infectious Diseases, Firenze, Italy. Fax: 0113955/4277293. Objective: To describe a case of cutaneous HIV-related Kaposi s Sarcoma associated with severe thrombocytopenia successfully managed by continuous infusion of bleomycin. Methods: A 60 year-old male with diffuse cutaneous HIV-related Kaposi s Sarcoma presented with large ecchymoses developing around tumoral lesions. CD4 |
| Mo.B.1253 | Response and cosmesis of two, short duration radiotherapy regimes for epidemic cutaneous Kaposi's sarcoma. Int Conf AIDS 1996 Jul 7-12; 11:98 (abstract no. Mo.B.1253) Harrison M, Harrington K, Tomlinson D, Stewart S; Dept. of Oncology, St. Mary's Hospital, London, UK. Fax: 0171-725-1840. E-mail: harrismk@icrt.icnet.uk. Objectives: To determine the optimal radiotherapy protocol for response and surrounding normal tissue cosmesis in the treatment of localized epidemic Kaposi s sarcoma. Methods: Five hundred and ninety six cutaneous KS lesions in 57 patients were prospectively treated using two, short duration, radiotherapy regimes. Les |
| Mo.B.1254 | Risk of cytomegalovirus (CMV) disease in patients with AIDS-related Kaposi's sarcoma (KS) on chemotherapy. Int Conf AIDS 1996 Jul 7-12; 11:98 (abstract no. Mo.B.1254) Bruce M, Antoniskis D, Rarick MU; Kaiser Permanente, Portland, OR, USA. Fax: (503) 638-0242. Objective: To determine whether chemotherapy for advanced AIDS-related KS is a risk factor for the development of symptomatic CMV disease. Methods: All AIDS patients from 1990 through 1995 cared for in this large health maintenance organization were cross-matched to find those with a diagnosis of both KS and CMV. Chart |
| Mo.B.1255 | Simultaneous Castleman's disease, Kaposi's sarcoma & immunoblastic non-Hodgkin's lymphoma in a patient with AIDS: speculations on pathogenesis. Int Conf AIDS 1996 Jul 7-12; 11:98 (abstract no. Mo.B.1255) Aboulafia DM, Picozzi VJ, Patterson S; Virginia Mason Med. Ctr., Seattle, WA, USA. Fax: 206-223-6914. Problem Considered: HIV-infected individuals possess a variety of B-cell abnormalities which result in polyclonal B-cell activation, aberrant immunoregulation, and a higher incidence of B-cell non-Hodgkin s lymphomas (NHL) and Kaposi s sarcoma (KS). Multicentric Castleman s disease (MCD), a manifestation of B-cell dysr |
| Mo.B.1256 | Liposomal daunorubicin (DaunoXome) has enhanced cytotoxicity in an AIDS-related Kaposi's sarcoma cell line. Int Conf AIDS 1996 Jul 7-12; 11:99 (abstract no. Mo.B.1256) Masood R, Lee MJ, Espina BM, Adler-Moore JP, Gill PS; Norris Cancer Institute, School of Medicine USC, Los Angeles, CA. Fax: (213) 764-0061. E-mail: masood@hsc.usc.edu. Objective: 1. To determine the in vitro activity of liposomal daunorubicin ( DaunoXome ) in HIV-related KS as well as other myeloproliferative tumor cell lines. 2. To determine the relative intracellular concentration over time of DaunoXome compared to free drug by microscopy and fluorimetry. |
| Mo.B.1257 | Long term survivors with continuously high levels of HIV-1. Int Conf AIDS 1996 Jul 7-12; 11:99 (abstract no. Mo.B.1257) Rump JA, Schneider J, Peter HH, Haller O, Meyerhans A; Department of Rheumatology and Clinical Immunology, University of Freiburg, Freiburg, Germany. Fax: -49-761-270-3446. Objective: To understand the mechanism of long survival in the presence of high plasma viremia. Methods: HIV-infected individuals of a cohort in Freiburg were followed with respect to their clinical status. Plasma viremia was measured by the p24 antigen alkaline dissociation assay (Organon) and the branched DNA assay ( |
| Mo.B.1258 | Lack of HIV isolation from PBMC defines a subgroup of LTNP with very low viremia and plasma sIL-2R Int Conf AIDS 1996 Jul 7-12; 11:99 (abstract no. Mo.B.1258) Vicenzi E, Bagnarelli P, Soldini L, Novati R, Ghezzi S, Sinnone M, Santagostino E, Gringeri A, Mannucci PM, Clementi M, Lazzarin A, Poli G; San Raffaele Scientific Institute, Milan, Italy. Fax: 39-2-2643.7989. Objective: To investigate the virological and immunological characteristics of HIV LTNP. Methods: A cohort of 29 LTNP, including 7 hemophiliacs and 15 ex-IVDU was evaluated for: HIV RNA in plasma and PBMC; quantitative proviral DNA load in PBMC; viral isolation from PBMC and plasma; cytokines/cytokine-receptor (R) conc |
| Mo.B.1259 | A decade of HIV-infected haemophiliacs: low virus burden in non- and slow progressors of HIV infection in 1985. Int Conf AIDS 1996 Jul 7-12; 11:99 (abstract no. Mo.B.1259) Yasuyuki Y, Nishida Y, Fukue H, Fukutake K, Shiga K, Meguro T; Tokyo Medical College, Tokyo, Japan. Fax: 03-3340-5448. E-mail: gaf07614@niftyserve.or.jp. Objective: To delineate virologic and immunologic attributes of long-term survival in haemophiliacs infected with human immunodeficiency virus (HIV) for more than a decade. Methods: Seventy four HIV-infected haemophiliacs have been followed since 1985. To be considered non- and slow progressors, subjects had to be asym |
| Mo.B.1260 | Correlates of long-term survival and immunologic nonprogression among HIV-1 infected sex workers in Nairobi. Int Conf AIDS 1996 Jul 7-12; 11:99 (abstract no. Mo.B.1260) Kimani J, Kaul R, Njagi E, MacDonald K, Anzala O, Nagelkerke N, Bwayo J, Plummer F; Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya, East Africa. Much interest has recently been focused on the characterization of disease progression among HIV-1 infected individuals. The average time from infection to death is 10 years, and most long-term survivors have immunologic evidence of disease progression. Since 1985 we have studied the immuno-e |
| Mo.B.1261 | Discordance of genital and plasma HIV expression associated with long-term nonprogression in women. Int Conf AIDS 1996 Jul 7-12; 11:100 (abstract no. Mo.B.1261) CuUvin S, Flanigan TP, Greenough TC, Anderson DJ, Parekh B, Mayer KH, Carpenter CC; Brown University, Providence, RI. Fax: 401-331-8501. Objective: To determine the relation between plasma viral load and genital HIV shedding in HIV-infected women who meet strict criteria for long-term non-progression. Methods: In a cohort of 73 HIV-infected women who had been followed at less than or equal to 6 month intervals for 6-10 years, 4 met the following criteri |
| Mo.B.1262 | Taenia crassiceps infection in AIDS. Int Conf AIDS 1996 Jul 7-12; 11:100 (abstract no. Mo.B.1262) Marionneau J, Maillard H, Prophette B, Boyer E, Celerier P; Coordination VIH-SIDA, Centre Hospitalier, France. Fax: 43.43.24.14. E-mail: marionneauj@hiv.france. Objective: To describe a new opportunistic infection in AIDS through a personal case report and literature review. Methods: Case report. A 34 year-old patient with AIDS, developed in 11/94 a traumatic haematoma of left arm without cutaneous wound. Two months later, the volume increasing of arm persisted, extending over |
| Mo.B.1263 | Effectiveness and side-effects of steroid therapy in renal disease associated with HIV infection. Int Conf AIDS 1996 Jul 7-12; 11:100 (abstract no. Mo.B.1263) Karmochkine M, Oksenhendler E, Martinez F, Beaufils H, Valantin MA, Coutellier A, Idatte JM, Herson S; Internal Medicine Dept. (Pr Herson), Hopital La Salpetriere, Paris, France. Fax: 33 1 42 16 10 58. Objective: To determine efficacy and tolerance of steroid therapy in different types of renal disease encountered during HIV infection: specific HIV associated nephropathy (HIV-AN), immune-complex glomerulonephritis (ICGN) and interstitial nephritis (IN). Methods: Retrospective analysis of all cases of biopsy-proven re |
| Mo.B.1264 | Intracranial sigmoid and lateral-sinuses thrombosis due to a protein deficiency in a patient with AIDS. Int Conf AIDS 1996 Jul 7-12; 11:100 (abstract no. Mo.B.1264) Iranzo A, Cadafalch Jose, Sambeat MA, Negredo E, Ris J, Fuster M, Ruscalleda J, Nolla J; Department of Internal Medicine, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Fax: 34-3-291.92.69. Objective: To describe the clinical and radiographic picture of a patient with AIDS diagnosed of intracranial venous thrombosis secondary to a protein S deficiency. Methods: A 37-year-old HIV-infected woman with previous history of cerebral toxoplasmosis was admitted with severe and persistent headache that began two w |
| Mo.B.1265 | Unusual malignant tumors in association with acquired immunodeficiency syndrome. Int Conf AIDS 1996 Jul 7-12; 11:100 (abstract no. Mo.B.1265) Santos J, Fernandez A, Velasco JL, Marquez M, Rivero A, Abarca M; University Hospital, Malaga, Spain. Objective: To determine the incidence and types of malignant tumours other than non-Hodgkin s lymphoma (NHL) and Kaposi s sarcoma (KS) in association with HIV infection. Setting: A teaching hospital in Malaga ( Spain ). Method: A retrospective chart review was conducted in the tumor registry and all cases of tumor (his |
| Mo.B.1266 | Changes in the incidence of rare HIV-associated diseases in the swiss HIV cohort study (SHCS). Int Conf AIDS 1996 Jul 7-12; 11:100 (abstract no. Mo.B.1266) Burckhardt B, Nuesch R, Itin P, Zimmerli W, Gyr K, Battegay M; Kantonsspital Basel, Medizinische Poliklinik, Basel, Switzerland. Fax: 011 41-61-265 46 04. Objective: To determine trends in rare diseases in the SHCS before and after start of antiretroviral and prophylactic treatment in 1.1.90. Methods: Data source: SHCS. All patients (pts) registered to the SHCS until 20.4.95 were analysed; 3,102 pts before, 5,024 pts after 1.1.90. All diseases affecting less than 1% of a |
| Mo.B.1267 | Association between diarrhoea and the presence of HIV-RNA in stool samples of HIV-infected patients. Int Conf AIDS 1996 Jul 7-12; 11:101 (abstract no. Mo.B.1267) Fransje S, van der Hoek L, Danner SA, Goudsmit J, Sol C; AMC, Division of Infectious Diseases, Tropical Medicine and AIDS, Amsterdam, The Netherlands. Fax: -31-20-6963271. Objectives: Diarrhoea is a common clinical problem in HIV-infected patients. Although many enteric pathogens have been implicated, the etiology remains unexplained in approximately one third of the patients. HIV itself might play a role, but studies on the relationship between the presence of HIV in the intestinal muco |
| Mo.B.1268 | How useful is routine intravenous gadolinium in MRI imaging of the brain in HIV-infected patients? Int Conf AIDS 1996 Jul 7-12; 11:101 (abstract no. Mo.B.1268) Banerjee AK, Malcolm PN, Howlett DC, Saks A, Bingham JS, Bingham JB, Cox TC; Department of Radiology, Birmingham Heartlands Hospital, Birmingham, UK. Fax: 0121 766 6919. Objective: To investigate whether the routine use of an intravenous contrast agent is useful in magnetic resonance imaging of the brain in HIV patients. Method: 110 HIV patients were studied prospectively and all were given intravenous gadopenate dimeglumine (0.1 mmol/kg) routinely for their brain scans. The scans were |
| Mo.B.1269 | Idiopathic CD4+ T-lymphocytopenia (ICL) - a follow-up of reported cases in the United States. Int Conf AIDS 1996 Jul 7-12; 11:101 (abstract no. Mo.B.1269) Spira TJ; CDC, Atlanta, GA, USA. Fax: 404-639-2108. E-mail: tjsl@ciddasl.em.cdc.gov. Objective: To determine the current status of ICL patients in the United States reported to CDC as of July 1993. Methods: State and local health departments and local physicians reporting ICL patients meeting the CDC case definition were asked to provide follow-up information by questionnaire between June and November |
| Mo.B.1270 | Study of electrocardiographic abnormalities in different evolutive phases of AIDS. Int Conf AIDS 1996 Jul 7-12; 11:101 (abstract no. Mo.B.1270) Meira DA, Zacchi B, Souza LR, Franco MF, Curi PR; Faculdade de Medicina, Botucatu, Sao Paulo, Brasil. Fax: 55-014-821-2711. E-mail: dmeira@fmb. une sp.br. Introduction and objective: The cardiac involvement in AIDS has been referred in the medical literature mainly by the presence of pathologic changes observed in autopsy. The objective of this study was to verify electrocardiographical (ECG) abnormalities in the different evolutive periods of infection by HIV in relatio |
| Mo.B.1271 | Acute heart failure due to CMV myocarditis confirmed by myocardial biopsy in a case with AIDS. Int Conf AIDS 1996 Jul 7-12; 11:101 (abstract no. Mo.B.1271) Kimura S, Masuo M, Ryu T, Oka S, Mori S; Social Health Insurance Medical Center, Tokyo, Japan. Case Report: Forty-six year-old HIV-positive homosexual man presented with DCM-like symptoms and acute cardiac failure in December, 1994. He had a history of Pneumocystis carinii pneumonia two years ago, which was successfully treated with Co-trimoxazole and pentamidine. Cardiac failure was controlled with diuretica an |
| Mo.B.1272 | Cardiac involvement is comparable among HIV-positive and HIV-negative patients at risk for acquired immune deficiency syndrome (AIDS). Int Conf AIDS 1996 Jul 7-12; 11:101 (abstract no. Mo.B.1272) Singal S, Sukernik MR, El-Sadr W, Connor JN, Vanderbush EJ, Francis CK; Harlem Hospital Center, New York, NY. Fax: (212) 939-2968. E-mail: ss472@columbia.edu. Objective: Cardiac abnormalities have been reported in persons at risk for HIV but the echocardiographic pattern and prevalence of these abnormalities have not been extensively studied. Methods: We reviewed 2-D Doppler echocardiograms (ECHO) in 294 HIV-positive and 230 HIV-negative patients from an inner city predomina |
| Mo.B.1273 | Myocardial dysfunction in HIV infection: an echocardiographic study of 157 hospitalized patients in Zimbabwe. Int Conf AIDS 1996 Jul 7-12; 11:102 (abstract no. Mo.B.1273) Hakim JG, Matenga JA, Siziya S; University Of Zimbabwe Medical School, Avondale, Harare. Fax: 26(4)791995. Objective: To determine the prevalence and characteristics of myocardial dysfunction and other cardiac manifestations in acutely ill hospitalized HIV-infected patients in Zimbabwe using a cross-sectional study design. The main outcome measure was detection of myocardial dysfunction and other cardiac abnormalities on tw |
| Mo.B.1274 | Are cardiac abnormalities associated with a poorer vital prognosis in AIDS? A prospective study of 34 patients. Int Conf AIDS 1996 Jul 7-12; 11:102 (abstract no. Mo.B.1274) d'Ivernois C, Chene G, Dupon M, Cales V, Dabis F, Salamon R, Lacut JY; Service de Cardiologie, Centre Hospitalier Universitaire, Bordeaux, France. Fax: (33) 53 07 73 94. Objective: Previous studies have documented cardiac abnormalities (AN) in HIV-infected patients. Only a few patients experience cardiac symptoms, but echocardiographic AN are observed in 30-55 % of the patients and appear more frequent when HIV infection is at an advanced stage. The aim of our study was to determine th |
| Mo.B.1275 | Porphyria cutanea tarda (PCT) and HIV infection. Int Conf AIDS 1996 Jul 7-12; 11:102 (abstract no. Mo.B.1275) Drobacheff C, Van Landuyt H, Devred D, Derancourt C, De Wazieres B, Vuitton DA, Rey D, Cribier B, Lang JM, Laurent R; Dept of Dermatology, Hospital, Besancon, France. Fax: (33) 81 21 86 29. Objectives: Since 1987, about 60 cases of PCT in HIV-positive patients have been reported. The respective roles of HIV and toxic hepatic factors (particularly hepatitis C ) in PCT remain unclear. Our aim was to study the following toxic hepatic factors: hepatitis C and B, alcoholism, drugs. Methods: We report 7 cases o |
| Mo.B.1276 | A case series of dermatological manifestations of HIV seropositives attending the central STD clinic Colombo. Int Conf AIDS 1996 Jul 7-12; 11:102 (abstract no. Mo.B.1276) Piyadigamage A, De Silva GA; STD/AIDS Control Programme, Colombo, Sri Lanka. Objective: Case series to describe the dermatological manifestations of HIV sero positives in an out-patient clinic, Colombo. Methods: Descriptive case series study of dermatological manifestations in HIV seropositive persons attending the Central STD Clinic of the National STD/AIDS Control Programme (NSACP) on an out- |
| Mo.B.1277 | Impact of risk group on the prevalence of seborrheic dermatitis in HIV-infected patients. Int Conf AIDS 1996 Jul 7-12; 11:102 (abstract no. Mo.B.1277) Schaub NA, Drewe J, Sponagel L, Gilli L, Courvoisier S, Gyr N, Rufli TH, Battegay M, Itin P; Department of Dermatology, Basel, Switzerland. Fax: 011 41 61 265 42 00. Objective: To investigate whether there is a difference in the prevalence of seborrheic dermatitis (SD) in homo/bisexual HIV-infected patients compared with HIV-infected intravenous drug users (IVD). Furthermore to analyze whether antiretroviral treatment (aRVT) influenced prevalence and time course of SD. Methods: We |
| Mo.B.1278 | Corynebacterium striatum skin ulceration in a patient with advanced HIV infection. Int Conf AIDS 1996 Jul 7-12; 11:102 (abstract no. Mo.B.1278) Knox K, Howe P, Conlon C, Edwards A, Byren Ivor; Harrison Dept, Radcliffe Infirmary, Oxford, UK. Fax: 1865-224378. Objective: We report a case of Corynebacterium striatum skin ulceration in an African patient with advanced HIV infection. Case Report: A 27 year old Ugandan man resident in the United Kingdom , who tested HIV-positive in 1990, presented with a 1 month history of a profusely discharging 7cm x 5cm ulcerating lesion on h |
| Mo.B.1279 | Significance of peripheral eosinophilia in HIV-infected individuals. Int Conf AIDS 1996 Jul 7-12; 11:102 (abstract no. Mo.B.1279) Skiest DJ, Keiser P; The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA. Fax: 214-648-9478. E-mail: SKIEST@UTSW.SWMED.EDU. Objective: To determine the clinical significance of peripheral blood eosinophilia in HIV+ patients. Methods: 42 HIV+ patients with an absolute eosinophil count (AEC) greater than 500 (study group) were compared to a randomly chosen cohort of 84 HIV+ patients without eosinophilia, matched by CD4 cell count and date in |
| Mo.B.1280 | Leprosy and HIV coinfection in an endemic developing country: how to interpret occurrence of lepromatous leprosy in a HIV+ hemophiliac with no known contact with leprosy patients? Int Conf AIDS 1996 Jul 7-12; 11:103 (abstract no. Mo.B.1280) Petri V, Nishio CE, Nishio PA, Takizawa CM, Michalany NS; Federal University of Sao Paulo, Escola Paulista de Medicina-Dept. of Dermatology, Sao Paulo, Brazil. Fax: 55-11-5492127. In spite of immunological findings being crucial to understanding important events of HIV disease, leprosy and HIV/AIDS coinfection is not sufficiently focused as a threatening occurence in endemic developing countries. Leprosy may occur in HIV +/AIDS patients with no known contact with leprosy patients, and HIV |
| Mo.B.1281 | Molluscum contagiosum infection in three population groups. Int Conf AIDS 1996 Jul 7-12; 11:103 (abstract no. Mo.B.1281) Rea AJ, Goh BT, Eldridge S, Glover M; Ambrose King Centre, Royal London Hospital, Whitechapel, London, UK. Objective: To study molluscum contagiosum (MC) infection in patients seen in an HIV clinic (Gp1), compared to patients seen in a non-HIV Genito-urinary Medicine (Gp2) and Dermatology (Gp3) clinics. Methods: MC infections seen in Gp 1,2,3 from April 1993 to September 1994 were retrospectively analysed. Total number of c |
| Mo.B.1282 | Symptomatic systemic CD8 lymphocytosis in HIV-1 infection: a cohort study. Int Conf AIDS 1996 Jul 7-12; 11:103 (abstract no. Mo.B.1282) Jarrousse B, Lortholary O, Cohen P, Zeller V, Berlureau P, Arene JP, Guillevin L; Department of Internal Medicine, Hopital Avicenne, Universite Paris-Nord, France. Fax: 33 1 48 95 54 50 Objective: To describe the clinical, immunologic features and outcome of symptomatic diffuse infiltrative CD8 lymphocytosis resembling Sjogren syndrome in a monocentric cohort of HIV-1 infected patients. Patients: Consecutive sample of 8 patients Results: Among 171 patients with increased numbers of CD8 lymphocytes (gr |
| Mo.B.1283 | Polyarteritis nodosa in an HIV-infected patient with Castleman's disease: potential role of KSHV and efficacy of treatment with immunoglobulin. Int Conf AIDS 1996 Jul 7-12; 11:103 (abstract no. Mo.B.1283) Lesueur A, Salmon D, Blanche P, Essam E, Dupin N, Clauvel JP, Sicard D; Departement de medecine interne, Hopital Cochin, Paris, France. Fax: 42 34 13 49. Case report: A 49 year old seropositive homosexual male patient presented in September 92 with fever, associated with multiple lymphadenopathy, splenomegaly and pancytopenia. CD4 cell count was 200/mm3. 1- After 5 months of unexplained fever, multicentric Castleman s disease was diagnosed after splenectomy, on histopat |
| Mo.B.1284 | CD3+ CD8+ CD16- clonal large granular lymphocyte leukaemia and HIV infection. Int Conf AIDS 1996 Jul 7-12; 11:103 (abstract no. Mo.B.1284) Pulik M, Lionnet F, Genet P, Petitdidier C, Jary L, Fourcade C, Touahri T; Centre Hospitalier d'Argenteuil, Department of Haematology, Argenteuil, France. Fax: 33-1-34-23-23-15. Objective: To report a case of clonal CD3+ CD8+ CD16- large granular lymphocyte leukaemia (T-LGL) in an HIV-infected patient. T-cells derived leukaemias are very unusual in association with HIV infection. Methods: Surface immunophenotyping of the lymphocytes was performed with flow cytometry using a broad panel of lymp |
| Mo.B.1285 | Induction of G-CSF by acute febrile infection but not by neutropenia in HIV-seropositive individuals. Int Conf AIDS 1996 Jul 7-12; 11:104 (abstract no. Mo.B.1285) Mauss S, Steinmetz HT, Willers R, Jablonowski H, Haussinger D; Klinik fur Gastroenterologie und Infektiologie, Universitat Duesseldorf, Dusseldorf, Germany. Fax: +49/211/811-8752. Objective: Persistent neutropenia is frequent in HIV-seropositive (HIV+) individuals particularly with advanced HIV-infection. The pathogenesis of this neutropenia remains unexplained so far. G-CSF is an important factor in neutropoesis. In HIV-seronegative individuals the endogenous G-CSF serum level seems to be regul |
| Mo.B.1286 | Prevalence of thrombotic microangiopathy in a cohort of HIV-infected patients. Int Conf AIDS 1996 Jul 7-12; 11:104 (abstract no. Mo.B.1286) Ripamonti D, Gregis G, Casari S, Suardi MG, Chitoni M, Gregorini G, Rossi G, Carosi G; Clinic of Infectious Diseases, Ospedale Civile di Brescia, Brescia, Italy. Objective: To determine 1) the prevalence of thrombotic microangiopathy (TMA) in a cohort of HIV-infected patients (pts), 2) the relation of TMA with clinical stage of HIV infection and CD4 cell count and 3) to establish the predictive value of hematologic abnormalities for TMA. Methods: All in- and out-pts from 06/01/ |
| Mo.B.1287 | Acute myelomonocytic leukemia associated with HIV infection and granulocyte colony-stimulating factor therapy. Int Conf AIDS 1996 Jul 7-12; 11:104 (abstract no. Mo.B.1287) Gonzalez-Garcia J, Lorenzo A, Jimenez-Yuste V, De Castro M, Jimenez C, Martin MP, Herranz P, Fernandez-Capitan C, Pena JM; Madrid, Spain. Fax: 33 (1) 358 10 56. Introduction: Patients with HIV infection frequently have myelodysplastic syndrome but acute myeloid leukemia is unusual. If these alterations are related to HIV infection of bone marrow progenitor cells, antiretroviral therapy or viral coinfections are unknown. Acute myeloid leukemia has developed after the administra |
| Mo.B.1288 | Anti-beta 2 glycoprotein I and anti-cardiolipin antibodies in HIV-positive patients. Int Conf AIDS 1996 Jul 7-12; 11:104 (abstract no. Mo.B.1288) Sirera G, Reverter JC, Teixido M, Tassies D, Romeu J, Raventos A, Tural C, Segura A, Font J, Ordinas A, Clotet B; AIDS Unit, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain. Fax: 343 46376 02. Objective: Anti-cardiolipin antibodies (aCL) are associated with thrombosis in autoimmune diseases but not in AIDS patients. A 50 kDa serum cofactor, identified as beta 2-glycoprotein I (beta 2GPI), enhances aCL activity in autoimmune diseases and antibodies anti- beta 2GPI (a beta 2GPI) had been found. We developed an |
| Mo.B.1289 | Waldenstrom's macroglobulinemia in an HIV-positive patient without evidence of EBV association. Int Conf AIDS 1996 Jul 7-12; 11:104 (abstract no. Mo.B.1289) Sings DJ; Northeastern Ohio Universities College of Medicine, Akron, Ohio. Objectives: To describe the first case of Waldenstrom s macroglobulinemia in an HIV-infected patient, to present the course of this usually benign malignancy, and to explore a possible association with EBV. Methods: A 52 year old Caucasian man, known to be HIV-positive since 1988 with a stable CD4 cell count in the low |
| Mo.B.1290 | HIV-associated thrombotic disease: pathogenic role of microvascular endothelial cell apoptosis. Int Conf AIDS 1996 Jul 7-12; 11:105 (abstract no. Mo.B.1290) Laurence J, Mitra D, Steiner M, Staiano-Coico L, Jaffe E; Dept. of Medicine, Cornell University Medical College, New York, NY, USA. Fax: 212-746-8601. Objective: Identify mechanisms of idiopathic microvascular thrombotic disease-thrombotic thrombocytopenic purpura (TTP), hemolytic-uremic syndrome (HUS), and cardiac and cerebrovascular disorders-which occur with elevated frequency in HIV infection. Methods: Plasma and limited tissue samples were obtained from HIV-1+ a |
| Mo.B.1291 | Multicentric Castleman's disease in HIV infection. A clinical, pathological and molecular study of 20 patients. Int Conf AIDS 1996 Jul 7-12; 11:105 (abstract no. Mo.B.1291) Oksenhendler E, Soulier J, Duarte M, Cazals-Hatem D, Clauvel JP, Raphael M; Immuno-Hematologie, Hopital Saint-Louis, Paris, France. Fax: 33(1)42499472. Objective: To describe, in a retrospective study, multicentric Castleman s disease (MCD) in HIV infection. Patients: The diagnosis of MCD was established by lymph node biopsy in 20 HIV+ patients. All patients had been HIV-infected by sexual contact. At diagnosis, HIV infection was asymptomatic in 8 patients and Kaposi |
| Mo.B.1292 | High dose chemotherapy (CT) and autologous bone marrow transplantation (ABMT) for malignant hemopathies in HIV-infected patients. Int Conf AIDS 1996 Jul 7-12; 11:105 (abstract no. Mo.B.1292) Rio B, Compagnucci A, Rochemaure J, Zittoun R; Service de Pneumologie, Hotel Dieu, Notre Dame, Paris, France. Improvement of prognosis of the HIV-infection leads to discuss the therapy of coincidental or HIV-associated hematological malignancies. Long term continuous complete remission (CR) can be achieved after intensive treatment with ABMT in seronegative patients (pts). We report the results of a feasibility study of ABMT f |
| Mo.B.1293 | Thrombocytopenia in HIV-infected children. Int Conf AIDS 1996 Jul 7-12; 11:105 (abstract no. Mo.B.1293) Aquino MZ, Sato HK, Kamikawa J, Marques HH, Gusmao Filho FA, Valente MT, Sakane PT, Okay Y; Depto of Pediatrics Universidade de Sao Paulo, Sao Paulo, Brazil. Fax: 55-11 30665703. Objective: To describe the occurrence and management of thrombocytopenia in HIV-infected children.Methods: Two hundred and five children with AIDS have been followed since June 1985. Twenty developed thrombocytopenia (less than 50.000cells/mm).Nineteen were vertically infected and one infected by blood products. Subjec |
| Mo.B.1294 | Oxidative stress and thrombin generation during HIV infection. Int Conf AIDS 1996 Jul 7-12; 11:105 (abstract no. Mo.B.1294) Trotti R, Rondanelli M, Brustia R, Anesi A, Belloni E, Minoli L, Ferrari E, Melzi D'Eril GV; "IRCCS C. Mondino", Pavia, Italy. Fax: 0039-382-380286. Objective: Evidence has accumulated suggesting that oxidative stress is an activator of immunodeficiency virus (HIV) replication in vitro and can lead to increased lipid peroxidation and DNA damage in infected cells. Otherwise, products resulting from lipid peroxidation have been shown to promote thrombin generation in |
| Mo.B.1295 | The count and functional activity of blood platelets in patients with AIDS-indicated diseases. Int Conf AIDS 1996 Jul 7-12; 11:106 (abstract no. Mo.B.1295) Kravtchenko A, Polyakova AM, Astrina O, Shakhgildian V, Maleev V; Central Institute of Epidemiology, Moscow, Russia. Fax: 7-095-365-46-80. Objective: To study platelet count and their function in patients (pts.) with AIDS-indicated diseases. Methods and patients: We determined count of thrombocytes, their aggregation (Hal - adenosinediphosphate- ADP-2x10-5 M, Ha2 -2x10-6 M), accumulation and secretion of fluorescence marker by thrombocytes (Al -endocytose |
| Mo.B.1296 | Focal clear hystiocytes thyroiditis in the acquired immunodefficiency syndrome (AIDS): direct HIV aggression? Int Conf AIDS 1996 Jul 7-12; 11:106 (abstract no. Mo.B.1296) Basilio CA, Pires ML, Silva MA, Lima MB, Ribeiro JE; Universidade Do Rio De Janeiro, Rio De Janeiro, Brasil. Objective: To asses the direct thyroid gland attainment by the HIV in AIDS patients. Methodology: The study has been done through the anatomo-pathological examination of 100 AIDS patients seen in the Pathological Anatomy Service of the HUGG from 1985 to 1994. Results: Clear hystiocytes focal thyroiditis,not reported up |
| Mo.B.1297 | Still's disease with HIV infection: pathophysiological link or incidental association? Int Conf AIDS 1996 Jul 7-12; 11:106 (abstract no. Mo.B.1297) Riche A, Rogez JP, Leport C, Bertin P, Gissot V, Vilde JL, Weinbreck P; Service de Maladies Infectieuses, Limoges, France. Fax: 55-05-66-48. Objective: We describe the first case of Adult onset Still s disease (AOSD) revealing HIV infection. Material and Method: A 35-year-old white bisexual man presented in July 1994 with three weeks of fever, sore throat, lymphadenopathy and splenomegaly. He had leukocytosis with neutrophilia and anemia with high level of |
| Mo.B.1298 | Avascular necrosis of bone in HIV-infected patients with antiphospholipid antibodies. Int Conf AIDS 1996 Jul 7-12; 11:106 (abstract no. Mo.B.1298) De Truchis P, Saillour M, Pigne E, Carlier R, Marty C, Peretti A, Perronne C; Hopital Raymond Poincare, Garches, France. Fax: (33)-1-47107767. Objective: To describe clinical, radiological and biological features of avascular necrosis in HIV-infected patients (pts). Methods: Charts of 3 pts diagnosed with bone avascular necrosis between 1992 and 1995 in a cohort of 450 HIV-infected pts, were reviewed. Case reports: the pts were 3 men, aged 31 to 62 years, inf |
| Mo.B.1299 | Thrombotic thrombocytopenic purpura and haemolytic-uraemic syndrome in HIV-infected patients. Int Conf AIDS 1996 Jul 7-12; 11:106 (abstract no. Mo.B.1299) Gervasoni C, Ridolfo AL, Bini T, Santambrogio S, Lupo A, Bertoli S, Galli M; Clinic of Infectious Diseases, Dept. of Nefrology, L.Sacco Hospital, University of Milan, Italy. Fax: ++3923560805. Objective: to evaluate the clinical and laboratory findings and the outcome of thrombotic microangiopathy (TM) in HIV patients. Methods: 16 patients with TM admitted to our Clinic from 1/1985 to 12/1994 were reviewed. 2 patients showed thrombotic-thrombocytopenic purpura (TTP) and 14 haemolytic uraemic syndrome (HUS). |
| Mo.B.1300 | A longitudinal study of rheumatic complications in patients infected with HIV. Int Conf AIDS 1996 Jul 7-12; 11:106 (abstract no. Mo.B.1300) Calabrese LH, Bacon A, Chow H, Easley K; Cleveland Clinic Foundation, Cleveland, OH. Fax: 216-445-7569. E-mail: calabrl@cesmtp.ccf.org. Objective: Rheumatic disorders have been well-reported in the setting of HIV infection though available epidemiologic studies are of short-term design and little is known about the influence of such complications on the natural history of HIV infection. The present study was designed to prospectively detect rheumatic s |
| Mo.B.1301 | Sleep disorders in HIV-positive patients. Curable causes of daytime fatigue and sleepiness. Int Conf AIDS 1996 Jul 7-12; 11:107 (abstract no. Mo.B.1301) Buda FB; ABSM, ABPN, Atlanta, GA. Fax: FBBMD@aol.com. Issues: HIV+ patients complain of daytime fatigue/excessive daytime somnolence (EDS) and insomnia. Previous studies on sleep in HIV+ have identified disrupted sleep architecture, and recently obstructive sleep apnea (OSA) secondary to tonsillar hypertrophy. Project: Six HIV+ patients were evaluated by a board certified |
| Mo.B.1302 | Evidence for an increased incidence of renal cell carcinoma in patients with HIV infection. Int Conf AIDS 1996 Jul 7-12; 11:107 (abstract no. Mo.B.1302) Baynham SA, Cleveland KB, Katner HP, Smith MU; FACP, Mercer University School of Medicine, Macon, Georgia, USA. Fax: 912-749-9119. Objective: To determine if the incidence of renal cell carcinoma (RCC) in a population of patients with HIV is greater than in the general population. Methods: All 85,532 adult admissions to a 518 bed general hospital in the USA from 1990 to 1994 were reviewed to determine the total number of HIV admissions, the total |
| Mo.B.1303 | Otoneurology alterations in HIV patients. Int Conf AIDS 1996 Jul 7-12; 11:107 (abstract no. Mo.B.1303) Pena C, Cano C; Hospital General Centro Medico La Raza IMSS, Mexico, D.F. Objective: To determine the otoneurology alterations presents in patients HIV (+). Methods: 50 patients HIV + were evaluated, none oportunistic infection previous, none otoneurology disease previous, none eighth nerve previous alteration, none ototoxic drugs antecedent or central nervous system disease were included. C |
| Mo.B.1304 | Routine childhood vaccinations: effect on HIV-1 seroconversion. Int Conf AIDS 1996 Jul 7-12; 11:107 (abstract no. Mo.B.1304) Embree J, Nagelkerke N, Datta P, Njenga S, Ndinya-Achola JO, Plummer FA; Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada. Concerns have been expressed regarding the effect of childhood vaccinations and on the transmission of HIV-1 virus from mother to child. Certain vaccines may stimulate Th1 to Th2 switches of primary immune responses resulting in a predominantly humoral rather than cell mediated responses to a |
| Mo.B.1305 | Painful peripheral neuropathy with CMV infection in a pediatric AIDS patient. Int Conf AIDS 1996 Jul 7-12; 11:107 (abstract no. Mo.B.1305) Leroy J, Estavoyer JM, Lassauge F, Desmurs H, Mueller E, Jeangirard M, Couaquette A; University Hospital of Besancon, Besancon, France. Fax: (33) 81 21 87 72. Introduction: Cytomegalovirus ( CMV ) is well recognized as an opportunistic pathogen in children with HIV infection. Neuropathy caused by CMV is a rare but serious neurological disorder that occurs late in the course of HIV - 1 infection in adults. To date cases of peripheral nerve dysfunction in pediatric patients ha |
| Mo.B.1306 | Effect of combination therapy with ZDV/ddI or ZDV/3TC on plasma HIV-RNA in HIV-infected infants and adolescents. Int Conf AIDS 1996 Jul 7-12; 11:107 (abstract no. Mo.B.1306) Solder B, Wintergerst U, Notheis G, Eberle J, Gurtler L, Belohradsky B; University Children's Hospital, Munich, FRG. Fax: +49-89-51603964. To assess HIV-RNA load in HIV-infected children and adolescents (less than 18 years, mean age 7.1 years) under antiretroviral combination therapy . Patients and Methods: 5 patients with disease progression under their prior antiretroviral therapy were treated with ZDV (4x90mg/m2/d)/DDI (2x100mg/m2/d) (group A) a |
| Mo.B.1307 | CNS - affection in perinatally HIV-infected children. Int Conf AIDS 1996 Jul 7-12; 11:108 (abstract no. Mo.B.1307) Josep-Steiner J, Funk M, Mentzer D, Jakobi G, Kreuz W; Department of Pediatrics, Johann Wolfgang Goethe-University Frankfurt, Frankfurt am Main, Germany. Fax: 06 9/ 6301 6491. Introduction: Soon after the initial description of paediatric AIDS, central nervous system (CNS) involvement was recognized as a frequent manifestation. This presentation summarizes the neurological impairments, the diagnostic tools used and the therapies, in a paediatric cohort seen in our out-patient clinic. Patient |
| Mo.B.1308 | Chronic hepatitis in children with vertically acquired HIV infection. Int Conf AIDS 1996 Jul 7-12; 11:108 (abstract no. Mo.B.1308) Ruga, Sartor M, Giaquinto C, D'Elia R, Zacchello F, Zancan L; Dipartimento di Pediatria, Universita degli Studi di Padova, Padova, Italy. Fax: + 39.49.8753865. E-mail: carlog@c |